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sPIrOmETry
Spirometry is a technique to evaluate the pulmonary ventilatory function and is a reflec-
tion of several forces implied in lung volumes. The lung volume is dependent on the 
elastic recoil of the lungs and chest wall and the muscular efforts of the chest wall, dia-
phragm, and abdomen. Contraction of the inspiratory muscles, such as the diaphragm, 
expands the thorax, creating an increased negative pressure. This pressure is lower than 
the atmospheric pressure, drawing air into the lungs. Expiration is mainly a passive 
process. When the muscles relax, due to elastic recoil of the lungs, air will flow out. This 
process can be assisted by contraction of intercostal and abdominal wall muscles, result-
ing in a positive pleural pressure 1. Using the spirogram, several different types of lung 
volume can be evaluated.
Apart from the tidal volume, a person is capable of recruiting the expiratory residual vol-
ume and inspiratory residual volume, e.g. during exercise but also when the participant 
performs a specific diagnostic maneuver (figure 1). The figure below (figure 2) shows 
three flow-volume curves. To assess airway obstruction, the patient needs to take a deep 
breath, then exhales as much air as possible as quickly as possible for at least six seconds; 
lastly, he inhales deeply again when the end of the expiratory capacity is reached.
Two of the most important measures are the Forced Expiratory Volume in the first sec-
ond, (FEV1) and the Forced Vital Capacity (FVC). The FEV1 provides information about the 
Figure 1. Normal spirogram with normal breaths, 1 maximal expiration and inspiration.
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airflow, while the FVC provides an estimate of the vital capacity. In obstructive disease, 
the FEV1 is disproportionally decreased in comparison to FVC, resulting in a decreased 
ratio. In restrictive disease the FEV1 and FVC are often equally decreased, resulting in 
a normal ratio. In early adulthood, the peak levels of lung function are attained, after 
which they gradually decline with age 2,3. The individual maximal lung capacity is de-
pendent on genetic factors and environmental exposures, e.g. parental smoking during 
childhood4. Similarly, the rate of lung function decline is dependent on a plethora of 
factors, of which smoking is one of the strongest risk factors for an accelerated decline 2.
Both FEV1 and FVC are predictors of mortality, even in subjects without pulmonary 
disease 5-12.
ChrOnIC ObsTruCTIVE PuLmOnary DIsEasE
Chronic Obstructive Pulmonary Disease (COPD) is the most frequently occurring chronic 
disease of the lungs and is estimated to become the third cause of death worldwide 
in 2020 13. According to the definition by the Global Initiative For Chronic Obstructive 
Lung Disease (GOLD), COPD is ”a common preventable and treatable disease, is char-
acterized by persistent airflow limitation that is usually progressive and associated with 
an enhanced chronic inflammatory response in the airways and the lung to noxious 
particles or gases. Exacerbations and co-morbidities contribute to the overall severity 
in individual patients.” 14. Although the definition of disease is based on airflow obstruc-
tion, exacerbations and co-morbidities contribute to the overall severity, prognosis and, 
eventually, mortality 14,15. Spirometry, or pulmonary function testing, is an essential tool 
in diagnosing COPD and evaluating the effect of treatment of COPD 16.
Figure 2. Three flow-volume curves; one normal curve, one showing airflow obstruction and one curve 
showing severe airflow obstruction
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PaThOPhysIOLOGy anD PaThOGEnEsIs OF COPD
COPD is a complex disease on a clinical, cellular and molecular level 17. The most well-
studied cause of COPD is tobacco smoking 18. The inhaled cigarette smoke causes 
damage to the airways and lung parenchyma via several pathways. The damage can 
occur directly through epithelial cell destruction, exaggerated inflammatory responses 
and oxidative stress 19,20. However, only approximately 20 percent of the smokers actu-
ally develop COPD 21. Conversely, not all COPD patients have smoked 22, leading to the 
hypothesis that COPD is a consequence of synergy between several direct or indirect 
risk factors. Other risk factors which are thought to play a role in the development of 
COPD are airway hyper-responsiveness, environmental and occupational exposure and 
genetic determinants 23-27.
GEnETICs
Until recently, the genetic variation causing alpha-1-antitrypsin deficiency was the 
most well-known genetic mutation causing COPD. The prevalence of this disease is ap-
proximately 1 in 2,000 to 1 in 5,000 and the effects are enhanced by cigarette smoking, 
leading to emphysema at a young age 28. Since the prevalence of COPD is much higher 
than that and because of the above-mentioned discrepancy between smokers and the 
development of COPD, we hypothesized that other genetic variations exert their effects 
on the development of COPD or the decline of lung function. With the introduction of 
Genome-Wide Association studies, various efforts have been made to identify these 
variants 25,26,29-32. While these projects have proven to be successful in identifying com-
mon variants underlying COPD and spirometry measurements (FEV1 and FEV1/FVC) in 
general, the proportion of variance explained by these common variant alleles was low, 
implicating that a large part of the heritability is still unexplained.
DIaGnOsIs
Although COPD is mainly characterized by not fully reversible airflow limitation, patients 
can present themselves with a wide array of symptoms, including coughing, dyspnea, 
respiratory mucus production and recurrent lower respiratory tract infections. To define 
airflow limitation in a patient with clinical symptoms, the most widely used diagnostic 
lung function test for COPD is spirometry. Spirometry is the most reproducible and 
objective measurement of airflow limitation currently available 14,16. Airflow limitation 
is currently defined by the Global initiative of Obstructive Lung disease (GOLD) as an 
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FEV1/FVC below 70% (measured post-bronchodilator). For staging of COPD, FEV1 percent 
predicted is used. Together with frequency of exacerbations and amount of symptoms, 
spirometry is used in the recently updated GOLD staging 33.
ThEraPy
Essential in treatment of COPD is smoking cessation. It is important to emphasize that it 
is never too late to stop smoking.
Besides smoking cessation, there are several pharmacological and non-pharma-
cological treatment options to reduce symptoms, but also to prevent exacerbations. 
Bronchodilating agents, such as β2-agonists and anticholinergics, play a central role in 
the treatment of COPD symptoms, but there is also evidence that these products may 
improve survival.
Recent evidence shows that in COPD patients with frequent exacerbations, chronic 
treatment with low dose macrolide antibiotics may reduce exacerbations 34. However, 
the adverse events caused by these antibiotics and the microbial resistance will need to 
be weighed against the benefits.
PharmaCOGEnETICs
Genetic association testing not only provides insight into biological processes influenc-
ing the lungs and their function, it may point to possible targets for new therapies. 
Furthermore, identifying genetic modifiers for drug response and the occurrence of 
adverse events can help in the goal to tailor specific treatments to individual patients 
(i.e. personalized medicine). This might pertain to the preferable drug choice, as well 
as to the recommended starting dose. The most well-known gene influencing one of 
the therapeutic strategies in pulmonary function is the ADRB2 -gene, coding for the β2-
adrenergic receptor. This receptor is the target of the inhaled β2-agonists, which can be 
distinguished into two groups according to their duration of action: Long- and Short-
Acting β2-agonists (LABA & SABA). These products cause airway relaxation through de-
crease of airway smooth muscle tone activity. The differences in therapeutic responses 
in patients have been associated with polymorphisms in ADRB2 , but the results have 
been inconclusive so far 35. Another treatment strategy of asthma and COPD is focused 
on the reduction of inflammation (e.g. inhaled corticosteroids). An interesting target 
would be the gene encoding for the protein histone deacetylase 2 (HDAC2), possibly 
influencing glucocorticoid resistance 36. More efforts are needed to further elucidate the 
highly variable responses to treatment.
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ObjECTIVEs
The main objectives of this PhD thesis are 1) to explore the epidemiology of spirometric 
measurements, 2) to identify genetic determinants for lung function, smoking suscepti-
bility, lung function decline and COPD, 3) to assess the effects of drugs on lung function 
or disease progression and to elucidate the genetic and environmental modifiers for 
drug response. In part I, we provide a general introduction and some background to 
spirometry. Part II focuses on the epidemiologic exploration of pulmonary function. 
Chapter 2.1 describes our efforts to redefine the reference values for spirometry in the 
general (elderly) population and chapter 2.2 describes the association between spiro-
metric measures and pulmonary artery systolic pressure, investigating the lung-heart 
interaction. Part III consists of several studies aimed to identify genetic determinants 
for lung function, specifically FEV1 and FEV1/FVC (chapter 3.1) and FVC (chapter 3.2) us-
ing genome-wide association studies. Furthermore, we investigated common variants 
and their association with FEV1 decline over time (chapter 3.3) using GWAs. To better 
understand the interaction between smoking and lung function, we investigated the 
interaction between genetic variants and cigarette smoke exposure (chapter 3.4) by a 
joint-meta-analysis of genome-wide main and interaction effects. Lastly, our objective 
was to identify genetic determinants for COPD (chapter 3.5). Part IV of this thesis focuses 
on pharmaco-epidemiology, encompassing two studies in which we investigated the 
effects of β-blocker exposure on pulmonary function (chapter 4.1) in the general popu-
lation and the effect of statin use on survival in COPD patients (Chapter 4.2). The final 
part (Part V) will provide a general discussion.
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absTraCT
Introduction Although many different reference values for spirometry are available 
from various studies, the elderly are usually underrepresented. Therefore, our objective 
was to assess reference values in a sample of healthy participants from a prospective 
population-based cohort study, including a large proportion of elderly.
methods We included spirometry measurements of healthy, never smokers, from the 
Rotterdam Study and excluded participants with respiratory symptoms or prescriptions 
for respiratory medication. Age- and height-specific curves for the 5th (lower limit of 
normal) and the 50th (median) percentile of Forced Expiratory Volume in 1 second (FEV1), 
Forced Vital Capacity (FVC), and the ratio (FEV1/FVC) were calculated by quantile regres-
sion models.
results The group of healthy elderly study subjects consisted of 1,125 individuals, with 
a mean age of 68 years, ranging from 47 to 96 years of age. Sex stratified equations for 
the median and the lower limit of normal were calculated adjusted for age and height.
Conclusions In this study, we report age- and height-dependent reference limits for FEV1, 
FVC, and FEV1/FVC in a large population, and prediction equations for the lower limit of 
normal and median values for a sample containing a large proportion of healthy elderly.
Conclusions In this study, we report age- and height-dependent reference limits for 
FEV1, FVC, and FEV1/FVC in a large population, and prediction equations for the lower 
limit of normal and median values for a sample containing a large proportion of healthy 
elderly.
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InTrODuCTIOn
Pulmonary function testing plays a vital role in diagnosing obstructive airway diseases 
such as asthma or chronic obstructive pulmonary disease (COPD), assessing disease 
severity, and monitoring treatment responses 1-3. Pulmonary function also predicts mor-
tality in the general population, even among people who have never smoked, who have 
only modestly reduced pulmonary function, and who have no respiratory symptoms 4. 
Studies consistently find that reduced pulmonary function (usually Forced Expiratory 
Volume in 1 second or FEV1) is associated with an increased risk of mortality from respi-
ratory and non-respiratory diseases 5,6. The peak level of pulmonary function is attained 
in early adulthood and declines subsequently over time 7. When measured at some point 
in a person’s lifetime and reduced levels of FEV1, Forced Vital Capacity (FVC) and FEV1/
FVC are found, these can be due to impaired lung growth during fetal life, childhood or 
adolescence and/or due to an accelerated decline of lung function in adulthood. Both of 
these processes can be influenced by genetics 8-11, or can be due to exposure to noxious 
substances, e.g. cigarette smoke or fine particulate matter from combustion of fossil 
fuels 12.
During the last decade, many worldwide efforts have been made to calculate reference 
values for pulmonary function tests, resulting in several equations 13-20. Many of the 
currently used reference values were calculated several decades ago, but also more 
recent studies demonstrate the clinical interest in this topic 14,15,17,19,21. However, studies 
performed in the elderly are scarce and usually comprise only a few dozen people aged 
above 70 years 16,18,19. Extrapolation of reference equations calculated in relatively young 
participants to an elderly population may lead to misclassification of disease. Therefore, 
international guidelines discourage extrapolation of values to elderly when calculating 
reference values.
Recently the authors of the Global Lung Initiative, European Respiratory Society Task 
Force concluded, in their large effort to establish global reference values, that data on 
participants with ages of 75 years and older is scarce. Consequently, it is necessary to 
collect more data from healthy elderly to obtain more precise reference values in this 
group 16-18,21,22. Therefore, the objective of our study was to evaluate normal values of 
spirometry measurements in the elderly. Hereto, we used spirometry measurements 
from a prospective population-based cohort study, to calculate reference equations for 
spirometric measures in healthy elderly.
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mEThODs
setting
The Rotterdam Study is a prospective population-based cohort study, which was initi-
ated in 1990 in Ommoord, a suburb of Rotterdam, the Netherlands. The Medical Ethics 
Committee of the Erasmus Medical Centre, Rotterdam, approved the study. At baseline, 
all participants were visited for a standardized questionnaire, and were subsequently ex-
amined at the Rotterdam Study’s research centre, located in Ommoord, Rotterdam. The 
initial cohort (RS I) consists of 7,983 participants, aged 55 years and over. Since the start 
of the first cohort, two more cohorts have been defined in the same suburb. The second 
cohort (RS II) started in 2000 and included 3,011 participants aged 55 years and over. The 
third cohort (RS III) was enrolled in 2006 and included 3,932 participants aged 45 years 
and over. As of 2009, the total of the combined cohorts encompassed 14,926 subjects 
aged 45 years or over. The main focus of the Rotterdam Study is on studying common 
chronic diseases in the elderly. During a follow-up of up to 22 years, extensive data on 
morbidity, mortality, and medical interventions have been gathered. Main objectives 
and methods of the Rotterdam Study have been described earlier 23,24.
study population
The source population consisted of all participants of the Rotterdam Study with a valid 
pulmonary function test. We used the most recent pulmonary function test, performed 
at any study round. The tests were analysed by two research physicians, and validated 
by a specialist in pulmonary medicine (GB). During the validation process the quality 
control was performed by two researchers. Reproducible and interpretable spirometry 
recordings were classified and the values for the separate pulmonary function measures 
were stored digitally in a database. For the selection of the study population of healthy 
elderly, we excluded current and ex-smokers and participants with symptoms of respira-
tory diseases, participants taking inhaled short-acting β-adrenoreceptor-agonists (SA-
BAs), long-acting β-adrenoreceptor-agonists (LABAs), anticholinergic agents, inhaled 
glucocorticosteroids, or combinations of the above mentioned substances, xanthine 
derivatives, leukotriene-receptor antagonists and β-blockers.
spirometry
All measurements were performed pre- bronchodilator. Spirometry was performed 
by trained paramedical personnel using a SpiroPro® portable spirometer (Erich Jaeger, 
Hoechberg, Germany) from 2002 to 2009, and with the Jaeger Masterscreen PFT (Care 
Fusion, the Netherlands) since 2009, according to American Thoracic Society (ATS)/Euro-
pean Respiratory Society (ERS) guidelines 2. FEV1, FVC and FEV1/FVC-ratio were measured. 
Quality control of pulmonary function tests was done by a researcher (DL or LL) and a 
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respiratory specialist (GB). Quality assessment includes assessment of the flow-volume 
loop including reproducibility and volume-time loop or maximal expiration. Spirometry 
results that did not meet ATS/ERS criteria for acceptability and reproducibility were clas-
sified as not interpretable 25,26.
Covariables
Information on potential confounders or effect modifiers such as age, sex, height, weight 
and body mass index (BMI) was gathered at the centre visit during which the pulmonary 
function test was conducted.
statistical analyses
Statistical analyses were performed using STATA/SE 12 for Windows (StataCorp, College 
Station, Texas, USA). For the evaluation of reference values we used quantile regression 
analysis, a statistical method for estimating models for the conditional quantile func-
tions instead of the conditional mean of the response variable. This method is more 
robust against outliers in the outcome measurements27. The prediction equations were 
calculated using the median, whereas the 5th percentile was chosen as cut off to define 
the lower limit of normal (LLN), as previously proposed 28. For the prediction equations 
the median (50th percentile) was chosen.
Fractional Polynomials (FP) were applied to explore and graph nonlinear associations 29 
between continuous exposure variables (age, height, weight) and the respective out-
come. The dose-response relation was found using FP up to degree 2 with all possible 
combinations of powers selected from the set (-2, -1, -0.5, 0, 0.5, 1, 2, 3). The best fitting 
two-factorial FP was compared with the best fitting one-factorial FP by a deviance test. 
If the goodness of fit was not significantly better in the model with the two-factorial FP 
(p>0.1), we tested by a deviance test whether the model with the best fitting one-factorial 
FP was significantly better than the model with the untransformed exposure variable. If 
none of the FP models with the transformed exposure variable fitted the data significantly 
better than the model with the untransformed exposure variable, the exposure variable 
remained untransformed. Otherwise the exposure variable was transformed.
rEsuLTs
Of the total of 14,926 subjects from the Rotterdam Study and since the introduction 
of spirometry in the cohort study in 2002, in 6,959 individuals one or more pulmonary 
function tests were performed. Of these, a total of 4,324 spirometry tests were of suf-
ficient quality. A total of 1,125 participants were never smokers, had no prescription for 
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pulmonary medication or beta-blockers, and did not have symptoms indicating respira-
tory diseases. The spirometry results of these participants were used for our analyses.
subject characteristics
The population consisted of 334 men (29.7%) and 791 (70.3%) women with a mean age 
of 68.2 years, ranging from 47.1 years to 94.6 years old. As expected, the inter-quartile 
ranges of age for males and females differed and are shown separately (Table 1).
reference values
Prediction equations are shown in table 2. We calculated sex specific prediction equa-
tions for FEV1, FVC and FEV1/FVC by age adjusted for height. Age was linearly associated 
with FEV1 and FVC, for both the lower limit of normal (5
th percentile) and the median 
(50th percentile). Reference curves for age are shown in figures 1 and 2.
For the LLN of FEV1/FVC in males, the prediction equation followed a more complex 
correlation with transformations for height (figure 3). In females, age was linearly associ-
ated with LLN and the median of FVC and FEV1. Height was non-linearly associated with 
these two outcomes (Table 2, Figures 1 and 2) and FEV1/FVC, for both the lower limit of 
normal and the predicted values. Figures 1, 2 and 3 show the individual measurements 
and the regression curves for the lower limit of normal and the median values in males 
and females.
Table 1. Baseline characteristics
Characteristics male Female
n (%) 334 (29.7%) 791 (70.3%)
mean age Years (SD) 64.7 (10.0) 69.7 (10.0)
age in years
1st quartile 47.1 - 56.5 47.1 – 61.7
2nd quartile 56.5 – 64.6 61.7 – 71.2
3rd quartile 64.9 – 72.0 71.2 – 77.0
4th quartile 72.0 – 88.4 77.0 – 94.6
height cm (SD) 176.4 (7.1) 162.8 (6.7)
Weight kg (SD) 84.2 (11.9) 71.4 (12.3)
bmI kg/m2 (SD) 27.0 (3.3) 26.9 (4.3)
FEV1 L (SD) 3.51 (0.72) 2.32 (0.57)
FVC L (SD) 4.46 (0.93) 3.00 (0.70)
FEV1/FVC (SD) 79.2 (6.7) 78.7 (6.8)
FEV1 % predicted
* (SD) 109.1 (15.4) 109.9 (21.0)
Continuous variables are listed as mean (SD). FEV1: Forced Expiratory Volume in 1 second (FEV1), FVC: 
Forced Vital Capacity. *According to the European Community for Coal and Steel/ European Respiratory 
Society (ECCS/ERS)
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Table 2. Equations derived from individual measurements.
Lower Limit of normal median
males
FEV1 -0.4982893 - 0.0307421 x A + 0.0298244 x Hcm 0.5688802 - 0.0428957 x A + 0.0325003 x Hcm
FVC 0.4088557 - 0.0331373 x A + 0.0294108 x Hcm -2.888613 - 0.0418384 x A + 0.0568359 x Hcm
FEV1/FVC
 
yearsAgeA    
10
years
trans
AgeA    
Hcm= Height in centimetres 
10
cm
trans
HH   
Hm= Height in meters 
In this table, we give prediction equations for the 50th percentile (Predicted Values, or Median) and the 5th percentile (Lower Limit of Normal). These equations are 
based on measurements in healthy elderly individuals.  
 
 ower Limit of Normal Me ian 
Males   
FEV1 cmHA  0298244.00307421.04982893.0  cmHA  0325003.00428957.05688802.0  
FVC 
cmHA  0294108.00331373.04088557.0  cmHA  0568359.00418384.0888613.2  
FEV1/FVC )ln(167.14207117.128241581655.0755.6574 trans
transtrans
H
HH
A   cmHA  0724344.01405519.04621.101  
Females  
FEV1 
mm HH
A 1528179.31258029.60247535.0576269.3 2   )ln(655085.1
1279633.70309816.0055922.8 2 m
m
H
H
A   
FVC 23267878.0520033.30306052.06304702.0 mm HHA   
mm HH
A 112663.37168719.320332075.0745469.3   
FEV1/FVC 
22
118434.4218654.39411051.43
mtrans HA
  2
190965.221353647.076162.79
mH
A   
101.4 1 - 0.1405519 x A - 0.0724344 x Hcm
Females
FEV1 3.576269 - 0.0247535 x A - 6.258029 x (1/Hm
2) + 
3.528179 x (1/Hm)
8.055922 - 0.0309816 x A - 7.279633 x (1/Hm
2) 
- 1.655085 x ln(Hm)
FVC -0.6304702 - 0.0306052 x A + 3.520033 x Hm - 
0.3267878 x Hm
2
-3.745469 - 0.0332075 x A - 32.68719 x (1/Hm) 
+ 37.12663 x (1/√Hm)
FEV1/FVC
43.11051 + 394.8654 x (1/Atrans
2) + 42.18434 x (1/
Hm
2)
79.76162 - 0.1353647 x A + 22.90965 x (1/Hm
2)
A = Ageyears
Atrans = Ageyears / 10
Hcm = Height in centimetres
Htrans = Hcm / 10
Hm = Height in meters
In this table, we give prediction equations for the 50th percentile (Predicted Values, or Median) and the 
5th percentile (Lower Limit of Normal). These equations are based on measurements in healthy elderly 
individuals.
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Figure 1. This figure shows individual measurements for FEV1 for males (a) and females (b)separately. The 
solid line shows the equation for the lower limit of normal or 5th percentile. The dashed line shows the 
prediction equation for the median or 50th percentile. Both these regression curves are corrected for age 
and height and their respective transformations.
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Comparison to other reference values
In the supplementary figures we show comparisons with existing reference equations. 
As can be seen in the graphs, our prediction equations allow for lower values in the 
elderly than both the Hankinson and standard output equations and have a more nar-
row range of values for different heights.
These supplementary figures can be found via
http://link.springer.com/article/10.1007%2Fs10654-013-9800-4
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Figure 2. This figure shows individual measurements for FEV1 for males (a) and females (b)separately. The 
solid line shows the equation for the lower limit of normal or 5th percentile. The dashed line shows the 
prediction equation for the median or 50th percentile. Both these regression curves are corrected for age 
and height and their respective transformations. 
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Figure 3. This figure shows individual measurements for FEV1 for males (a) and females (b)separately. 
These values are not a derivative from the predicted values for FEV1 and FVC but predicted directly from 
the ratio of FEV1 to FVC. The solid line shows the equation for the lower limit of normal or 5
th percentile. 
The dashed line shows the prediction equation for the median or 50th percentile. Both these regression 
curves are corrected for age and height and their respective transformations.
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DIsCussIOn
In this study, we calculated spirometry reference values for elderly without respiratory 
disease. These data are relevant because there are hardly precise reference values for 
spirometry in elderly. These analyses were done in a large prospective population-
based cohort study in which assessment of pulmonary function is routinely performed 
since 2002. To assess spirometry measures in a sample of healthy elderly, we excluded 
participants with a history of smoking, pulmonary medication or respiratory symptoms. 
Although height decreases in elderly during ageing, this change over time is slow com-
pared to growth spurts during adolescence. Therefore, we think that quantile regression 
analysis is a valid approach. Furthermore, we show a comparison between our equations, 
the set of prediction equations by Hankinson e.a. 15 and the “standard” or pre-installed 
formula’s output from our spirometry-device. Our prediction equations allow for lower 
values in the elderly than both the Hankinson and standard output equations and have 
a more narrow range of values (e.g. FEV1) for different heights. Especially a physiologi-
cally lower FEV1, which is in fact normal for a person of a certain age and height, would 
be interpreted differently. Using reference values which are unsuitable for the higher 
age categories, could lead to misclassification of disease.
The importance of reference values for spirometry is underlined by the large combined 
effort which has recently been made by the Global Lung Initiative (GLI) European Respi-
ratory Society Task Force to calculate multi-ethnic equations across an age-range from 3 
to 95 years old 21. This extensive overview provides reference values for subjects of four 
different ethnicities and across a broad age spectrum. However, the authors conclude in 
their paper that predicted values for participants over the age of approximately 75 years 
old should be used and interpreted with caution, because of the relatively low number 
of participants in that particular age-group the authors conclude that additional data 
about this age-group is required.
The strengths of our study include the high quality prospectively gathered data in a 
large sample of the aging population with standardized assessments of height, weight, 
and spirometry. Due to collection of several covariables and the continuous collection 
of medication, we were able to include a healthy population for our analyses, of which 
25% of males was 72 years of age or older, and 25% of females 77 years of age or older. 
Taking into account one of the conclusions of the GLI European Respiratory Society Task 
Force 21, this underlines the importance of our findings. A limitation of calculating refer-
ence values in a population such as the Rotterdam Study may be that the calculated 
reference equation is population specific. These could arise due to different population 
characteristics. Therefore, there is a need for validation of our equations to evaluate 
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generalizability across populations and especially across the higher age categories. We 
were not able to include this in our manuscript because, to our knowledge, there are 
no studies with a similar design and such a large proportion of healthy elderly in the 
higher age categories. Perhaps in the future, an approach where these formulas could 
be compared in a different (e.g. clinical) setting would be very interesting.
In conclusion we show normal values for FEV1, FVC and FEV1/FVC in a large population 
with a large proportion of elderly subjects. Furthermore we show equations for the 
lower limit of normal and prediction values.
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absTraCT
Pulmonary function measures reflect respiratory health and are used in the diagnosis of 
chronic obstructive pulmonary disease. We tested genome-wide association with forced 
expiratory volume in 1 second and the ratio of forced expiratory volume in 1 second to 
forced vital capacity in 48,201 individuals of European ancestry with follow up of the top 
associations in up to an additional 46,411 individuals. We identified new regions showing 
association (combined P < 5 × 10−8) with pulmonary function in or near MFAP2, TGFB2, 
HDAC4, RARB, MECOM (also known as EVI1), SPATA9, ARMC2, NCR3, ZKSCAN3, CDC123, 
C10orf11, LRP1, CCDC38, MMP15, CFDP1 and KCNE2. Identification of these 16 new loci 
may provide insight into the molecular mechanisms regulating pulmonary function and 
into molecular targets for future therapy to alleviate reduced lung function.
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InTrODuCTIOn
Pulmonary function, reliably measurable by spirometry, is a herit able trait reflecting the 
physiological state of the airways and lungs1. Pulmonary function measures are impor-
tant predictors of population morbidity and mortality2–4 and are used in the diagnosis of 
chronic obstructive pulmonary disease (COPD), which ranks among the leading causes 
of death in developed and developing countries5,6. A reduced ratio of forced expiratory 
volume in 1 second (FEV1) to forced vital capacity (FVC) is used to define airway obstruc-
tion, and a reduced FEV1 is used to grade the severity of airway obstruction
7.
Recently, two large genome-wide association studies (GWAS), each comprising discovery 
sets of more than 20,000 individuals of European ancestry, identified new loci for lung 
function8,9. Recognizing the need for larger data sets to increase the power to detect 
loci of indi vidually modest effect size, we conducted a meta-analysis of 23 lung function 
GWAS comprising a total of 48,201 individuals of European ancestry (stage 1) and fol-
lowed up potentially new loci in 17 further studies comprising up to 46,411 individuals 
(stage 2). We identified 16 additional new loci for lung function and provided evidence 
corrobo rating the association of loci previously associated with lung func tion8–11. Our 
findings implicate a number of different mechanisms underlying regulation of lung 
function and highlight loci shared with complex traits and diseases, including height, 
lung cancer and myo cardial infarction.
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rEsuLTs
Genome-wide analysis (stage 1)
We undertook meta-analyses for cross-sectional lung function meas ures for ap-
proximately 2.5 million genotyped or imputed SNPs across 23 studies with a combined 
sample size of 48,201 adult individu als of European ancestry. Characteristics of the 
cohort participants and the genotyping are shown in Supplementary Table 1a and b. 
We adjusted FEV1 and FEV1/FVC measures for ancestry principal components, age, age
2, 
sex and height as covariates. Our association testing of the inverse-normal–transformed 
residuals for FEV1 and FEV1/FVC assumed an additive genetic model and was stratified 
by ever-smoking versus never-smoking status. We performed the meta-analyses of the 
smoking strata within each study and of the study-specific results using inverse-variance 
weighting (and used the inverse of the standard error squared as the weight). We ap-
plied genomic control twice at the study level (to each smoking stratum separately 
and to the study-level pooled estimates) and also at the meta-analysis level to avoid 
inflation of the test statistics caused by cryptic population structure or relatedness (see 
Supplementary Table 1a for study-level estimates). Our application of genomic control 
at the three stages is likely to be overly conservative because it has recently been shown 
that in large meta-analyses, test statistics are expected to be elevated under polygenic 
inheritance even when there is no population structure12. The test statistic inflation (λGC) 
before apply ing genomic control at the meta-analysis level was 1.12 for FEV1 and 1.09 
for FEV1/FVC. Genomic inflation estimates increase with sample size, as has been shown 
for other traits13–15; the standardized estimates to a sample of 1,000 individuals (λGC_1,000) 
were 1.002 for FEV1 and 1.002 for FEV1/FVC. Plots of the meta-analysis P values for FEV1 
and FEV1/FVC against a uniform distribution of P values expected under the null hy-
pothesis showed deviations which were attenuated, but which persisted, after removal 
of SNPs in loci reported previously, consistent with additional loci being associated with 
lung function (Supplementary Fig. 1a).
Follow-up analysis (stage 2)
Twenty-nine new loci showing evidence of association with lung function (P < 3 × 10−6) 
in stage 1 were followed up in stage 2 by using in silico data from seven studies and by 
undertaking additional genotyping in ten studies for the ten highest ranked SNPs (Fig. 
1). Full details of the SNP selection are given in the Online Methods. We performed an 
inverse-variance–weighting meta-analysis across stages 1 and 2 and obtained two-sided 
P values for the pooled estimates. Sixteen new loci reached genome-wide significance 
(P < 5 × 10−8) and showed consistent direction of effects in both stages, comprising 
12 new loci for FEV1/FVC, 3 new loci for FEV1 and 1 new locus reaching genome-wide 
significance for both traits (Fig. 2 and Table 1). To assess the heterogeneity across the 
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Figure 1. Study design. 
We followed up in stage 2 a total of 34 SNPs showing new evidence of association (P < 3 × 10−6) with FEV1 
and/or FEV1/FVC in a meta-analysis of the stage 1 studies. Studies with a combined total of 24,737 individuals 
undertook genotyping and association testing of the top ten SNPs. Seven studies (marked with an asterisk) 
with a combined total of 11,275 individuals had genome-wide association data and provided results for up to 
34 SNPs. Researchers from GS: SFHS (marked with #) undertook genotyping on a 32-SNP multiplex genotyping 
platform and so included the 32 top ranking SNPs (including proxies and both SNPs from regions that showed 
association with both FEV1 and FEV1/FVC). This assay failed for one SNP (rs3769124), which was subsequently 
replaced with the thirty-third SNP (rs4762767). We excluded rs2284746 because of poor clustering. Although 
rs3743563 was chosen as proxy for rs12447804, which had an effective N < 80% in the stage 1 meta-analysis, 
researchers from BHS2 were unable to genotype rs3743563 and so undertook genotyping for rs12447804 
instead. See Supplementary Table 1 for definitions of all study abbreviations.
Figure 2. Manhattan plots of association results for FEV1/FVC and FEV1 (analysis stage 1). 
The Manhattan plots for FEV1/FVC (a) and FEV1 (b) are ordered by chromosome position. SNPs for which 
−log10 P > 5 are indicated in red. Newly associated regions that reached genome-wide significance after 
meta-analysis of stages 1 and 2 are labeled.
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studies included in stage 1 and 2, we performed χ2 tests for all 16 SNPs, and none of 
these SNPs was statistically significant after applying a Bonferroni correction for 16 tests. 
The sentinel SNPs at these loci were in or near MFAP2 (1p36.13), TGFB2-LYPLAL1 (1q41), 
HDAC4-FLJ43879 (2q37.3), RARB (3p24.2), MECOM (also known as EVI1) (3q26.2), SPATA9- 
RHOBTB3 (5q15), ARMC2 (6q21), NCR3-AIF1 (6p21.33), ZKSCAN3 (6p22.1), CDC123 (10p13), 
C10orf11 (10q22.3), LRP1 (12q13.3), CCDC38 (12q22), MMP15 (16q13), CFDP1 (16q23.1) 
and KCNE2- LINC00310 (also known as C21orf82) (21q22.11) (Supplementary Fig. 1b,c). 
The strongest signals in AGER (rs2070600)8,9 and two of the new signals (rs6903823 in 
ZKSCAN3 and rs2857595, upstream of NCR3) lie within a ~3.8-Mb interval at 6p21.32-
22.1 that is char acterized by long-range linkage disequilibrium (LD). Nevertheless, the 
leading SNPs in these regions, which are within the major his tocompatibility complex 
(MHC), were statistically independent (Supplementary Note).
Gene expression
We investigated mRNA expression of the nearest gene for each of the 16 new loci in 
human lung tissue and a range of human primary cells including lung, brain, airway 
smooth muscle cells and bronchial epithelial cells. We detected transcripts for all the 
selected genes in lung tissue except CCDC38, and we also detected transcripts for most 
genes in airway smooth muscle cells and in bronchial epithelial cells (Table 2). As we 
were unable to detect expression of CCDC38 in any tissue, we also examined expression 
of SNPRF, which is the gene adjacent to CCDC38 (Table 2), and found its expression in 
all four cell types. TGFB2, MFAP2, EVI1 and MMP15 were expressed in one or more lung 
cell types but not in peripheral blood mononuclear cells, providing evidence that these 
genes may show tissue-specific expression. We assessed whether SNPs in these new 
regions or their prox ies (r2 > 0.6) were associated with gene expression using a data base 
of expression-associated SNPs in lymphoblastoid cell lines16. Four loci showed regional 
(cis) effects on expression (P < 1 × 10−7; Supplementary Note). A proxy for our sentinel 
SNP in CFDP1, rs2865531, coincided with the peak of the expression signal for CFDP1, 
and the strongest proxy for rs6903823 in ZKSCAN3 coincided with the peak of expres-
sion for ZSCAN12.
Plausible pathways for lung function involving new loci
The putative function of the genes within, or closest to, the asso ciation peaks iden-
tify a range of plausible mechanisms for affect ing lung function. The most statistically 
significant new signal for FEV1/FVC (P = 7.5 × 10
−16) was in the gene encoding MFAP2, 
an antigen of elastin-associated microfibrils17, although correlated SNPs in the region 
potentially implicate other genes that could plausibly influence lung function, such 
as CROCC, which encodes rootletin, a component of cilia18. Our second strongest new 
signal, also for FEV1/FVC, was in RARB, the gene encoding the retinoic acid recep tor β. 
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Table 2. Expression profiling of candidate genes in the lung and periphery
sentinel snP 
(relationship 
to gene) Chr. Gene
Putative Function of encoded 
protein
Tissue
Lung hasm hbEC PbmC
rs993925 
(intron) 1 TGFB2
Cytokine with roles in pro-fibrotic 
cytokine modulating epithelial repair 
mechanisms and extracellular matrix 
homeostasis including collagen 
deposition40 + + - -
rs2284746 
(intron) 1 MFAP2
Major antigen of elastin-associated 
microfibrils17 and a candidate for 
involvement in the etiology of 
inherited connective tissue diseases. + + + -
rs12477314 
(downstream) 2 HDAC4
Deacetylase of histone surrounding 
DNA thus influencing transcription 
factor access to the DNA possibly 
repressing gene transcription. + + + +
rs1344555 
(intron) 3 EVI1
Zinc finger transcription factor, 
encoded as part of MDS1/EVI1 
complex locus (MECOM). + + + -
rs1529672 
(intron) 3 RARB
Nuclear retinoic acid receptor 
responsive to retinoic acid, a vitamin 
A derivative and which also controls 
cell proliferation and differentiation. + + + +
rs153916 
(intron) 5 SPATA9
Initially identified as a mediator 
of spermatogenesis, other family 
members may have a role in 
pancreatic development and β-cell 
proliferation41 + + + +
rs2798641 
(intron) 6 ARMC2
Function unknown although other 
family members have been identified 
as having roles in cell signaling, 
protein degradation and cytoskeleton 
functions42 + + + +
rs2857595 
(upstream) 6 NCR3
Required for efficient cytotoxicity 
responses by natural killer cells 
against normal cells and tumours43 + - - +
rs6903823 
(intron) 6 ZKSCAN3
Transcription factor involved in cell 
growth/cell cycle/signal transduction + + + +
rs7068966 
(intron) 10 CDC123
Homologue in yeast shown to be a 
critical control protein modulating 
Eukaryotic initiation factor 2 in times 
of cell stress + + + +
rs11001819 
(intron) 10 C10orf11 Function unknown + + + +
rs11172113 
(intron) 12 LRP1
Potentially diverse roles including cell 
signaling and migration44 + + + +
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Rarb-null knockout mice have premature alveolar septation19. The third most statistically 
significant new signal for FEV1/FVC, and the most statistically significant new signal for 
FEV1, was in CDC123.
This was the only new region to show genome-wide association with both traits. CDC123 
encodes a homolog of a yeast cell-division–cycle protein that plays a critical role in mod-
ulating eukaryotic initiation factor 2 in times of cell stress20. The fourth signal for FEV1/
FVC is downstream of HDAC4, which encodes a histone deacetylase; reductions in the 
expression of other histone deacetylases (specifi cally HDAC2, HDAC5 and HDAC8) have 
been noted in COPD21. The regions we observed in the MHC are much more difficult to 
local ize, with multiple genes being tagged by the top SNP, including non-synonymous 
SNPs in ZKSCAN3, PGBD1, ZSCAN12, ZNF323, TCF19, LTA, C6orf15 and GPANK1 (also known 
as BAT4) (Supplementary Table 2). At 6p21.33, we observed the strongest association 
with lung function for rs2857595, which is in LD (r2 = 0.47) with a non-synonymous SNP 
rs1036429 
(intron) 12 CCDC38
Function unknown although other 
family members involved in a diverse 
array of functions skeletal and motor 
function45 - - - -
rs1036429 
(r2=0.96 with 
rs4762633 in 
SNRPF) 12 SNRPF Small nuclear ribonucleoprotein F + + + +
rs12447804 
(intron) 16 MMP15
Member of a large protease family 
with diverse functional roles via 
protease activity and specificity 
including; tissue remodeling, wound 
healing, angiogenesis, and tumor 
invasion. + + + -
rs2865531 
(intron) 16 CFDP1 Craniofacial Development Protein 1 + + + +
rs9978142 
(upstream) 21 KCNE2
KCNQ1-KCNE2 K+ channels may 
modulate transepithelial anion 
secretion in Calu3 airway epithelial 
cells46. + - - +
Reference 
gene 12 GAPDH + + + +
+ indicates the gene is expressed in the cell type used, and − indicates that we did not detect the gene 
expression at the mRNA level following 40 cycles of PCR. PCR profiling of gene transcripts in the human 
lung showed expression of all candidates except CCDC38, for which two sets of primers were designed 
and tested under different optimization conditions. None of these assays detected expression of CCDC38 
in the cell types analyzed. We instead assayed SNRPF, which neighbors CCDC38 and harbors SNPs in strong 
LD with CCDC38’s sentinel SNP. All PCR products were sequence verified. We used GAPDH (encoding 
glyceraldehyde-3-phosphate dehydrogenase) as a positive control for the complementary DNA, and this 
gene was expressed in all tissues. Chr., chromosome; HASM, human airway smooth muscle; HBEC, human 
bronchial epithelial cells; PBMC, peripheral blood mononuclear cells.
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in LTA (encoding lymphotoxin α) and with a SNP in the upstream promoter region of TNFA 
(encoding tumor necrosis factor α) (r2 = 0.86), both of which are plausible candidates22,23. 
Our top SNP in MMP15 is in strong LD (r2 = 1) with a non-synonymous SNP (rs3743563, 
which has an association with FEV1/FVC at P = 1.8 × 10
−7) within the same gene. Among 
the plausible mecha nisms implicated by the other new signals of association with lung 
function reported here is TGF-β signaling; TGFB2 expression is up regulated in bronchial 
epithelial cells in asthma24. The putative function of key genes (as defined by LD with 
the leading SNP) in each of the 16 loci, and relevant findings from animal models, are 
summa rized in Table 2 and are detailed in Supplementary Table 2.
associations with lung function in children
Alleles representing 11 of the 16 new loci showed directionally con sistent effects on 
lung function in 6,281 children (7–9 years of age) (Supplementary Table 3a), suggesting 
that genetic determination of lung function in adults may in part act through effects on 
lung development, or alternatively, that some genetic determinants of lung growth and 
lung function decline are shared.
association of lung function loci with other traits
Although we stratified for ever smoking versus never smoking, we did not adjust for the 
amount smoked. In order to investigate the possibility that the associations at any of our 
16 new regions were driven by an effect of the SNP on smoking behavior, we evaluated 
in silico data for associations with smoking amount from the Oxford-GlaxoSmithKline 
(Ox-GSK) consortium25 for the leading SNPs in these 16 regions. None of these 16 SNPs 
showed statistically significant association with the number of cigarettes smoked per 
day (Supplementary Table 3b). In addition, in our stage 1 and 2 datasets combined, we 
assessed whether the estimated effect sizes of the variants on lung function phenotypes 
differed substantially between ever smokers and never smokers (Supplementary Table 4) 
across the 16 loci. For the most strongly associated trait at each locus, we tested the SNP 
interaction with ever smoking versus never smoking. None of the 16 new loci showed 
a significant interaction (Bonferroni-corrected threshold for 16 independent SNPs P = 
0.003125). These analyses suggest that the genetic effects we have identified underlie 
lung function variability irrespective of smoking exposure.
We adjusted our lung function associations for height, but there are some overlaps 
between loci associated with height and those associated with lung function. Therefore, 
we evaluated in silico data for height associations of our new regions in the GIANT 
consortium14 dataset. The G allele of rs2284746 (in an intron of MFAP2), which was asso-
ciated with decreased FEV1/FVC, was associated with increased height (Supplementary 
Table 3c).
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Given reported associations between lung cancer and either COPD or lung function 
decline, we also assessed in silico data for sentinel or proxy SNPs in these 16 regions 
for associations with lung cancer in the International Lung Cancer Consortium (ILCCO) 
GWAS meta-analysis26. Alleles associated with reduced lung function were associated 
with risk of lung cancer at the strongest available proxy SNP for rs2857595 (upstream of 
NCR3) at 6p21.33 (rs3099844, r2 = 0.67) and for the strongest proxy SNP for rs6903823 
(a SNP in an intron of ZKSCAN3 and ZNF323) at 6p22.1 (rs209181, r2 = 0.69) (lung cancer 
associations at P = 2.2 × 10−7 and P = 3.4 × 10−5, respectively; Supplementary Table 3d). 
We saw no significant associations with lung cancer at the other new loci (proxy SNPs 
were available for 15 of the 16 loci, Bonferroni-corrected P < 0.0033).
In addition to the effects on height, smoking and lung cancer described above, we 
examined the literature for evidence of associations with other traits for each of the 16 
new loci (detailed in Supplementary Table 2). Genome-wide significant associations (P < 
5 × 10−8) have been reported in KCNE2 with myocardial infarction27 and at 6p21.33 near 
NCR3-AIF1 with neonatal lupus28 and systemic lupus erythema tosus29. Other significant 
complex disease associations have also been noted in the regions of CDC123 (type 2 
diabetes30), CFDP1 (type 1 diabetes31) and MECOM (blood pressure32,33), but with weaker 
LD (r2 < 0.3) being seen between the reported SNP and the sentinel SNP for lung func-
tion in the region (Supplementary Table 2).
Proportion of variance explained by loci discovered to date
Associations in ten loci previously reported for lung function8,9 reached genome-wide 
significance (P < 5 × 10−8) in our stage 1 data, namely loci in or near TNS1, FAM13A, 
GSTCD-NPNT, HHIP, HTR4, ADAM19, AGER, GPR126, PTCH1 and TSHD4 (Supplementary 
Table 5a). Thus, a total of 26 regions showed genome-wide significant associa tion with 
lung function in our study. In aggregate, variants at these 26 regions explain approxi-
mately 3.2% of the additive polygenic variance for FEV1/FVC and 1.5% of the variance 
for FEV1 (Supplementary Note). Following the approach previously described
34, we 
estimated that there are a total of 102 (95% confidence interval 57–155) inde pendent 
variants with similar effect sizes to the 26 variants we report here. In combination, these 
102 variants, comprising 26 discovered variants and 76 putative undiscovered variants, 
collectively explain around 7.5% of the additive polygenic variance for FEV1/FVC and 
3.4% of the variance for FEV1 (Supplementary Table 6 and Supplementary Note)
DIsCussIOn
In meta-analysis of 23 studies comprising 48,201 individuals of European ancestry and 
follow up in 17 studies comprising up to 46,411 individuals, we report genome-wide 
62 Chapter 3.1
significant associations with an additional 12 regions for FEV1/FVC, an additional 3 
regions for FEV1 and 1 additional region associated with both FEV1 and FEV1/FVC. We 
also confirmed genome-wide association with ten regions previ ously associated with 
lung function, bringing to 26 the total number of loci associated with lung function from 
analyses of these datasets. Most of the new loci are in regions not previously suspected 
to have been involved in lung development, the control of pulmonary func tion or the 
risk of developing COPD. Elucidating the mechanisms through which these regions 
influence lung function should lead to a more complete understanding of lung func-
tion regulation and the pathogenesis of COPD. Four of the new loci (MFAP2, ZKSCAN3, 
near NCR3 and near KCNE2) that we showed to be associated with lung function are also 
associated with other complex traits and diseases (with P < 5 × 10−8 for the other trait 
at a SNP having r2 > 0.3 with the top lung function SNP in the region). Understanding 
the intermedi ates underlying these pleiotropic effects could also lead to crucial insights 
into the pathophysiology of lung disease. One potential expla nation is that these loci 
underlie control of the mechanisms regulat ing the development and resolution of 
inflammation and subsequent tissue remodeling in a range of tissues.
The effect sizes of the variants in the 26 loci associated with lung function collectively 
explain a modest proportion of the additive genetic variance in FEV1/FVC and in FEV1, 
even after accounting for putative undetected variants with a similar distribution of ef-
fect sizes34. Our findings are consistent with those from other common complex traits, 
where it is thought that many as yet unidentified common and rare sequence variants, 
and potentially structural variants, could explain the remaining heritability35. That our 
study more than doubled the number of loci known to be associated with lung func-
tion underlines the utility of large sample sizes to achieve the power to detect common 
variants associated with complex traits. Nevertheless, it is likely that additional variants 
with similar effect sizes remain undiscovered14. In addition, our study was not designed 
to detect rare variants or structural variants associated with lung function. Identification 
of rare variants associated with lung function could be helpful in narrowing the scope of 
ongoing functional work to those genes most likely to be causally related to the associa-
tion signals we detected.
Our study focused on cross-sectional measures of lung function. Adult lung function at 
a particular time point is influenced by the peak lung function achieved by 25–35 years 
of age as well as the rate of decline of lung function after that peak36. The 26 loci now 
confirmed to be associated with lung function could affect either pre- or post-natal lung 
development and growth or decline in lung function during adulthood, or both. We 
showed consistent directions of estimated effects on lung function between adults and 
children 7–9 years of age for SNPs at 11 of the 16 new loci and 8 of the 10 previously re-
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ported loci (Supplementary Table 3a). The results we show for lung function in children 
provide some indication that these loci affect lung function development, although 
studies in larger populations of children would provide greater clarity for SNPs in the 
new loci. Further investigations will be required in large populations with longitudinal 
data to deline ate the influence of these variants on the rates of development of, and 
decline in, lung function and on the risk of developing COPD.
Of the sentinel SNPs at the 16 new loci associated with lung function, only rs2284746 
(MFAP2) was associated with height in the GIANT consortium14 dataset. The G allele of 
rs2284746 was associated with both increased height and reduced lung function. A 
similar relationship between lung function and height was previously reported for the 
G allele of rs3817928 in GPR126 refs. 8,14, which is associated with decreased height but 
with increased FEV1/FVC. A further 3 of the 180 loci found to be associated with height
14 
showed association (for the 180 loci, we used a Bonferroni-corrected threshold of P = 2.8 
× 10−4) with either FEV1 (CLIC4 and BMP6) or FEV1/FVC (PIP4K2B) (Supplementary Table 
3e). In each case, the allele associated with an increase in height was associated with a 
decrease in lung function. This is not the case for the association of rs1032296 near HHIP, 
which has shown consistent directions of effects on lung function and height11,14. How-
ever, the strongest SNP associated with height in the HHIP region lies within an intron of 
HHIP but shows no association with FEV1 or FEV1/FVC. Furthermore, although height is 
an important predictor of FEV1, this is not true for its ratio to FVC
37. These observations 
argue against the associations with lung function at these loci being simply caused by 
incomplete adjustment for height.
We stratified by ever- and never-smoker status in our analyses, and in our investigation 
of amount smoked in the Ox-GSK consortium25, none of the sentinel SNPs in the 16 new 
regions showed association with the number of cigarettes smoked per day. Additionally, 
none of these regions was associated with ever smoking in the Ox-GSK con sortium data 
(Supplementary Table 3b). Thus, the SNP associations with lung function we observed 
are unlikely to have arisen simply as a consequence of inadequate adjustment for smok-
ing.
We did not observe any interactions with ever smoking for any of the sentinel SNPs 
in the 16 new regions that exceeded a Bonferroni-corrected significance level (for 16 
SNPs). Thus, the effects on lung function of the newly associated variants we identified 
are apparent in both ever smokers and in never smokers, and the effects of smoking and 
of these genetic variants may be independent and additive.
In other common complex diseases, follow-up studies that incor porate common genetic 
risk variants into models to predict disease have not been shown to add substantially 
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to existing risk models, particularly when such models already include family history38,39. 
The same may also prove to be true for the 26 genetic variants described in this paper, as 
the effect size of any individual variant is small, but further work is required in this area. 
The major utility of our findings will be in the knowledge they provide about previously 
unknown pathways underlying lung function. Elucidating the mechanisms that these 
genes are involved in will lead to improved understanding of the regulation of lung 
function and potentially to new therapeutic targets for COPD.
mEThODs
study design
The study consisted of two stages. Stage 1 was a meta-analy sis conducted on directly 
genotyped and imputed SNPs from individu als of European ancestry in 23 studies with 
a total of 48,201 individuals. Supplementary Table 1a gives the details of these studies. 
Thirty-four SNPs selected according to the results in stage 1 were followed up in stage 2. 
The ten leading SNPs were followed up in up to 46,411 individuals of European ancestry, 
and the remaining 24 SNPs were followed up in a subset of up to 21,674 individuals (Fig. 
1).
stage 1 samples
A total of 23 studies, 17 from the SpiroMeta consortium and 6 from the CHARGE consor-
tium, formed stage 1: AGES, ARIC, B58C T1DGC, B58C WTCCC, BHS1, CHS, ECRHS, EPIC 
(obese cases and population-based studies), the EUROSPAN studies (CROATIA-Korcula, 
ORCADES and CROATIA-Vis), FHS, FTC (incorporating the FinnTwin16 and Finnish Twin 
Study on Aging), Health 2000, Health ABC, KORA F4, KORA S3, NFBC1966, RS-I, RS-II, 
SHIP and TwinsUK-I (see Supplementary Table 1 for the definitions of all abbreviations). 
Measurements of spirometry for each study are described in the Supplementary Note. 
The genotyping platforms and quality-control criteria implemented by each study are 
described in Supplementary Table 1b.
Imputation
Imputation of non-genotyped SNPs was undertaken with MACH47, IMPUTE48 or BIM-
BAM49 with pre-imputation filters and param eters as shown in Supplementary Table 1b. 
SNPs were excluded if the imputa tion information, assessed using r2.hat (MACH), .info 
(IMPUTE) or OEvar (BIMBAM), was <0.3. In total, 2,706,349 SNPs were analyzed.
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Transformation of data and genotype-phenotype association analysis
Linear regression of age, age2, sex, height and ancestry principal components was un-
dertaken on FEV1 (milliliters) and FEV1/FVC (percent). The residuals were transformed to 
ranks and then transformed to normally distributed z-scores. These transformed residu-
als were then used as the phenotype for association testing under an additive genetic 
model, separately for ever smokers and never smokers. The software used is specified 
in Supplementary Table 1b. Appropriate tests for association in related individuals were 
applied where necessary, as described in the Supplementary Note.
meta-analysis of stage 1 data
All stage 1 study effect estimates, both for ever smokers and never smokers, were correct-
ed using genomic control50 and were oriented to the forward strand of the NCBI build 36 
reference sequence of the human genome, consistently using the alphabetically higher 
allele as the coded allele. Study-specific λ estimates are shown in Supplementary Table 
1. For each study, effect estimates and standard errors for ever smokers and never smok-
ers were meta-analyzed using inverse-variance weighting. Genomic control was applied 
again to the pooled effect-size estimates for each study. Finally, effect-size estimates 
and standard errors were combined across studies using an inverse-variance–weighting 
meta-analysis, and genomic control was applied to the pooled effect-size estimates. 
To describe the effect of imper fect imputation on power, for each SNP we report the 
effective sample size (N effective), which is the sum of the study-specific products of the 
sample size and the imputation quality metric. Meta-analysis statistics and figures were 
produced using R version 2.9.2 (see URLs).
selection of snPs for stage 2
All regions selected for follow up in stage 2 contained a lead SNP with new evidence of 
association (all with P < 3 × 10−6) with FEV1 and/or FEV1/FVC, an N effective ≥70% of the 
total stage 1 sample size and association signals from the surrounding SNPs that were 
consistent with their correlation (LD) with the leading SNP. Twenty-nine independent 
regions with a leading SNP meeting these criteria were assessed in stage 2. Regions 
were defined as independent if the leading SNP from one region was >500 kb from the 
leading SNP of any other region. Long-range LD was also investigated between leading 
SNPs of regions in or near the MHC on chromosome 6 (Supplementary Note). For two 
regions, the leading SNP had an N effective ≥70% but <80% of the stage 1 sample size 
and, therefore, a proxy SNP from each region (r2 = 1 and r2 = 0.97) was also taken forward. 
For three regions, there were different leading SNPs for FEV1 and FEV1/FVC, and so both 
leading SNPs were assessed. A total of 34 SNPs were analyzed in stage 2 and are listed 
in Supplementary Table 5b. Previously reported regions8–11,51,52 were not followed up. We 
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present in Supplementary Table 5a association test statistics in stage 1 only for relevant 
SNPs from previously reported regions.
stage 2 samples
The 34 SNPs were followed up in up to 11,275 individuals from seven studies with in 
silico data: CARDIA, CROATIA-Split, LifeLines, LBC1936, MESA-Lung, RS-III and TwinsUK-II 
(Supplementary Table 1). rs2647044 was not available from TwinsUK-II.
The 34 SNPs were ranked by P value (for association with either FEV1 or FEV1/FVC), and 
the top ten leading SNPs were selected for follow up by genotyping in up to 35,136 
individuals from ADONIX, BHS2, BRHS, BWHHS, Gedling, GS: SFHS, HCS, Nottingham 
Smokers, NSHD and SAPALDIA (Supplementary Table 1). If a SNP in the top ten had an N 
effective <80%, only the proxy SNP was included in the top ten for follow up. For regions 
that showed association with both FEV1 and FEV1/FVC, only the leading SNP with the 
lowest P value for either trait was included if it was within the top ten SNPs. The study 
design is illustrated in Figure 1.
meta-analysis of stage 2 data
All stage 2 studies provided effect estimates for ever smokers and never smokers, apart 
from Nottingham Smokers, as that study only included smokers. Studies with family 
data (BHS2 and GS: SFHS) analyzed ever smokers and never smokers together to ac-
count for the family correlation, adding the smoking status as a covariate in the model, 
and therefore provided smoking-adjusted effect estimates. All stage 2 study effect 
estimates were oriented to the forward strand of the NCBI build 36 reference sequence 
of the human genome, consistently using the alphabetically higher allele as the coded 
allele. For each study with separate results for ever smok ers and never smokers, effect 
estimates and standard errors for ever smokers and never smokers were meta-analyzed 
using inverse-variance weighting. Genomic control was applied to the pooled effect 
sizes of those studies with in silico data that undertook the analysis genome wide. Ef-
fect estimates and standard errors were combined across the stage 2 studies using an 
inverse-variance–weighting meta-analysis.
Combined analysis of stage 1 and stage 2 samples
A meta-analysis of stage 1 and 2 results was undertaken using inverse-variance weight-
ing. We described associations as genome-wide significant if they had P < 5 × 10−8.
PCr expression profiling
The mRNA expression profiles of TGFB2, MFAP2, HDAC4, EVI1, RARB, SPATA9, ARMC2, 
NCR3, CDC123, LRP1, CCDC38, SNRPF, MMP15, CFDP1, ZKSCAN3, KCNE2 and C10orf11 
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were determined in human lung tissue and primary cell samples using RT-PCR, including 
RNA from lung (Ambion/ABI), brain, airway smooth muscle cells and human bronchial 
epithelial cells (Clonetics42). Primer sequences are listed in Supplementary Table 2. Full 
details are provided in the Supplementary Note.
Lung function associations in our data of snPs previously associated with lung 
function
In order to permit comparison of findings with recent studies of relevance to the field, 
we present association test statistics (in stage 1 only) for relevant SNPs from previously 
reported regions (Supplementary Table 5a). We included the regions (i) reported as 
showing genome-wide significant association (P < 5 × 10−8) with lung function, (ii) 
reported as showing genome-wide significant association with COPD, providing that 
there was additional evidence of association with lung function and (iii) DAAM2, which 
reached borderline significance in the SpiroMeta consortium9. Within each of these 
regions, if multiple SNPs had been reported, we included all relevant SNPs and also the 
SNP that showed the strongest association in our data.
association to other traits of lung-function–associated snPs
Regions asso ciated (P < 5 × 10−8) with lung function or COPD (and also associated with 
lung function) were looked up for other traits. Where multiple SNPs were reported for 
different traits or by different investigators, we aimed to include all relevant SNPs, except 
those having r2 > 0.9 with another SNP in the region. We also included the SNPs that 
showed the strongest association in our data for each region. The following related 
traits were assessed: (i) lung function in children (Supplementary Table 3a); (ii) smoking 
amount and ever smoking versus never smoking in the Ox-GSK consortium25 dataset 
(Supplementary Table 3b); (iii) height in the GIANT consortium14 dataset (Supplemen-
tary Table 3c,e); and (iv) lung cancer in the International Lung Cancer Consortium (ILCCO) 
GWAS meta-analysis26 (Supplementary Table 3d).
Estimation of the number of undiscovered variants and calculation of the 
proportion of variance explained
We used the approach previously proposed34 to estimate the number of independent 
variants associated with lung function measures that have similar effect sizes to the vari-
ants already reported and to calculate the proportion of the variance explained by them. 
We excluded discovery data when estimating effect sizes to avoid winner’s curse bias 
and obtained the number of undiscovered variants using the dis covery power to detect 
the unbiased effect sizes (Supplementary Table 6 and Supplementary Note).
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additional analyses
The top SNPs from our new loci and their proxies were searched for correlation with 
known common copy number variants and expres sion SNPs. Analyses to identify com-
mon pathways underlying the association signals for lung function were undertaken 
using MAGENTA v2 53 and GRAIL54. 
Full methods and results are given in the Supplementary Note.
http://www.nature.com/ng/journal/v43/n11/extref/ng.941-S1.pdf
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absTraCT
Genome-wide association studies have identified numerous genetic loci for spirometric 
measures of pulmonary function, forced expiratory volume in one second (FEV1), and its 
ratio to forced vital capacity (FEV1/FVC). Given that cigarette smoking adversely affects 
pulmonary function, we conducted genome-wide joint meta-analyses (JMA) of single 
nucleotide polymorphism (SNP) and SNP-by-smoking (ever-smoking or pack-years) 
associations on FEV1 and FEV1/FVC across 19 studies (total N = 50,047). We identified 
three novel loci not previously associated with pulmonary function. SNPs in or near 
DNER (smallest PJMA = 5.00×10
−11), HLA-DQB1 and HLA-DQA2 (smallest PJMA = 4.35×10
−9), 
and KCNJ2 and SOX9 (smallest PJMA = 1.28×10
−8) were associated with FEV1/FVC or FEV1 
in meta-analysis models including SNP main effects, smoking main effects, and SNP-by-
smoking (ever-smoking or pack-years) interaction. The HLA region has been widely im-
plicated for autoimmune and lung phenotypes, unlike the other novel loci, which have 
not been widely implicated. We evaluated DNER, KCNJ2, and SOX9 and found them to be 
expressed in human lung tissue. DNER and SOX9 further showed evidence of differential 
expression in human airway epithelium in smokers compared to non-smokers. Our 
findings demonstrated that joint testing of SNP and SNP-by-environment interaction 
identified novel loci associated with complex traits that are missed when considering 
only the genetic main effects.
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InTrODuCTIOn
Spirometric measures of pulmonary function, particularly forced expiratory volume in 
one second (FEV1) and its ratio to forced vital capacity (FEV1/FVC), are important clini-
cal tools for diagnosing pulmonary disease, classifying its severity, and evaluating its 
progression over time. These measures also predict other morbidities and mortality in 
the general population 1-3. Genetic factors likely play a prominent role in determining 
the maximal level of pulmonary function in early adulthood and its subsequent decline 
with age 4,5. A relatively uncommon deficiency of α-1 antitrypsin, due to homozygous 
mutations of the SERPINA1 gene, is a well-established genetic risk factor for accelerated 
decline in pulmonary function, but it accounts for little of the population variability in 
pulmonary function.
Genome-wide association studies (GWAS) have identified many common genetic vari-
ants underlying pulmonary function. The first GWAS of pulmonary function implicated 
HHIP for FEV1/FVC 
6,7. GWAS meta-analyses for FEV1/FVC and FEV1 from the Cohorts for 
Heart and Aging Research in Genomic Epidemiology (CHARGE) and SpiroMeta Consortia 
have together identified 26 additional novel loci in or near the following genes: ADAM19, 
AGER-PPT2, ARMC2, C10orf11, CCDC38, CDC123, CFDP1, FAM13A, GPR126, HDAC4, HTR4, 
INTS12-GSTCD-NPNT, KCNE2, LRP1, MECOM (EVI1), MFAP2, MMP15, NCR3, PID1, PTCH1, 
RARB, SPATA9, TGFB2, THSD4, TNS1, and ZKSCAN3 8-10.
Inhaled pollutants, especially cigarette smoking, can have important adverse effects on 
pulmonary function. Candidate gene studies have not consistently identified interac-
tions with cigarette smoking in relation to pulmonary function. Despite the importance 
of smoking and other environmental factors in the etiology of many complex human 
diseases and traits, few GWAS have incorporated gene-by-environment interactions 
11-14. Meta-analyses are generally necessary to provide sufficient sample size to detect 
moderate effects, and methods for joint testing of single nucleotide polymorphism 
(SNP) main effects and SNP-by-environment interactions in the meta-analysis setting 
have only recently been developed 15,16. This strategy has the potential to identify novel 
loci that would not emerge from analyses based on the SNP main or interactive effects 
alone 15-17.
The well-documented and consistent deleterious effect of cigarette smoking on 
pulmonary function 18 makes it a good candidate for such an approach, since genetic 
factors may have heterogeneous effects on pulmonary function depending on smoking 
exposure. We conducted genome-wide joint meta-analyses (JMA) of SNP and SNP-by-
smoking interaction (ever-smoking or pack-years) associations with cross-sectional pul-
96 Chapter 3.3
monary function measures (FEV1/FVC and FEV1) in 50,047 study participants of European 
ancestry.
rEsuLTs
Table S1 presents characteristics of the 50,047 participants from 19 studies contributing 
to our analyses. As expected, mean FEV1 and FVC values were lower in studies with the 
oldest participants. Standardized residuals of FEV1 and FEV1/FVC (see Methods) were 
used as the phenotypes for the JMA, in order to maximize comparability with our recent 
GWAS meta-analysis from the CHARGE and SpiroMeta Consortia 10. Our original GWAS 
meta-analyses, conducted separately in CHARGE and SpiroMeta, showed that we were 
able to identify replicable genetic loci whether using actual pulmonary function mea-
sures 8 or their standardized residuals 9. The standardized residual approach was similarly 
taken in GWAS of other complex quantitative traits, such as height and body mass index 
from the Genetic Investigation of ANthropometric Traits (GIANT) Consortium 19,20.
In each of the 19 studies, four regression models with differing SNP-by-smoking interac-
tion terms were run: (1) SNP-by-ever-smoking for standardized FEV1/FVC residuals, (2) 
SNP-by-pack-years for standardized FEV1/FVC residuals, (3) SNP-by-ever-smoking for 
standardized FEV1 residuals, and (4) SNP-by-pack-years for standardized FEV1 residuals. 
Study-specific genomic inflation factors (λgc) were calculated for the 1 degree-of-freedom 
(d.f.) SNP-by-smoking interaction term, to ensure that there was no substantial inflation 
due to the main effect of smoking being misspecified 21. All study-specific results had 1 
d.f. λgc≤1.09 (Table S2), which is of comparable magnitude to other studies with large 
sample sizes 10,19,22,23.
The study-specific regression coefficients from each of the four models were then 
combined in JMA, and the resulting λgc values from the 2 d.f. JMA, calculated across 
all SNPs, ranged from 1.056 to 1.064. The quantile-quantile plots (Figure S1) show sub-
stantial deviation from expectation for SNPs having low P values from the JMA (PJMA). 
The JMA results corresponding to the top SNP from each previously implicated locus 
8-10 are presented in Table S3. To identify novel loci among the genome-wide significant 
loci implicated by our JMA models, the genomic regions surrounding the most signifi-
cant SNP from each of the 27 previously implicated loci 8-10 (500 kb upstream to 500 kb 
downstream of each SNP) were removed from consideration (Table S3). Following the 
removal of all previously implicated loci 8-10, the quantile-quantile plots show that some 
deviation remained between observed and expected P values for high-signal SNPs sug-
gesting the presence of novel signals.
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In the JMA of SNP and SNP-by-smoking in relation to FEV1/FVC, we observed two 
novel loci containing several significant SNP associations at the standard genome-wide 
Bonferroni-corrected threshold of PJMA<5×10
−8, when considering interaction with ever-
smoking (Figure 1A) or pack-years (Figure 1B). The SNP associations from both loci also 
exceeded the more conservative genome-wide significance threshold of PJMA<1.25×10
−8, 
based on additional Bonferroni correction for the four JMA models.
The most statistically significant result was for rs7594321, an intronic SNP located in 
DNER (delta/notch-like EGF-related receptor) on chromosome 2, which gave PJMA = 
2.64×10−9 (corresponding PINT = 0.27) in the ever-smoking model and PJMA = 5.00×10
−11 
a
b
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C
D
Figure 1. Genome-wide joint meta-analysis (JMA) of SNP and SNP-by-smoking interaction in relation to 
pulmonary function.
The Manhattan plots show the chromosomal position of SNPs in comparison to their 2log10 PJMA values. 
JMA results are shown for models with (A) SNP by-ever-smoking interaction term in relation to FEV1/FVC, 
(B) SNP-by-pack-years interaction term in relation to FEV1/FVC, (C) SNP-by-ever-smoking interaction term 
in relation to FEV1, and (D) SNP-by-pack-years interaction term in relation to FEV1. SNPs located within 
previously implicated loci are shown, but these loci were not considered when identifying novel loci from 
the joint modeling of SNP main effects and smoking interactive effects. Novel loci on chromosomes 2, 6, 
and 17 (shown in blue and circled) were identified as those having SNPs with genome-wide significant P 
values at the standard threshold (P < 5 x 10-8 as indicated by the solid red line). Names of the novel gene 
(or closest genes) are provided.
98 Chapter 3.3 Gene-by-Environment interaction and pulmonary function 99
Ta
bl
e 
1.
 G
en
om
e-
w
id
e 
si
gn
ifi
ca
nt
 S
N
Ps
 fr
om
 th
e 
jo
in
t m
et
a-
an
al
ys
is
 (J
M
A
) o
f S
N
P 
an
d 
SN
P-
by
-s
m
ok
in
g 
(e
ve
r-
sm
ok
in
g 
or
 p
ac
ky
ea
rs
) i
nt
er
ac
tio
n 
in
 re
la
tio
n 
to
 
pu
lm
on
ar
y 
fu
nc
tio
n.
sn
P 
(c
od
ed
al
le
le
)
Ch
r
G
en
e/
cl
os
es
t
ge
ne
(s
)
Co
de
d 
al
le
le
fr
eq
ue
nc
y1
jm
a
 re
su
lt
s
sm
ok
in
g
m
et
ri
c
β s
n
P
sE
sn
P2
P s
n
P
β I
n
T3
sE
In
T
P I
n
T
P j
m
a
SN
Ps
 im
pl
ic
at
ed
 in
 re
la
tio
n 
to
 F
EV
1/
FV
C
rs
75
94
32
1 
(T
)
2q
36
.3
D
N
ER
0.
35
Ev
er
-s
m
ok
in
g
0.
04
9
0.
00
97
4.
14
 x
 1
0-
7
-0
.0
15
0.
01
3
0.
27
2.
64
 x
 1
0-
9
Pa
ck
-y
ea
rs
0.
04
8
0.
00
70
7.
03
 x
 1
0-
12
-0
.0
00
20
0.
00
00
74
6.
88
 x
 1
0-
3
5.
00
 x
 1
0-
11
rs
77
64
81
9 
(T
)
6p
21
.3
2
H
LA
-D
Q
B1
/ 
H
LA
D
Q
A2
0.
89
Ev
er
-s
m
ok
in
g
-0
.0
60
0.
01
5
6.
32
 x
 1
0-
5
-0
.0
01
0
0.
02
1
0.
63
4.
39
 x
 1
0-
9
Pa
ck
-y
ea
rs
-0
.0
64
0.
01
1
5.
95
 x
 1
0-
9
-0
.0
00
05
8
0.
00
01
0
0.
56
4.
35
 x
 1
0-
9
SN
Ps
 im
pl
ic
at
ed
 in
 re
la
tio
n 
to
 F
EV
1
rs
11
65
47
49
 (T
)
17
q2
4.
3
KC
N
J2
/S
O
X9
0.
39
Ev
er
-s
m
ok
in
g
-0
.0
28
0.
00
94
2.
46
 x
 1
0-
3
-0
.0
17
0.
01
3
0.
17
1.
28
 x
 1
0-
8
Pa
ck
-y
ea
rs
-0
.0
38
0.
00
6
2.
29
 x
 1
0-
8
0.
00
00
47
0.
00
00
68
0.
49
6.
63
 x
 1
0-
8
A
ft
er
 re
m
ov
in
g 
SN
Ps
 w
ith
 k
no
w
n 
as
so
ci
at
io
ns
 w
ith
 F
EV
1/
FV
C 
or
 F
EV
1, 
th
re
e 
no
ve
l l
oc
i w
ith
 g
en
om
e-
w
id
e 
si
gn
ifi
ca
nt
 S
N
Ps
 (s
ta
nd
ar
d 
th
re
sh
ol
d 
of
 P
 <
 5
 x
 1
0-
8 ) 
re
m
ai
ne
d 
fr
om
 th
e 
JM
A
 te
st
in
g 
in
 th
e 
cu
rr
en
t s
tu
dy
. T
he
 m
os
t s
ig
ni
fic
an
t S
N
P 
fr
om
 e
ac
h 
lo
cu
s 
is
 s
ho
w
n.
 F
EV
1, 
fo
rc
ed
 e
xp
ira
to
ry
 v
ol
um
e 
in
 th
e 
fir
st
 s
ec
on
d;
 F
VC
, f
or
ce
d 
vi
ta
l 
ca
pa
ci
ty
; J
M
A
, j
oi
nt
 m
et
a-
an
al
ys
is
; S
E,
 s
ta
nd
ar
d 
er
ro
r ;
 S
N
P, 
si
ng
le
 n
uc
le
ot
id
e 
po
ly
m
or
ph
is
m
. 1
W
ei
gh
te
d 
av
er
ag
e 
co
de
d 
al
le
le
 fr
eq
ue
nc
y 
ac
ro
ss
 th
e 
19
 s
tu
di
es
. T
he
 
co
de
d 
al
le
le
 re
fe
rs
 to
 th
e 
eff
ec
t a
lle
le
. 2
β S
N
P, 
pe
r a
lle
le
 c
ha
ng
e 
in
 th
e 
FE
V 1
/F
VC
 s
ta
nd
ar
di
ze
d 
re
si
du
al
 d
ue
 to
 th
e 
SN
P 
m
ai
n 
as
so
ci
at
io
n.
 3 β
IN
T, 
pe
r a
lle
le
 c
ha
ng
e 
in
 th
e 
FE
V 1
/
FV
C 
st
an
da
rd
iz
ed
 re
si
du
al
 d
ue
 to
 th
e 
in
te
ra
ct
io
n 
be
tw
ee
n 
SN
P 
an
d 
sm
ok
in
g.
100 Chapter 3.3
a
b
Gene-by-Environment interaction and pulmonary function 101
(corresponding PINT = 0.0069) in the pack-years model (Table 1). For the ever/never-
smoking interaction model, the observed level of significance for the JMA is plausible 
in the presence of a nominally significant SNP main effect and a nonsignificant interac-
tive effect, as detailed in Text S1. The rs7594321 T allele had a positive β coefficient for 
the genetic main association and a negative β coefficient for the interaction (Table 1, 
Table S4 for study-specific results). The regression coefficients correspond to a per allele 
change of 0.049 (95% CI: 0.030, 0.068) in never-smokers and 0.035 (95% CI: 0.016, 0.053) 
in ever-smokers. A conserved binding site for the Zic1 transcription factor is located 
115 base pairs away from rs7594321. Further, rs7594321 is located upstream of the 
previously implicated PID1 gene (Figure 2A), but it is 713 kb away from the previously 
implicated SNP (rs1435867), which is located downstream of PID1. There is no linkage 
disequilibrium (LD) between rs7594321 and rs1435867 (r2 = 0, D’ = 0).
Our next most statistically significant SNP (rs7764819) is intergenic between two human 
leukocyte antigen (HLA) genes, HLA-DQB1 and HLA-DQA2, on chromosome 6 (Figure 2B). 
C
Figure 2. Regional association plots of novel loci implicated for pulmonary function
Three novel loci contained SNPs associated with FEV1/FVC or FEV1 at the standard genome-wide 
significance threshold (P< 5 x 10-8) in joint meta-analyses of SNP and SNP-by smoking interaction. SNPs 
are shown within 500 kb of the most significant SNPs on chromosomes (A) 2q36.3 associated with FEV1/
FVC, (B) 6p21.32 associated with FEV1/FVC, and (C) 17q24.3 associated with FEV1. Pairwise r
2 values were 
based on the HapMap CEU population, and progressively darker shades of gray indicate higher r2 values. 
Estimated recombination rates from HapMap are shown as background lines.
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The HLA-DQ region is highly variable, and the association signal in this region is largely 
driven by two SNPs that are in high LD with one another (rs7764819 and rs7765379, r2 
= 1) but only low to moderate LD with all other genotyped and imputed SNPs. A GWAS 
meta-analysis of asthma implicating the HLA-DQ region similarly found highly signifi-
cant associations with only a few SNPs 24. Our top SNP rs7764819 gave PJMA = 4.39×10
−9 
in the ever-smoking model and PJMA = 4.35×10
−9 in the pack-years model for FEV1/FVC 
(Table 1). The corresponding PINT values were >0.05 (see Text S1). The rs7764819 T allele 
had negative β coefficients for both the main association and interaction (Table 1, Table 
S5 for study-specific results), which correspond to a SNP effect of −0.060 (95% CI: −0.09, 
−0.031) in never-smokers and −0.070 (95% CI: −0.10, −0.042) in ever-smokers. Although 
rs7764819 is located 529 kb away from a previously implicated AGER SNP (rs2070600), 
there is some LD between the two SNPs (r2 = 0.29, D’ = 0.81). Conserved binding sites for 
two transcription factors, HTF and Lmo2, are located within 100 kb of rs7764819.
‘Besides the DNER and HLA-DQB1/HLA-DQA2 loci, SNPs from 12 other chromosomal 
regions having PJMA values between 5×10
−8 and 1×10−6 from either smoking model in 
relation to FEV1/FVC are presented in Table S6. Secondary meta-analyses of the interac-
tion product terms alone identified no SNP-by-smoking (ever-smoking or pack-years) 
interactions at genome-wide statistical significance with FEV1/FVC. SNPs from two 
chromosomal regions had PINT values between 5×10
−8 and 1×10−6 in relation to FEV1/
FVC, as shown in Table S7.
For FEV1, the JMA of SNP and SNP-by-smoking gave genome-wide significant associa-
tions (PJMA<5×10
−8) in the ever-smoking model for four SNPs on chromosome 17 (Figure 
1C). However, these SNP associations did not exceed the more conservative significance 
threshold of PJMA<1.25×10
−8. No novel loci reached genome-wide significance level in 
the pack-years model in relation to FEV1 (Figure 1D).
The most significant SNP (rs11654749) from both smoking models is intergenic between 
KCNJ2 (a potassium inwardly-rectifying channel also known as KIR2.1) and SOX9 (sex 
determining region Y-box 9) (Figure 2C). Conserved binding sites for four transcription 
factors (HNF-1, CP2, Cdc5, and FOXF2) are located within 100 kb upstream or down-
stream of rs11654749. The rs11654749 SNP gave PJMA = 1.28×10
−8 in the ever-smoking 
model and PJMA = 6.63×10
−8 in the pack-years model (Table 1). The corresponding PINT 
values were >0.05 (see Text S1). The rs11654749 T allele had negative β coefficients for 
both the main association and interaction (Table 1, Table S8 for study-specific results). 
These estimates correspond to a SNP effect of −0.028 (95% CI: −0.047, −0.010) in never-
smokers and −0.046 (95% CI: −0.063, −0.029) in ever-smokers. To better understand the 
magnitude of these β estimates, we compared our results with those observed in one of 
our previous GWAS meta-analyses of SNP main effects 9, where standardized residuals of 
the pulmonary function measures were similarly computed. For a SNP with MAF around 
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40%, an absolute β value of 0.028 would be equivalent to 19 mL per copy of the risk 
allele (comparable to a year of FEV1 decline in healthy never-smokers), and an absolute 
β value of 0.046 would be equivalent to 31 mL per copy of the risk allele (comparable to 
a year and a half of FEV1 decline in healthy never-smokers) 
25.
Besides this KCNJ2/SOX9 locus, SNPs from five other chromosomal regions have PJMA val-
ues between 5×10−8 and 1×10−6 from either smoking model in relation to FEV1 as shown 
in Table S6. In secondary meta-analyses of the interaction product terms, there were no 
SNP-by-smoking (ever-smoking or pack-years) interactions implicated at genome-wide 
statistical significance with FEV1. SNPs from four chromosomal regions had PINT values 
between 5×10−8 and 1×10−6 in relation to FEV1, as shown in Table S7.
None of the most significant SNPs from the three novel loci we identified by the JMA 
were associated with FEV1/FVC or FEV1 at or near genome-wide significance in our 
previous GWAS meta-analysis of 48,201 participants from the CHARGE and SpiroMeta 
Consortia. In fact, the lowest P value observed for these SNPs was 1.04×10−5 (Table 2) 10.
To evaluate whether the three novel loci identified by the JMA were related to smoking, 
we evaluated their SNP associations with ever-smoking and cigarettes per day using 
GWAS meta-analysis results from the Oxford-GlaxoSmithKline (Ox-GSK) Consortium (N = 
41,150) 26. None of our implicated SNPs were associated with these smoking phenotypes 
at P<0.05 (Table S9), adding confidence that our JMA-implicated SNP associations were 
not simply reflective of smoking main effects.
Table 2. Look-up evaluation of SNP main associations with FEV1/FVC and FEV1 using data generated by 
our previous genome wide association study meta-analysis (N = 48,201), for the most significant SNP from 
each of the three novel loci implicated at genome-wide significance in the joint meta-analysis.
snP (coded 
allele)
Gene/
closest 
gene(s)
FEV1/FVC FEV1
β1 sE P β1 sE P
rs7594321 (T) DNER 0.032 0.0072 1.04 x 10-5 0.0081 0.0074 0.27
rs7764819 (T) HLA-DQB1/
HLA-DQA2
-0.044 0.011 8.79 x 10-5 -0.0073 0.011 0.52
rs11654749 (T) KCNJ2/
SOX9
-0.023 0.0071 0.0015 -0.031 0.0072 1.23 x 10-5
FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; SE, standard error; SNP, single 
nucleotide polymorphism. 1βSNP, per allele change in the FEV1/FVC standardized residual due to the SNP 
main association.
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Expression analyses
Three genes (DNER, KCNJ2, and SOX9) harboring or flanking novel genome-wide signifi-
cant SNPs were selected for follow-up mRNA expression profiling in human lung tissue 
and a series of primary cells. Transcripts of all three genes were found in lung tissue, 
airway smooth muscle, and bronchial epithelial cells; DNER and KCNJ2 transcripts were 
also found in peripheral blood cells (Table S10).
In a separate line of investigation, using the publically available Gene Expression Om-
nibus repository 27,28, we found that the expression profiling of DNER and SOX9 showed 
differential expression in human airway epithelium of smokers compared to non-
smokers (Figure S2A and S2B) 29. Expression profiling of KCNJ2 did not show statistically 
significant differential expression by smoking status (Figure S2C) 30. We also identified 
novel genome-wide significant SNPs in the HLA-DQ region, but we did not examine 
HLA-DQ expression given the known expression of class II MHC antigens on a range of 
airway cell types 31, 32. However, the lead SNP in this region (rs7764819) was associated 
with statistically significant effects on HLA-DQB1 expression (P = 1.2×10−14), according to 
an eQTL analysis database of lymphoblastoid cell lines 33.
DIsCussIOn
Few GWAS have accounted for potential interaction with environmental risk factors. To 
identify novel genetic risk factors that are missed when considering only genetic main 
effects 34, we used the newly available JMA method 15 to simultaneously summarize re-
gression coefficients for the main SNP and SNP-by-smoking interactive effects in 50,047 
participants from 19 studies, based on models that were fully saturated for the main 
effect of smoking. This study represents the most comprehensive analysis to date of 
gene-by-smoking interaction in relation to pulmonary function. We identified two novel 
loci (DNER and HLA-DQB1/HLA-DQA2) having highly significant evidence for association 
with FEV1/FVC. A third novel locus (KCNJ2/SOX9) was associated with FEV1. For the most 
significant SNPs at each of these three loci, there was no evidence for heterogeneity 
across the studies (smallest heterogeneity P = 0.59), indicating that the associations 
were not driven by one or a few studies and thus reflect accumulation of evidence across 
the studies. None of these three loci had previously been associated with pulmonary 
function.
The comparison of results with our prior GWAS meta-analysis of SNP main effects 10, 
using a comparable sample size, suggested that the SNP associations for our top SNPs 
were weaker in our previous analyses that examined only genetic main effects. However, 
our analyses and those of Manning et al. 14 suggest that some of the benefit of using the 
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joint test for some findings comes from the careful adjustment for the environmental 
main effect. Thus, future studies aimed at replicating these findings may wish to jointly 
test the SNP main and interactive effects 15,16,33 instead of implementing a standard test 
of only the SNP main effects. If there is no evidence for interaction at a given locus, 
the saturation of the main effect of the environmental factor may be important. The 
joint testing is applicable for both candidate gene 15 and genome-wide 14 approaches. 
Further, there was minimal overlap in the top SNPs associated with FEV1/FVC and FEV1, 
as similarly observed in our previous GWAS meta-analyses of SNP main effects 8-10. 
Given that the biological underpinnings of these discrepant association findings remain 
unknown, future studies should evaluate these genetic loci in the context of the pulmo-
nary function measure for which they were originally implicated.
Given that pulmonary function is a phenotype for which numerous genetic loci have 
been identified in GWAS and smoking is clearly associated with pulmonary function, it 
might seem surprising that none of the genome-wide significant SNPs implicated by the 
JMA demonstrated a substantial interaction per se. The lack of strong interactive effects 
does not negate the well-established harmful effects of cigarette smoking nor the need 
for broad public health campaigns to curb smoking. Instead, our findings demonstrate 
the value of applying the newly developed joint methods to uncover novel genetic risk 
factors that might shed light on the mechanisms leading to reduced pulmonary func-
tion.
Our pattern of SNP main and interactive results resemble the patterns seen in another 
recent application of the same JMA method to incorporate the interaction with body 
mass index (BMI) into GWAS of type 2 diabetes traits (fasting insulin and blood glucose) 
14. In that study with a sample size of 96,453, nearly double that of ours, the top JMA 
finding had a corresponding interaction P value of 1.6×10−4 14. In our study, the smallest 
interaction P value for our top JMA finding was 6.9×10−3. In both our GWAS of smoking 
and pulmonary function and the recent GWAS of BMI and diabetes traits 14, the SNPs 
newly implicated by the JMA had marginally significant associations with the trait under 
study in models with no interaction term, but they became genome-wide significant 
when accounting for the environmental factor (cigarette smoking or BMI) and the SNP-
by-environment interaction. Our JMA included careful modeling of the environmental 
factor to saturate the environmental main effects along with the interaction testing. 
In the GWAS of diabetes traits 14, the careful modeling of the environmental factor ap-
peared to account for some of the novel findings from the JMA, consistent with the 
modest evidence for interaction 14. Although our previous GWAS meta-analysis was 
conducted in ever/never-smoking strata, the regression models were not adjusted for 
smoking status or pack-years 10. Some of our novel JMA findings compared with our 
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previous GWAS findings may reflect, in part, the saturated modeling of the smoking 
main effect rather than the interaction per se.
The current analysis of 50,047 participants included only 1,846 more participants than 
our previous GWAS meta-analysis of SNP main effects 10. To evaluate the likelihood that 
this 3.8% increase in sample size above that in our previous meta-analysis of pulmonary 
function was sufficient to explain our identification of these three novel loci at genome-
wide statistical significance in the current JMA, we calculated the statistical power to 
detect genetic main associations (QUANTO 35) with minor allele frequency (MAF) and β 
estimates comparable to the three genome-wide significant SNPs presented in Table 1. 
The current study (total N = 50,047 participants) had only 0.7% to 4.2% more statistical 
power than our previous GWAS meta-analysis (total N = 48,201 participants) 10, suggest-
ing that the JMA-implicated SNPs are not merely reflective of increased power to detect 
genetic main effects. Instead, our novel JMA findings demonstrate an advantage of the 
method used to jointly test the SNP and SNP-by-smoking interactive effects, including 
the benefit of the saturated modeling of the smoking main effect.
SNPs located in the DNER gene were significantly associated with FEV1/FVC, even at 
the more conservative P value threshold of 1.25×10−8. The JMA results for DNER SNPs 
were driven by both smoking-adjusted main effects and interaction with quantitative 
smoking history. The DNER protein product is a ligand of the Notch signaling pathway 
that has been implicated in neuronal differentiation and maturation 36,37, adipogenesis 38, 
and hair-cell development 39. The Notch pathway is a critical controller of cellular differ-
entiation in multiple organs including the lung 40,41. Interestingly, the expression levels 
of many members of the Notch signaling cascade are significantly altered in airway 
epithelial cells of smokers 30. We confirmed the expression of DNER transcripts in lung 
and peripheral cells, and by mining publicly available transcriptional profiling databases 
29, we found that DNER is expressed in bronchial epithelial cells of non-smoking adults 
and, importantly, its expression is significantly higher in smokers (Figure S2A). Collec-
tively, these results suggest that DNER plays a role in cigarette smoke-induced airflow 
obstruction and further corroborate the importance of the Notch signaling circuitry in 
the pathogenesis of obstructive lung disease.
Also in relation to FEV1/FVC, intergenic SNPs between HLA-DQB1 and HLA-DQA2 ex-
ceeded the more conservative genome-wide significance threshold. The eQTL analyses 
indicated that the lead SNP is associated with expression of HLA-DQB1 specifically. How-
ever, the major histocompatibility complex region is highly polymorphic with complex 
LD patterns, and a few specific functional SNPs might explain the observed associations 
42. Genetic variations within this region have been associated with several autoimmune 
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disorders 43 and asthma 24,44,45, and an interaction between HLA variants and cigarette 
smoking has been previously implicated 46. We found little evidence for interaction 
with smoking at this locus, suggesting that the JMA results were primarily driven by 
smoking-adjusted genetic main effects. It is most likely that this locus was not identified 
in our previous GWAS meta-analysis, because the genetic main associations were not 
evaluated with careful adjustment for smoking status and pack-years. Adjustment for 
smoking in the current analysis may have removed residual variance in the outcome 
that is not attributable to genetic variation 14, thus making the identification of the 
newly associated SNPs possible.
Intergenic SNPs between KCNJ2 and SOX9 were significantly associated with FEV1 at the 
standard P value threshold, but not the more conservative threshold. Similar to the HLA 
region, it appears that the JMA results for the KCNJ2/SOX9 region were primarily driven 
by smoking-adjusted genetic main effects. This region is enriched for long-range regula-
tory elements for SOX9, although the possibility of this region containing KCNJ2 regula-
tory elements cannot be discounted 47. KCNJ2 is a member of the inwardly-rectifying 
potassium channel family, which regulates membrane potential and cell excitability 
and is expressed in many tissues including myocardium, neurons, and vasculature. This 
potassium channel also affects human bronchial smooth muscle tone and airflow limita-
tion 48. Dominant negative mutations in KCNJ2 cause the Andersen syndrome, character-
ized by ventricular arrhythmias, periodic paralysis, and a number of skeletal and cardiac 
abnormalities 49. SOX9 is a transcription factor that is essential for cartilage formation, 50 
but it is also abundantly expressed in other tissues including the respiratory epithelium 
during development 51. Sox9−/− and Sox9+/− mice have multiple skeletal anomalies and 
severe tracheal cartilage malformations and die prematurely from respiratory insuf-
ficiency 50,52. Mutations in SOX9 cause campomelic dysplasia characterized by skeletal 
defects and autosomal sex reversal 53. These individuals develop respiratory distress due 
to chest wall abnormalities, narrowed airways resulting from tracheobronchial defects 
and hypoplastic lungs 54. We confirmed that KCNJ2 and SOX9 transcripts were present in 
human lung tissue and peripheral cells. Using publicly available microarray data 29, we 
established that SOX9 is expressed in human airway epithelial cells and its expression 
is significantly down-regulated in smokers relative to non-smoking adults (Figure S2B). 
Taken together, these results suggest that SOX9 may be involved in cigarette smoke-
induced airflow obstruction, but further investigation is required to elucidate putative 
mechanisms.
Most of the previously implicated SNPs had genome-wide significant (or nearly sig-
nificant) associations with pulmonary function in the JMA, but some were associated 
with pulmonary function at P values that did not approach the genome-wide statistical 
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significance threshold in the JMA analysis. This pattern has two possible explanations. 
First, the identification of these SNPs at genome-wide statistical significance in our most 
recent analysis 10 required a sample size of nearly 95,000 individuals, which was obtained 
by combining discovery and replication cohorts, including additional genotyping on 
thousands of participants from studies without GWAS data. In the current analysis, the 
sample size is greatly reduced because of the need for detailed quantitative smoking 
data and because we were unable to perform additional genotyping in studies without 
GWAS data. Second, Manning et al.15 showed that a meta-analysis of main SNP effects 
has slightly greater power than the JMA under the scenario of no interaction, so it is not 
surprising that a few of the prior SNP findings had varying levels of significance between 
our prior GWAS meta-analyses 8-10 and the current JMA study. While our sample size of 
over 50,000 study participants is large, and the study of Manning et al. 14 examining SNP-
by-BMI interaction in relation to fasting insulin is nearly twice as large, identification of 
interactions is challenging from a statistical power perspective. Given the multiple test-
ing issues in genome interaction testing, even larger sample sizes will likely be needed 
to identify gene-by-environment interactions with rare variants or with the modest 
effect sizes that we generally expect. Nonetheless, our findings exemplify the greater 
power achieved by using the joint methods, such as those reported by Manning et al. 
15 and Kraft et al. 16,34, to incorporate interaction with a clearly associated environmental 
risk factor. The novel genetic loci identified here for pulmonary function would have 
remained unknown using standard GWAS approaches.
mEThODs
Ethics statement
Nineteen independent studies contributed to our analyses. All study protocols were 
approved by the respective local Institutional Review Boards, and written informed 
consent for genetic studies was obtained from all participants included in our analyses.
Cohort studies
Of the 19 studies contributing to our analyses, 18 studies came from the CHARGE 8,55 
or SpiroMeta 9 Consortium: Age, Gene, Environment, Susceptibility (AGES) – Reykjavik 
Study 56; Atherosclerosis Risk in Communities (ARIC) Study 57; British 1958 Birth Cohort 
(B58C) 58; Coronary Artery Risk Development in Young Adults (CARDIA) 59,60; Cardiovas-
cular Health Study (CHS) 61; European Community Respiratory Health Survey (ECRHS) 
62; European Prospective Investigation into Cancer and Nutrition (EPIC, obese cases 
and population-based subsets) 63; Framingham Heart Study (FHS) 64,65; Health, Aging, 
and Body Composition (Health ABC) Study 66; Northern Finland Birth Cohort of 1966 
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(NFBC1966) 67,68; Multi-Ethnic Study of Atherosclerosis (MESA) 69,70; Rotterdam Study 
(RS-I, RS-II, and RS-III) 71; Swiss Study on Air Pollution and Lung Diseases in Adults (SA-
PALDIA) 72; Study of Health in Pomerania (SHIP) 73; and TwinsUK 74. We reached out to 
other population-based studies with GWAS genotyping and data available on cigarette 
smoking and pulmonary function, resulting in the inclusion of LifeLines 75. Given the 
greater power needed to detect novel genetic loci with subtle gene-environment in-
teraction regardless of the statistical method used 16, we chose to maximize statistical 
power to discover novel genetic loci by combining all available participants and to use 
the regression coefficients across the many different component studies as evidence for 
consistency. This approach was similarly taken by another large-scale GWAS consortium 
for discovering SNP main effects 24.
Pulmonary function measurements and smoking information
All studies were included in our previous GWAS meta-analysis of pulmonary function or 
the follow-up replication analyses, wherein their pulmonary function testing protocols 
were described 10. For studies with spirometry at a single visit (B58C, LifeLines, MESA, 
NFBC1966, SHIP, RS-I, RS-II, and RS-III), we analyzed FEV1/FVC and FEV1 measured at that 
visit. For studies with spirometry at more than one visit, we analyzed measurements from 
the baseline visit (AGES, ARIC, CARDIA, CHS, ECRHS, EPIC obese cases, EPIC population-
based, Health ABC, and SAPALDIA) or the most recent examination with spirometry data 
(FHS and TwinsUK).
Smoking history (current-, past-, and never-smoking) was ascertained by questionnaire 
at the time of pulmonary function testing. Pack-years of smoking were calculated for 
current and past smokers by multiplying smoking amount (packs/day) and duration 
(years smoked). Table S11 presents the specific questions used to ascertain smoking 
history and pack-years in each of the 19 studies.
Genotyping, quality control, and imputation
Study participants were genotyped on various genotyping platforms, and standard 
quality control filters for call rate, Hardy-Weinberg equilibrium p-value, MAF, and other 
measures were applied to the genotyped SNPs (Table S12). To generate a common set of 
SNPs for meta-analysis, imputation was conducted with reference haplotype panels from 
HapMap phase II subjects of European ancestry (CEU) (Table S12) 76. Imputed genotype 
dosage values (estimated reference allele count with a fractional value ranging from 0 
to 2.0) were generated for approximately 2.5 million autosomal SNPs. Among partici-
pants with genome-wide SNP genotyping data, exclusions were made due to standard 
quality control metrics (call rate, discordance with prior genotyping, and genotypic and 
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phenotypic sex mismatch among others), missing pulmonary function data, or missing 
covariate data (Table S13).
statistical analysis
Our analyses included 50,047 participants from 19 studies who passed their study-spe-
cific quality control and had complete data on pulmonary function and smoking. Each 
study transformed the pulmonary function measures to residuals using linear regres-
sion of FEV1/FVC (%) and FEV1 (mL) on age, age
2, sex, and standing height as predictors. 
Principal component eigenvectors and recruitment site were also included as covariates 
to adjust for population stratification (if applicable). The residuals were converted to 
z scores (henceforth referred to as standardized residuals). We confirmed that smok-
ing was inversely associated with the FEV1/FVC and FEV1 standardized residuals in all 
19 studies (meta-analysis β = −0.0030 and corresponding P<1×10−6 for pack-years of 
smoking).
The FEV1/FVC and FEV1 standardized residuals were used as the phenotypes for genome-
wide association testing with linear regression models, which included the following 
predictor variables: imputed SNP genotype dosages, smoking history (dichotomous 
variable, 0 = never-smokers and 1 = ever-smokers), smoking status (dichotomous vari-
able, 0 = never- and past-smokers and 1 = current-smokers), pack-years of smoking 
(continuous variable), and a SNP-by-smoking interaction product term. Two of the 19 
studies (FHS and TwinsUK) had much relatedness among participants, and we took ap-
propriate account of relatedness in the association testing (Table S12). Four regression 
models with interaction terms for ever-smoking or pack-years were specified in relation 
to standardized residuals for FEV1/FVC or FEV1. As it has long been advised in studying 
interactions, the regression models were designed to fully saturate the main smoking 
effect on pulmonary function, so that the interaction terms do not capture residual main 
effects 77. In each of the 19 studies, the genome-wide analyses were implemented with 
robust variance estimation using the software packages indicated in Table S12.
Our analyses were aimed at finding novel loci associated with pulmonary function when 
considering an interaction with cigarette smoking, so we chose to implement JMA of 
SNP main and interactive SNP-by-smoking effects (two d.f. test of the null hypothesis βSNP 
= 0 and βINT = 0) 
15. Manning et al. previously compared the joint methods, such as JMA, 
with other methods that incorporate gene-environment interaction (such as screening 
by main effects 78 or conducting a 1 d.f. meta-analysis of the interaction product term), 
and they found that the joint methods offer optimal statistical power over a range of 
scenarios for SNP main and interactive effects 15,34. Therefore, our analyses centered on 
the JMA method, which simultaneously estimates regression coefficients for the SNP and 
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SNP-by-smoking interaction terms, while accounting for their covariance, to generate a 
joint test of significance 15. It also accounts for the unequal variances from studies of dif-
ferent sample sizes. Secondarily, we implemented meta-analyses of just the β coefficient 
from the interaction term for comparison with the JMA results. Of note, the two-step 
gene-environment interaction study designs by Murcray et al. 79,80 and Gauderman et al. 
81 are applicable to case-control or case-parent trio studies, respectively, and were thus 
not considered for our population-based studies of continuous traits.
The JMA was conducted with fixed effects on approximately 2.5 million SNPs using 
METAL software (version 2010-02-08) 82 and patch source code provided by Manning 
et al. 82. Genomic control correction was applied by computing λgc as the ratio of the 
observed and expected (2 d.f.) median chi-square statistics and dividing the observed 
chi-square statistics by λgc. SNPs having PJMA<5×10
−8 (the standard Bonferroni-adjusted 
P value) were considered statistically significant 83. Further correction for the four dif-
ferent (albeit related) JMA models yielded a conservative PJMA threshold of 1.25×10
−8. 
In addition to reporting the PJMA for the most significant SNP from each novel locus, we 
used the β and standard error (SE) estimates from the JMA results to calculate the P 
values corresponding to the SNP main association (PSNP) and the SNP-by-ever-smoking 
interaction (PINT) 
15.
bioinformatics analysis
Gene annotation was performed using the gene prediction tracks “UCSC Genes” and 
“RefSeq Genes” in the UCSC browser (http://genome.ucsc.edu). The “sno/miRNA” track 
from the USCS browser was used to search for any microRNA within 100 kb upstream 
or downstream of each SNP, and the “TFBS Conserved” track was used to search for 
conserved transcription factor binding sites (TFBSs) at or near the most significant SNPs. 
The SNAP program 84 was used to infer LD patterns, based on the HapMap phase II CEU 
population.
Expression analyses
We used separate types of expression analyses to confirm the biologic plausibility of 
our findings. First, we carried out mRNA expression profiling to show whether or not the 
implicated genes are expressed in human tissues relevant to pulmonary function. The 
mRNA expression profiles of implicated genes were determined using reverse transcrip-
tion polymerase chain reaction (RT-PCR). RNA was sourced from lung (Ambion/ABI), 
human bronchial epithelial cells (Clonetics) 85, and peripheral blood mononuclear cells 
(3H Biomedica). RNA from human airway smooth muscle cells, cultured as previously 
described from tissue obtained at thoracotomy 86, was extracted using a commercially 
available kit (Qiagen). Ethical approval for the use of primary cells was obtained from 
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the local ethics committees. cDNA was generated using 1 µg of RNA template using 
random hexamers and a SuperScript kit (Invitrogen) as directed by the manufacturer. 
PCR assays were designed to cross intron-exon boundaries, where possible and where 
splice variation was known, in order to detect all variants. The GAPDH gene was used 
as a positive control for the cDNA quality, and water was used as a negative control. 
Primer sequences for the genes of interest are given in Table S14. All PCR were done 
using Platinum Taq High Fidelity (Invitrogen) with 100 ng of cDNA template in a 25 µL 
reaction. Cycling conditions were as follows: 94°C for 2 minutes, 35 cycles of 94°C for 45 
seconds, 55°C for 30 seconds, and 68°C for 90 seconds. Following PCR, gel bands were 
directly sequenced to confirm the presence of the gene’s transcript.
Second, we used another publically available data repository to investigate whether 
any of the implicated genes showed evidence for differential expression depending on 
smoking history. The gene expression profiles of human airway epithelium from healthy 
smokers (N = 10) and nonsmokers (N = 12) were obtained from the Gene Expression 
Omnibus site (http://www.ncbi.nlm.nih.gov/geo/) 27,28, based on robust multichip aver-
age processing of probe intensities from Affymetrix HG-U133 Plus 2.0 microarrays (GEO 
dataset number GSE4498) 29. Mean expression levels of genes around our genome-wide 
significant findings from the JMA were compared between smokers versus nonsmokers. 
The P value for the difference in means between smokers and nonsmokers was calcu-
lated using the nonparametric Mann-Whitney test.
Third, our genome-wide significant SNPs from novel loci were searched against an 
expression quantitative trait loci (eQTL) data repository based on lymphoblastoid cell 
lines 33, to investigate whether any of the implicated SNP variants might influence the 
expression of the nearby genes. P<5×10−8 was used to designate statistically significant 
eQTL associations.
All supplementary files and figures can be found via: 
http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1003098
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absTraCT
Introduction Rationale Genome-wide association studies (GWAS) have identified loci 
influencing lung function, but fewer genes influencing chronic obstructive pulmonary 
disease (COPD) are known.
Objectives Perform meta-analyses of GWAS for airflow obstruction, a key pathophysi-
ologic characteristic of COPD assessed by spirometry, in population-based cohorts ex-
amining all participants, ever smokers, never smokers, asthma-free participants, and 
more severe cases.
methods Fifteen cohorts were studied for discovery (3,368 affected; 29,507 unaffected), 
and a population-based family study and a meta-analysis of case-control studies were 
used for replication and regional follow-up (3,837 cases; 4,479 control subjects). Airflow 
obstruction was defined as FEV1 and its ratio to FVC (FEV1/FVC) both less than their 
respective lower limits of normal as determined by published reference equations.
measurements and main results The discovery meta-analyses identified one region 
on chromosome 15q25.1 meeting genome-wide significance in ever smokers that 
includes AGPHD1, IREB2, and CHRNA5/CHRNA3 genes. The region was also modestly 
associated among never smokers. Gene expression studies confirmed the presence 
of CHRNA5/3 in lung, airway smooth muscle, and bronchial epithelial cells. A single-
nucleotide polymorphism in HTR4, a gene previously related to FEV1/FVC, achieved 
genome-wide statistical significance in combined meta-analysis. Top single-nucleotide 
polymorphisms in ADAM19, RARB, PPAP2B, and ADAMTS19 were nominally replicated in 
the COPD meta-analysis.
Conclusions These results suggest an important role for the CHRNA5/3 region as a 
genetic risk factor for airflow obstruction that may be independent of smoking and 
implicate the HTR4 gene in the etiology of airflow obstruction.
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InTrODuCTIOn
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death world-
wide, and cigarette smoking is the most widely recognized risk factor for this disease. 
COPD is defined based on spirometry as airflow obstruction that is not fully reversible 
after administration of a bronchodilator. Airflow obstruction is a key pathophysiologic 
characteristic of COPD that is assessed by spirometry. Both COPD and spirometry mea-
sures of lung function have been demonstrated to have a genetic component. Family 
studies have reported an increased risk for COPD in relatives of a COPD proband 1 as well 
as significant heritability of pulmonary function measured by spirometry in population-
based cohorts 2. The α1-antitrypsin gene (SERPINA1/A1AT) is known to be associated 
with COPD and leads to increased risk for early-onset disease among individuals carry-
ing the susceptibility alleles, but few other genes have such a conclusive relationship to 
COPD.
Recent genome-wide association studies (GWAS) have examined two spirometry 
measures of lung function, FEV1 and its ratio to FVC (FEV1/FVC). Two large-scale GWAS 
meta-analyses identified a total of 11 loci related to FEV1 or FEV1/FVC 
3,4, and a larger 
meta-analysis incorporating these studies along with new studies identified an ad-
ditional 16 loci 5. Two genetic loci identified by the above studies, HHIP and FAM13A, 
have been demonstrated to influence risk of COPD at genome-wide levels of statistical 
significance 6-9. GWAS of COPD have also identified associations with SNPs in a region 
on chromosome 15q25.1 that includes cholinergic nicotinic receptor genes (CHRNA5-
CHRNA3-CHRNB4) and the iron-responsive element binding protein 2 (IREB2) 7, but some 
questions remain as to the underlying genetic signal because of substantial linkage 
disequilibrium in the region. This region has also been associated with lung cancer 10,11 
and nicotine dependence 12-15, leading to the hypothesis that the association with the 
various disease endpoints may be mediated through the nicotinic receptor genes and 
thus smoking, smoking intensity, and cessation 16. In a meta-analysis of lung cancer 
among never smokers, no association to the CHRNA genes was observed, supporting 
the hypothesis that association was mediated through smoking behavior 17. However, 
the observation of increased IREB2 protein and mRNA expression in COPD lung tissue 
compared with controls supports its potential involvement as well 18.
The standard definition of COPD is based on the presence of airflow obstruction that 
persists after administration of bronchodilator 19. In large population-based cohorts, 
post-bronchodilator spirometry is not generally available, so we have studied prebron-
chodilator airflow obstruction as a proxy for COPD. In this study, we performed GWAS 
using a standardized definition of airflow obstruction and control subjects across 15 
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population-based cohort studies and conducted a meta-analysis. We then sought rep-
lication of our top single-nucleotide polymorphisms (SNPs) and regions in a set of four 
COPD case-control studies previously included in a meta-analysis and in a population-
based family study that used the same airflow obstruction phenotype definitions used 
in the discovery analyses.
mEThODs
Discovery Phase
Most of the cohorts used in the discovery phase of this meta-analysis were included 
in meta-analyses of cross-sectional quantitative pulmonary function measures in the 
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium3, 
the SpiroMeta consortium 4, and/or their joint analysis 5. Cohorts not included in pre-
vious GWAS discovery sets for pulmonary function include Rotterdam Study III (RS3), 
Swiss Study on Air Pollution and Lung and Heart Disease in Adults (SAPALDIA), Lothian 
Birth Cohort (LBC1936), Multi-Ethnic Study of Atherosclerosis (MESA), and COPD Pathol-
ogy: Addressing Critical gaps, Early Treatment and diagnosis, and Innovative Concepts 
(COPACETIC). All of the included participants are white and of European descent.
Standardized definitions of airflow obstruction based on the lower limit of normal of 
FEV1 and FEV1/FVC from the National Health and Nutrition Examination Survey III predic-
tion equations 20 were used across all cohorts. The presence of airflow obstruction was 
defined as an FEV1 and FEV1/FVC both less than the lower limit of normal 
21 based on 
prediction equations that include age, age2, and height2 calculated separately by sex. 
Unaffected participants were defined by FEV1, FVC, and FEV1/FVC all above the lower 
limit of normal. Individuals below the lower limit of normal for FEV1 or FEV1/FVC but not 
both were excluded from these analyses. Logistic regression models were adjusted for 
current and former smoking dummy variables, pack-years of smoking, age, sex, stand-
ing height, center/cohort as needed, and principal components for genetic ancestry as 
needed.
Genome-wide imputation and analyses were performed by the cohort investigators, 
and results were shared for meta-analysis. Details of individual cohorts’ imputation and 
GWAS methods are provided in the online supplement text and Table E1 in the online 
supplement. Genome-wide and regional meta-analyses were performed using METAL 
software 22 with inverse variance weighting to combine effect size estimates after apply-
ing a genomic control correction 23.
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Five discovery analyses were performed. GWAS were performed in (1) all cohorts with 
both ever and never smokers, (2) ever smokers, (3) never smokers, (4) asthma-free par-
ticipants, and (5) the subset of more severe airflow obstruction with FEV1 less than 65% 
predicted (excluding milder cases from analysis). Never smoking GWAS were performed 
in eight cohorts. In the 10 cohorts that collected self-reported asthma data, an analysis 
was performed excluding all participants reporting a history of asthma with diagnosis 
before age 40 years or missing onset age.
regional meta-analysis and replication
Two strategies were implemented for follow-up of top results. In two regions with as-
sociation signals spanning multiple genes in discovery meta-analyses, results across the 
whole region were requested from the replication studies, and combined meta-analyses 
were performed to refine the association signal. These regions were located on chromo-
some 6 (27,599,278–32,787,304 bp) and chromosome 15 (76,499,754–76,711,042 bp). In 
addition, 60 SNPs with P values less than or equal to 1 × 10−5 in any of the five discovery 
meta-analyses were selected for replication. Combined meta-analysis was performed 
with the Family Heart Study (FamHS), which evaluated the same airflow obstruction 
phenotype as used in the discovery phase (331 affected and 2,550 unaffected). Rep-
lication was further evaluated in a meta-analysis of studies with clinically ascertained 
COPD (3,499 cases and 1,922 control subjects) 24. Gene expression in lung tissues was 
evaluated for two genes on chromosome 15. Additional details are included in the on-
line supplement: http://www.atsjournals.org/doi/suppl/10.1164/rccm.201202-0366OC/
suppl_file/Wilk_ODS.pdf
rEsuLTs
Descriptive characteristics of the 15 discovery cohorts are provided in Tables 1 and  2. 
The mean FEV1 % predicted for participants with airflow obstruction ranged from 48.9 to 
68.7% across cohorts, and for unaffected participants the means were generally around 
100%. The mean FEV1/FVC ratio ranged from 49.5 to 62.5% among affected participants 
and 74.1 to 81% among unaffected participants across the cohorts. The mean ages at 
measurement of spirometry across the cohorts ranged from 45 to 76 years. The num-
ber of participants contributing to each of the five discovery GWAS meta-analyses are 
provided in Table 3. The genomic control (λGC) values ranged from 0.946 to 1.045 for 
each cohort’s GWAS and from 1.011 to 1.060 in the meta-analysis (Table E2). Figures 
E1 to E5 present the Manhattan and quantile-quantile (QQ) plots for the five discovery 
meta-analyses.
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Discovery meta-analysis
One region on chromosome 15 had 11 SNPs with genome-wide significant results (P 
values < 5 × 10−8) in discovery meta-analysis of ever smokers (Table 4). An SNP in the 
AGPHD1 gene between the IREB2 gene and CHRN gene cluster was the top association 
with airflow obstruction among ever smokers (rs8031948, P value = 2.8 × 10−9) with the 
minor allele conferring a 22% higher risk of airflow obstruction. Among 14 cohorts with 
both smoking and never-smoking participants, the top SNP results for all subjects com-
bined were found in the same chromosome 15 region but localized to the CHRNA5 gene 
(rs17486278, P value = 1.9 × 10−7). For comparison, results among never smokers (504 
affected, 10,690 unaffected from eight cohorts) are included in Table 4, and the smallest 
P value in the region (8.4 × 10−5) occurs at a synonymous SNP (rs1051730) in CHRNA3. 
The odds ratios (OR) shown in Table 4 demonstrate consistency in the effect size for the 
tested allele across the analyses of all cohorts with both ever and never smoking partici-
pants (14 cohorts), ever smokers (15 cohorts), and never smokers (8 cohorts). The results 
Table 1. Descriptive characteristics of cohorts included in the discovery meta-analysis
arIC Fhs Chs COPaCETIC b58C EPIC mEsa
no. affected 914 571 402 312 264 127 104
no. 
unaffected
6,602 5,866 2,183 996 4,374 1,023 979
age, yr 54.3 (5.7) 51.6 (14.6) 72.3 (5.3) 60.2 (5.6) 45.2 (0.39) 58.2 (9.0) 66.1 (9.8)
male, % 47.2 46.4 39.4 39.4 49.6 46.8 49.6
height, cm 169 (9) 168 (10) 165 (9) 165 (9) 169 (9) 167 (9) 169 (10)
bmI, kg/m2 27.0 (4.7) 27.2 (5.2) 26.2 (4.3) - 27.4 (4.9) 26.4 (3.9) 28.0 (5.2)
Current 
smoker, %
21.8 14.2 9.3 9.3 21.3 10.1 7.9
Former 
smoker, %
35.8 38.1 39.7 39.7 49.1 44.6 50.8
Pack-years 
smoking *
27.5 (21.4) 21.9 (21.2) 32.2 (26.7) 39.6 (17.0) 14.7 (11.7) 17.6 (16.0) 29.4 (28.5)
FEV1/FVC
affected 58.1 (8.6) 58.6 (8.3) 52.0 (10.7) 51.0 (9.1) 62.5 (7.0) 57.0 (8.5) 56.6 (9.2)
unaffected 76.6 (4.4) 77.6 (5.3) 74.1 (5.6 75.5 (4.8) 80.9 (5.6) 81.0 (6.4) 75.5 (5.8)
FEV1 % 
predicted
affected 62.2 (13.4 63.2 (12.8) 52.1 (15.5) 58.9 (11.1) 68.7 (9.5) 57.1 (13.8) 61.0 (12.7)
unaffected 99.5 (11.1) 100.4 (11.8) 98.4 (13.5) 105.8 (12.8) 100.7 (10.7) 96.6 (9.9) 98.2 (12.0)
Definition of abbreviations: ARIC = Atherosclerosis Risk in Communities; B58C = British 1958 Birth 
Cohort; CHS = Cardiovascular Health Study; COPACETIC = COPD Pathology: Addressing Critical gaps, 
Early Treatment and diagnosis, and Innovative Concepts; EPIC = European Prospective Investigation into 
Cancer and Nutrition; FHS = Framingham Heart Study; MESA = Multi-Ethnic Study of Atherosclerosis. Data 
are presented as mean (SD) unless otherwise indicated. * Pack-years calculated among current and former 
smokers.
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in Table 4 were based on meta-analyses that included different cohorts as presented 
in Table 3, and thus the ever and never smoker results do not reflect a straightforward 
stratified analysis of all participants. The inclusion of the COPACETIC study in the ever 
smokers meta-analysis contributed to the improved association signal in the region. In 
the GWAS of a more severe airflow obstruction phenotype defined by FEV1 less than 
65% predicted, a missense SNP in the CHRNA5 gene (rs16969968, Asp398Asn) had the 
third ranked P value (5 × 10−7) with an OR of 1.22. No other genome-wide significant 
associations were identified among discovery meta-analyses. In the meta-analysis of 
never smokers (504 affected and 10,690 control subjects), several top SNPs were ob-
served 570 kb away from ADARB2 (the closest gene), and results from the FEV1 less than 
65% meta-analysis also implicated this locus. Among never smokers, the chromosome 
Table 2. Descriptive characteristics of additional cohorts included in the discovery meta-analysis
aGEs health 
abC
rs1 sapaldia bhs rs3 LbC1936 rs2
no. affected 109 108 99 98 89 70 61 40
no. 
unaffected
1,562 1,129 1,003 833 661 1,001 627 668
age, yr 76.2 (5.6) 73.8 (2.8) 74.4 (5.7) 51.0 (11.1) 54.6 
(16.3)
56.6 (5.5) 69.6 (0.9) 67.1 (6.3)
male, % 40.6 52.1 42.9 48.1 44.0 42.3 49.4 43.8
height, cm 167(9) 167 (9) 167 (9) 169 (9) 168 (9) 171 (9) 166 (9) 168 (9)
bmI, kg/m2 27.1 (4.5) 26.5 (4.1) 27.4 (4.0) 25.7 (4.3) 25.8 (4.0) 27.4 (4.6) 27.4 (4.1) 27.6 (4.0)
Current 
smoker, %
9.7 6.6 10.7 20.4 16.4 19..0 11.1 13.4
Former 
smoker, %
42.2 49.0 56.2 32.9 26.8 47.0 40.7 51.7
Pack-years 
smoking *
24.5 
(22.0)
36.0 (32.4) 25.8 (23.0) 21.5 (23.0) 20.1 
(19.6)
18.5 
(18.0)
34.3 (23.1) 23.8 (22.9)
FEV1/FVC
affected 49.5 
(18.1)
56.3 (6.1) 56.0 (7.2) 59.2 (7.3) 58.2 (9.8) 59.2 (8.4) 54.6 (8.6) 56.7 (6.9)
unaffected 75.6 (7.2) 76.0 (5.1) 75.6 (5.4) 76.8 (5.0) 78.4 (5.4) 80.2 (5.8) 80.4 (6.7) 78.2 (5.9
FEV1 % 
predicted
affected 48.9 
(20.2)
55.3 (11.6) 56.9 (11.0) 67.6(10.4) 57.3 (16) 60.4 
(13.3)
50.8 (10) 58.8 (10.5)
unaffected 93.2 
(18.3)
100.2 
(14.0)
102.8 
(18.7)
103.5 
(11.3)
98.9 
(11.7)
104.6 
(13.1)
100.4 
(12.2)
105.5 
(17.3)
Definition of abbreviations: AGES = Age, Gene, Environment Susceptibility; BHS = Busselton Health 
Study; Health ABC = Health, Aging and Body Composition; LBC1936 = Lothian Birth Cohort 1936; RS1 
= Rotterdam Study I; RS2 = Rotterdam Study II; RS3 = Rotterdam Study III; SAPALDIA = Swiss Study on 
Air Pollution and Lung and Heart Disease in Adults. Data are presented as mean (SD) unless otherwise 
indicated. * Pack-years calculated among current and former smokers.
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6 major histocompatability locus (MHC) region was among top results. The discovery 
meta-analysis results for the 60 SNPs selected for replication are included in Table 5. 
Genome-wide results for all five definitions of airflow obstruction are available in the 
online supplement.
meta-analysis of Chromosome 6 and 15 regions with replication studies
Regional meta-analyses were performed to further evaluate the regions on chromo-
somes 6 and 15 with the additional two replication studies. In discovery analysis of all 
Table 3. Sample Sizes Contributed by each cohort for the five discovery meta-analyses of airflow 
obstruction
all Participants Ever smokers never smokers asthma Free* FEV1 < 65 %
†
af-
fected
unaf-
fected
af-
fected
unaf-
fected
af-
fected
unaf-
fected
af-
fected
unaf-
fected
af-
fected
unaf-
fected
arIC 914 6,602 821 3,510 93 3,092 814 6,355 452 6,602
Fhs 571 5,866 457 2,909 114 2,957 391 5,210 274 5,866
Chs 402 2,183 317 950 85 1,233 363 2,135 292 2,183
rs1 99 1,003 87 650 12‡ 353‡ 97§ 967§ 68 1,003
rs2 40 668 37 424 3‡ 244‡ NA NA 29 668
rs3 70 1,001 57 650 13‡ 351‡ NA NA 39 1,001
health 
abC
108 1,129 94 593 14‡ 536‡ 70 1,077 80 1,129
aGEs 109 1,562 81 787 28 775 NA NA 34 1,562
EPIC 127 1,023 79 490 48 533 110 992 88 1,023
bhs 89 661 46 278 43 383 20 421 53 661
saPaLDIa 98 833 59 437 39 396 42 620 38 833
LbC1936 61 627 50 306 11‡ 321‡ 60 622 56 627
b58C 264 4,374 210 3,053 54 1321 183 4,036 75 4,374
COPaCETIC 0 0 312 996 NA NA NA NA 142 996
mEsa 104 979 89 533 15‡ 531‡ 85 923 54 979
Total 3,056 28,511 2,796 16,566 504 10,690 2,138 22,391 1,774 29,507
Definition of abbreviations: Definition of abbreviations: AGES = Age, Gene, Environment Susceptibility; 
ARIC = Atherosclerosis Risk in Communities; B58C = British 1958 Birth Cohort; BHS = Busselton Health 
Study; CHS = Cardiovascular Health Study; COPACETIC = COPD Pathology: Addressing Critical gaps, Early 
Treatment and diagnosis, and Innovative Concepts; EPIC = European Prospective Investigation into Cancer 
and Nutrition; FHS = Framingham Heart Study; Health ABC = Health, Aging and Body Composition; 
LBC1936 = Lothian Birth Cohort 1936; MESA = Multi-Ethnic Study of Atherosclerosis.; RS1 = Rotterdam 
Study I; RS2 = Rotterdam Study II; RS3 = Rotterdam Study III; SAPALDIA = Swiss Study on Air Pollution and 
Lung and Heart Disease in Adults. *Asthma-free: no history of an asthma diagnosis before age 40 years; 
participants reporting asthma with missing data on age at diagnosis were also excluded. † FEV1<65%: 
cases were restricted to those with FEV1 < 65% and FEV1/FVC less than the lower limit of normal; the 
definition of control subjects was the same as used for all participants. NA = Not analyzed due to low 
number of cases. §Results were not available for discovery meta-analysis.
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Table 4. Genome-wide significant results on chromosome 15 from discovery meta-analysis of airflow 
obstruction
Coded allele all*
14 cohorts
never-
smokers
8 cohorts
Ever-
smokers
15 cohorts
snP position gene function
al-
lele
fre-
quency Or
P_
value Or
P-
value Or
P-
value
rs8031948 76603112 AGPHD1 Intronic t 0.35 1.17
4.76E-
07 1.15
1.53E-
03 1.22
2.78E-
09
rs931794 76613235 AGPHD1 Intronic a 0.65 0.86
6.18E-
07 0.87
1.46E-
03 0.82
4.69E-
09
rs10519203 76601101 AGPHD1 Intronic a 0.65 0.86
7.16E-
07 0.86
1.27E-
03 0.82
5.67E-
09
rs9788721 76589924 AGPHD1 Intronic t 0.65 0.86
1.04E-
06 0.86
1.17E-
03 0.82
9.76E-
09
rs2036527 76638670 a 0.34 1.18
3.51E-
07 1.18
2.85E-
04 1.22
1.72E-
08
rs17486278 76654537 CHRNA5 Intronic a 0.66 0.85
1.91E-
07 0.84
1.06E-
04 0.83
2.43E-
08
rs7180002 76661048 CHRNA5 Intronic a 0.66 0.85
2.23E-
07 0.84
1.20E-
04 0.83
2.68E-
08
rs1051730 76681394 CHRNA3
synony-
mous a 0.33 1.17
3.29E-
07 1.20
8.36E-
05 1.21
3.36E-
08
rs16969968 76669980 CHRNA5 missense a 0.34 1.17
3.46E-
07 1.19
1.25E-
04 1.20
3.47E-
08
rs951266 76665596 CHRNA5 Intronic a 0.34 1.17
3.64E-
07 1.19
1.41E-
04 1.21
3.47E-
08
rs1317286 76683184 CHRNA3 Intronic a 0.66 0.85
3.93E-
07 0.84
1.18E-
04 0.83
4.74E-
08
Definition of abbreviation: OR = Odds Ratio. *All cohorts with both ever and never smoking participants
Table 5. Odds ratios (OR) and p-values for the 60 SNPs identified in the discovery meta-analysis and 
selected for replication and combined meta-analysis with the Family Heart Study. SNPs are ordered by the 
combined meta-analysis p-value.
Coded 
allele
Discovery meta-
analysis
Family 
heart 
study*
Combined
meta-
analysis
snP
al-
lele Freq Chr position
Closest 
gene Or
P-
value
analy-
sis Or
P-
val-
ue Or P-value
rs7733088 A 0.38 5 147836526 HTR4 0.82 6.53E-
08
smoker 0.75 0.015 0.81 4.09E-
09
rs2044029 A 0.4 15 69467013 THSD4 1.16 4.95E-
07
all 1.20 0.078 1.17 1.06E-07
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Table 5. (Continued)
Coded 
allele
Discovery meta-
analysis
Family 
heart 
study*
Combined
meta-
analysis
snP
al-
lele Freq Chr position
Closest 
gene Or
P-
value
analy-
sis Or
P-
val-
ue Or P-value
rs181654 A 0.28 10 119369646 EMX2 0.82 1.24E-
06
no 
asthma
0.76 0.030 0.81 1.31E-07
rs4597955 A 0.59 5 147827466 HTR4 0.84 3.12E-
06
smoker 0.76 0.011 0.83 1.57E-07
rs12905014 T 0.95 15 90684844 ST8SIA2 0.58 5.24E-
06
FEV1 
65%
0.47 0.020 0.57 3.83E-07
rs11744671 T 0.92 5 156853809 ADAM19 0.72 8.25E-
07
no 
asthma
0.77 0.264 0.72 4.51E-07
rs8033889 T 0.21 15 69467134 THSD4 1.18 2.49E-
06
all 1.23 0.066 1.19 4.67E-07
rs6684428 A 0.16 1 56132401 PPAP2B 1.24 3.60E-
07
smoker 1.08 0.574 1.23 4.73E-07
rs4767234 A 0.59 12 113122231 TBX5 1.18 1.28E-
06
smoker 1.15 0.242 1.17 6.32E-07
rs4534959 A 0.97 18 60028136 SERPINB8 0.57 4.19E-
07
FEV1 
65%
0.91 0.844 0.58 6.90E-07
rs715921 A 0.31 13 23693489 SPATA13 1.22 5.18E-
07
no 
asthma
1.07 0.551 1.20 7.60E-07
rs16889038 T 0.92 6 24414366 DCDC2 0.7 4.15E-
07
FEV1 
65%
0.95 0.845 0.72 7.94E-07
rs9536318 A 0.83 13 52392695 PCDH8 0.81 5.47E-
06
no 
asthma
0.75 0.051 0.80 8.24E-07
rs1997352 A 0.26 3 25513321 RARB 0.85 4.29E-
06
all 0.82 0.076 0.84 8.64E-07
rs10759102 A 0.33 9 9900123 PTPRD 0.81 4.66E-
06
FEV1 
65%
0.77 0.083 0.81 1.04E-06
rs13144621 T 0.32 4 109437378 LEF1 0.85 5.87E-
07
all 0.98 0.850 0.86 1.20E-06
rs1982234 C 0.63 15 69478345 THSD4 1.16 4.80E-
06
all 1.16 0.136 1.16 1.55E-06
rs7799265 C 0.95 7 28399001 CREB5 0.63 8.84E-
07
FEV1 
65%
0.91 0.742 0.65 1.71E-06
rs181652 A 0.54 10 119369077 EMX2 1.18 8.12E-
06
no 
asthma
1.19 0.097 1.18 1.94E-06
rs11766496 C 0.12 7 71026786 CALN1 1.34 3.90E-
07
all 0.97 0.855 1.30 2.01E-06
rs2263638 A 0.37 10 94158777 IDE 0.78
4.68E-
06
never 
smoker
0.80 0.275 0.78 2.53E-06
rs7850092 A 0.21 9 9899119 PTPRD 0.79 4.00E-
06
FEV1 
65%
0.85 0.324 0.79 2.60E-06
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Table 5. (Continued)
Coded 
allele
Discovery meta-
analysis
Family 
heart 
study*
Combined
meta-
analysis
snP
al-
lele Freq Chr position
Closest 
gene Or
P-
value
analy-
sis Or
P-
val-
ue Or P-value
rs1329705 A 0.2 6 142795031 GPR126 0.79 3.75E-
06
FEV1 
65%
0.85 0.342 0.79 2.63E-06
rs11209261 A 0.76 1 68557801 GPR177 0.81 6.76E-
06
FEV1 
65%
0.80 0.191 0.81 2.78E-06
rs7607316 A 0.21 2 237186581 CXCR7 1.28
9.19E-
06
never 
smoker
1.35 0.152 1.29 3.21E-06
rs9975851 T 0.57 21 26638525 CYYR1 1.18 4.92E-
06
no 
asthma
1.11 0.332 1.17 3.66E-06
rs12505749 C 0.92 4 57028869 SRP72 0.76 3.06E-
07
all 1.22 0.258 0.79 4.69E-06
rs1207393 C 0.36 22 24983362 SEZ6L 0.83 8.69E-
06
FEV1 
65%
0.85 0.283 0.84 4.78E-06
rs12744110 T 0.25 1 56168897 PPAP2B 1.18 4.51E-
06
smoker 1.06 0.681 1.17 5.95E-06
rs11097912 T 0.33 4 107219911 MGC16169 0.85 6.04E-
06
smoker 0.92 0.497 0.85 5.95E-06
rs17086172 T 0.94 18 68378001 CBLN2 0.73 7.13E-
06
no 
asthma
0.86 0.492 0.74 7.23E-06
rs2322734 A 0.96 3 4608492 ITPR1 0.67 7.19E-
06
FEV1 
65%
0.83 0.518 0.69 7.52E-06
rs8036030 A 0.39 15 72503662 SEMA7A 0.84 5.71E-
06
no 
asthma
0.95 0.653 0.85 8.31E-06
rs892961 A 0.41 17 72911695 SEPT9 0.85 8.00E-
06
no 
asthma
0.93 0.479 0.85 8.91E-06
rs7629245 T 0.15 3 186624551 MAP3K13 1.23 0.00001 smoker 1.12 0.456 1.22 9.06E-06
rs2830165 T 0.59 21 26598463 APP 0.81
5.27E-
06
never 
smoker
0.98 0.892 0.82 9.55E-06
rs7686928 T 0.14 4 188970823 ZFP42 1.21 8.77E-
06
smoker 1.08 0.630 1.21 9.65E-06
rs9632471 C 0.72 5 128761894 ADAMTS19 0.76 5.54E-
06
FEV1 
65%
0.95 0.776 0.77 1.07E-05
rs4837614 T 0.15 9 118350186 ASTN2 0.76 4.56E-
06
FEV1 
65%
0.98 0.911 0.78 1.20E-05
rs12960805 A 0.41 18 7909707 PTPRM 1.27
6.22E-
06
never 
smoker
1.00 0.995 1.25 1.27E-05
rs1799257 A 0.12 19 53664351 PSCD2 1.37 2.08E-
06
FEV1 
65%
0.78 0.337 1.33 1.38E-05
rs1868466 A 0.79 16 76301059 KIAA1576 0.85 5.45E-
06
all 1.00 0.997 0.86 1.39E-05
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Table 5. (Continued)
Coded 
allele
Discovery meta-
analysis
Family 
heart 
study*
Combined
meta-
analysis
snP
al-
lele Freq Chr position
Closest 
gene Or
P-
value
analy-
sis Or
P-
val-
ue Or P-value
rs10518948 C 0.93 15 69415023 THSD4 0.68
9.91E-
06
never 
smoker
0.97 0.931 0.69 1.51E-05
rs6901575 A 0.1 6 28358963 PGBD1 1.24 6.76E-
06
all 0.97 0.853 1.22 1.55E-05
rs3790728 T 0.97 1 215737150 GPATCH2 0.57 3.12E-
06
FEV1 
65%
4.24 0.060 0.60 1.58E-05
rs9511117 A 0.09 13 23660045 SPATA13 0.73 6.78E-
06
smoker 1.01 0.979 0.75 1.65E-05
rs4957070 A 0.63 5 600858 SLC9A3 0.85 9.09E-
06
smoker 0.98 0.874 0.86 1.65E-05
rs3814818 T 0.9 14 94263130 GSC 0.74 2.51E-
06
FEV1 
65%
1.24 0.357 0.77 1.68E-05
rs1895493 C 0.09 16 78122404 MAF 1.41
5.51E-
06
never 
smoker
0.77 0.460 1.37 1.72E-05
rs12872078 A 0.91 13 64002324 PCDH9 1.43 4.81E-
06
FEV1 
65%
0.96 0.876 1.37 1.75E-05
rs764593 T 0.11 3 3687236 LRRN1 0.76 3.89E-
06
smoker 1.11 0.563 0.79 2.64E-05
rs1408298 T 0.7 6 17199273 RBM24 0.81 8.19E-
06
no 
asthma
1.00 0.972 0.83 2.95E-05
rs2164220 T 0.08 7 157447986 PTPRN2 1.42
9.80E-
06
never 
smoker
0.61 0.266 1.38 3.14E-05
rs10496694 A 0.09 2 133252637 NAP5 1.31 7.42E-
06
smoker 0.86 0.512 1.27 3.30E-05
rs11023434 C 0.23 11 15083724 INSC 1.33
7.78E-
06
never 
smoker
0.95 0.766 1.28 3.70E-05
rs1567398 T 0.43 8 8764214 MFHAS1 1.2 8.20E-
06
FEV1 
65%
0.91 0.519 1.17 3.98E-05
rs1125729 T 0.81 8 93427586 RUNX1T1 0.8 1.63E-
06
FEV1 
65%
1.59 0.014 0.83 4.89E-05
rs7163331 A 0.04 15 96260720 ARRDC4 1.55 6.81E-
06
FEV1 
65%
0.56 0.132 1.46 6.34E-05
rs12265908 A 0.97 10 2339319 ADARB2 0.59 6.92E-
06
FEV1 
65%
1.81 0.157 0.64 7.54E-05
rs7719062 T 0.08 5 1222044 SLC6A19 1.42 9.79E-
06
smoker 0.81 0.393 1.34 7.71E-05
*Family Heart Study results are generated from phenotypes consistent with the discovery analysis 
indicated, with affected/unaffected sample sizes: 331/2550 all, 248/1003 smoker, 83/1547 never smoker, 
266/2350 no asthma, 155/2550 FEV1 65%.
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airflow obstruction, the chromosome 6 MHC locus at 6p21.33 was among the top results 
(smallest P value = 6.8 × 10−7, rs3094013). The closest gene to the top SNP was HLA 
complex P6 (HCP5), although the extensive linkage disequilibrium in the region makes 
interpretation difficult. When discovery results were meta-analyzed with the replication 
studies, the previous associations were attenuated. The top SNP from the meta-analysis 
of discovery and replication results had an OR of 1.13 for the common allele (66%) and 
a P value of 6.03 × 10−6 near the HLA-A gene. Thirty-six SNPs in chromosome 6 with 
combined meta-analysis P values less than 1 × 10−4 are provided in Table E3.
On chromosome 15, after meta-analysis of airflow obstruction in ever smokers from 
discovery populations with replication studies, the order of the top hits was generally 
unchanged and P values improved, reaching 2.6 × 10−15. The COPD case-control studies 
meta-analysis included only ever smokers, so the FamHS served as a sole replication 
study for the never smoker regional results. Figure 1 depicts the chromosome 15 regional 
association of the meta-analysis of combined discovery and replication cohorts for the 
separate groups of ever smokers (A) and never smokers (B), created using LocusZoom 25. 
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Figure 1a and 1b. Regional association plot for chromosome 15 presenting results from combined meta-
analysis of discovery and replication studies. X-axis is Megabase (Mb) position. Y-axis is negative log of the 
p-values. Linkage disequilibrium to the named SNP (in purple) is depicted by degree of color according 
to the legend. Non-synonymous SNPs are depicted by an inverted triangle and other coding SNPs by a 
square. A) ever smokers B) never smokers. 
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Figure 2 is a forest plot presenting the study-specific results among never smokers that 
demonstrates similar effect sizes across the cohorts.
replication of top 60 snPs and combined meta-analysis
Table 5 presents the 60 SNPs selected for replication studies (not including the chro-
mosome 6 and 15 SNPs included in the regional meta-analyses). A P value of 8 × 10−4, 
representing Bonferroni correction for 60 tests at the α = 0.05 level, was selected a priori 
as the threshold for statistically significant replication. No SNPs achieved the replication 
criterion. In a meta-analysis combining the discovery results with the FamHS, one SNP 
achieved genome-wide statistical significance (rs7733088 in HTR4) with a 38% frequent 
minor allele conferring an OR of 0.81 (P = 4.09 × 10−9). Of the top 60 SNPs, four had 
nominal association (P values < 0.05) in the COPD meta-analysis and a consistent risk 
allele; these SNPs were located in ADAM19, RARB, PPAP2B, and ADAMTS19 (Table 6).
association of spirometry-associated snPs with airflow obstruction
Previous meta-analyses in the CHARGE and SpiroMeta consortia 3-5 identified 75 SNPs 
associated with either FEV1 or FEV1/FVC at genome-wide significance (P value ≤ 5 × 
10−8). We examined the association P values for airflow obstruction for these 75 SNPs 
in the meta-analysis results from all subjects and from ever smokers. Association for 
these 75 SNPs represents 58 independent tests using a multiple-testing correction 
that incorporates the linkage disequilibrium structure derived from HapMap European 
(CEU) samples 26. Accordingly, we considered a P value of 8.6 × 10−4 as the criterion for 
statistically significant association with airflow obstruction (Bonferroni correction for 58 
tests at the α = 0.05 level) given the a priori association with spirometry. Among all 
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Figure 2. Forest plot depicting the association results for rs1051730 (CHRNA3) and airflow obstruction 
among never smokers in each cohort and the meta-analysis.  
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participants, SNPs in RARB, GPR126, HTR4, C10orf11, near HHIP, and near HLA-DRA were 
statistically significantly associated with airflow obstruction. Among smokers, HTR4, 
RARB, GPR126, and THSD4 were associated with airflow obstruction. Results for the 75 
SNPs are presented in Tables E4 and E5. When only cohorts that did not contribute to the 
published spirometry findings 3-5 were considered (RS3, SAPALDIA, LBC1936, MESA, and 
COPACETIC) as an independent sample, power was reduced, and only the ADAM19 SNP 
in smokers achieved the Bonferroni cutoff for significance (Table E6).
Gene expression results
Expression of CHRNA3 and CHRNA5 was evaluated in cDNA from human whole lung, 
peripheral blood mononuclear cells, and primary cultures of bronchial epithelial cells 
and airway myocytes, together with control tissues (kidney, brain, and placenta: see 
online supplement for methods). Both genes were expressed in all lung-derived tissues 
examined. Within the lung, expression of both CHRNA3 and CHRNA5 appeared strongest 
in airway myocytes and epithelial cells. The identity of reverse transcriptase–polymerase 
chain reaction products was confirmed by direct sequencing of bands of the relevant 
size from at least one tissue type for each gene.
DIsCussIOn
These meta-analyses included 32,875 participants from population-based studies for 
discovery of loci associated with airflow obstruction. In addition, we attempted to 
replicate results in 2,881 participants from a population-based family study and a meta-
analysis of 5,421 participants from case-control studies of clinically ascertained COPD. 
The present study confirms the previously identified 7 association between the chromo-
some 15q25 region and airflow obstruction among smokers. Although the number of 
Table 6. Four SNPs with nominal association to COPD and consistent risk allele out of 60 SNPs selected for 
replication from airflow obstruction discovery GWAS.
Coded allele
airflow obstruction
meta-analysis
COPD
meta-analysis
snP allele Freq Chr position
Closest 
gene analysis Or P-value Or P-value
rs11744671 T 0.92 5 156853809 ADAM19 no asthma 0.72 4.51E-07 0.8 0.027
rs1997352 A 0.26 3 25513321 RARB all 0.84 8.64E-07 0.88 0.038
rs12744110 T 0.25 1 56168897 PPAP2B smoker 1.17 5.95E-06 1.13 0.045
rs9632471 C 0.72 5 128761894 ADAMTS19 FEV1 65% 0.77 1.07E-05 0.86 0.045
Definition of abbreviations: Chr = chromosome; COPD = chronic obstructive pulmonary disease; Freq = 
frequency; OR = odds ratio; SNP = singly-nucleotide polymorphism
152 Chapter 3.5
participants with airflow obstruction among never smokers was low (504 affected), and 
statistical power is therefore limited, analyses of airflow obstruction among never smok-
ers also showed a nominal association to the Asp398Asn missense SNP in CHRNA5 and 
to a synonymous SNP in CHRNA3.
Results from gene expression studies demonstrated that both CHRNA5 and CHRNA3 
were expressed in whole lung, airway smooth muscle, and bronchial epithelial cells. 
In a publication reporting CHRNA5 gene expression in normal lung tissue samples, the 
Asp398Asn genotype was strongly related to mRNA levels, with homozygosity of the 
risk allele (A) associated with 2.5-fold lower mRNA levels compared with homozygosity 
for the G allele 27. A similar pattern was observed for rs1051730 in the sputum of COPD 
cases, in which the minor allele was associated with lower expression of CHRNA5 28. The 
correlation between associated SNP genotypes and CHRNA5 expression levels in the 
lung and sputum combined with our finding of increased risk for airflow obstruction in 
never smokers suggests that the variants in this region may have an influence on risk of 
airflow obstruction that is not simply mediated by an influence on nicotine dependence. 
Supporting a direct influence of variants in this region on lung phenotypes, a CHRNA3/5 
variant was recently found to be associated with bronchial hyperresponsiveness in 
children not exposed to cigarette smoke 29. Silencing CHRNA5 in bronchial epithelial 
cells was found to reduce expression of adhesion molecules, thereby increasing cell 
motility, which may influence the repair and remodeling processes that lead to COPD 30. 
Our results suggest that the A allele of rs16969968 confers as much as a 20% increased 
odds of airflow obstruction, and based on the prior report, this increased risk may be 
mediated by lower mRNA levels in lung tissue 27.
In addition to the chromosome 15q region, SNPs in HTR4 met genome-wide statistical 
significance in ever smokers. The HTR4 (5-hydroxytryptamine {serotonin} receptor 4) 
gene was originally identified with association to FEV1/FVC in CHARGE 
3 and SpiroMeta 4, 
and subsequently showed a statistically significant association with COPD in a targeted 
gene analysis of six loci in the SpiroMeta cohorts 31. Serotoninergic receptors have been 
demonstrated to regulate cytokine and chemokine release in human airway epithelial 
cells and have been implicated in the pathogenesis of asthma 32. The reduced risk of 
airflow obstruction was strongest when limited to ever smokers, suggesting that varia-
tion in HTR4 may contribute to the inflammatory response to cigarette smoke.
Several genes represented among the top SNP results were nominally replicated in the 
COPD case-control meta-analysis (ADAM19, RARB, PPAP2B, and ADAMTS19). Of them, 
both ADAM19 and RARB have been previously implicated in GWAS of lung function as 
measured by spirometry 3-5. ADAM19 (a disintegrin and metalloprotease domain 19) was 
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originally shown to be associated with FEV1/FVC in the CHARGE GWAS 
3, and these SNPs 
were subsequently reported to be associated with COPD in a case-control study 33. Here, 
we demonstrate that ADAM19 is associated with airflow obstruction in population-based 
cohort studies. ADAM19 is expressed in bronchial epithelial cells, bronchial smooth 
muscle, and interstitial inflammatory cells and may have a role in immune defense 
and the inflammatory process 34. ADAMTS19 (a disintegrin and metalloproteinase with 
thrombospondin motifs 19) has several of the same domains and has been shown to 
be expressed in fetal lung 35. PPAP2B is a lipid phosphate phosphohydrolase, which are 
generally believed to influence surfactant secretion and have a role in lung injury and 
repair 36.
RARB (retinoic acid receptor β) was recently demonstrated to be associated with lung 
function measures at genome-wide significance in the combined CHARGE and Spiro-
Meta meta-analysis 5. Retinoic acid (RA) has been evaluated as a potential therapeutic 
agent for emphysema after results in rats demonstrated reversibility of experimentally 
induced emphysema with administration of RA 37; however, subsequent studies in ani-
mal models had conflicting results 38, and a small feasibility study of RA for the treatment 
of emphysema did not show significant improvement in lung function 39. The finding 
that RARB minor alleles were associated with lower risk of airflow obstruction may pro-
vide insight into which patients may benefit from RA therapy or suggest modifying the 
design of RA therapeutics to target the β receptor.
The HHIP region was associated with airflow obstruction in our look-up replication of 
spirometry-associated SNPs, which was expected given the prior findings of association 
with COPD in earlier GWAS 7,9 and further replication in targeted studies of HHIP and 
COPD 8. This region of chromosome 4q31 including SNPs in HHIP and GYPA has also been 
shown to be associated with lung cancer 40. Recently, a COPD risk haplotype upstream 
of HHIP was identified to be associated with reductions in HHIP promoter activity 41. Our 
meta-analysis is able to confirm that rs6537296 is associated with airflow obstruction 
(P = 3.2 × 10−4), but the other SNP in the haplotype (rs1542725) was not studied. Also, 
previously identified SNPs in GPR126, THSD4, and near HLA-DRA were associated with 
airflow obstruction, and GPR126 demonstrated a nominal association with COPD in a 
prior report focusing on clinically ascertained cases and control subjects 33. It should 
be noted that the look-up replication that supports the relation of these genes with 
airflow obstruction is not statistically independent from the original meta-analyses 
of spirometry traits because of overlap between the samples. When only the cohorts 
not included in the earlier published meta-analyses 3-5 were analyzed separately, in this 
reduced sample size (567 affected, 2,922 unaffected) only the ADAM19 gene achieved 
the cutoff criterion for significant association with airflow obstruction.
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The chromosome 6 region identified in discovery meta-analysis did not replicate when 
additional studies were included in the meta-analysis. The regional meta-analysis results 
demonstrated modest association (P values < 1 × 10−4) across five megabases in the HLA 
region, including 17 SNPs in the histone gene cluster at 27.9 Mb. Our results are not 
able to clarify which gene or combination of genes may give rise to the underlying as-
sociation signal given the extensive linkage disequilibrium in the MHC. Recently, a meta-
analysis of the COPD case-control cohorts that served as replication cohorts in our study 
implicated a locus on chromosome 19q13 24 as a COPD susceptibility locus; however, the 
rs7937 SNP identified is not replicated in the discovery meta-analyses described here (P 
values ranged from 0.12 among never smokers to 0.87 among ever smokers).
Our study has several limitations. Our cohorts had only prebronchodilator spirometry, 
and thus we could not examine the formal definition of COPD. Our main analysis used 
a definition of airflow obstruction that includes persons with very mild ventilatory 
impairment, and the participants who meet this definition may not all have COPD. Our 
definition of more severe airflow obstruction is likely to be more comparable to clinically 
ascertained COPD in the replication studies, but the numbers of affected participants 
were reduced. In addition, our ability to address asthma in the context of airflow ob-
struction was limited to a subset of cohorts with self-reported asthma diagnoses. Last, 
as our study was limited to white participants of European descent, the generalizability 
of these findings to other ethnic groups is unknown.
In summary, we performed meta-analyses and replication studies using data from more 
than 40,000 study participants of European ancestry to identify genetic loci influencing 
airflow obstruction as a categorical disease phenotype. We identified the CHRNA3/5 
genes and HTR4 at genome-wide significance, and several genes that were implicated 
by previous GWAS of single spirometry measures as quantitative phenotypes (ADAM19, 
RARB) were among top results. Here we show, for the first time, that a CHRNA5 missense 
SNP is associated with airflow obstruction in never smokers, suggesting a main effect on 
risk of airflow obstruction that is independent of the influence mediated through effects 
on smoking habits. This was supported by gene expression findings demonstrating the 
CHRNA3/5 genes in relevant lung and airway tissues. Thus, CHRNA3/5 variants may medi-
ate airflow obstruction in both ever and never smokers.
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absTraCT
aim Beta-blockers have been used with caution in patients with obstructive lung 
diseases such as asthma or chronic obstructive pulmonary disease (COPD), due to the 
potentially increased airway reactivity and risk of bronchial obstruction. Cardioselective 
β-blockers have a more beneficial profile than non-cardioselective β-blockers and can 
be safely prescribed to patients with both cardiovascular disease and COPD. We hypoth-
esized that also cardioselective β-blockers affect pulmonary function.
methods This study was performed within the Rotterdam Study, a prospective popula-
tion-based cohort study. Effects of cardioselective and non-cardioselective β-blockers 
on pulmonary function were analyzed using regression techniques with multivariable 
adjustment for potential confounders.
results Current use of non-cardioselective β-blockers was significantly associated with 
a lower forced expiratory volume in 1 second (FEV1) of -198 ml (95%CI -301; -96), with 
a lower forced vital capacity (FVC) of -223 ml (95%CI -367; -79) and with a decreased 
FEV1/FVC of -1.38% (95%CI -2.74; -0.13%). Current use of cardioselective β-blockers was 
significantly associated with a lower FEV1 of -118 ml (95%CI -157; -78) and with a lower 
FVC of -167 ml (95%CI -222; -111), but did not affect FEV1/FVC. After exclusion of patients 
with COPD, asthma and heart failure the effects of cardioselective β-blockers remained 
significant for FEV1: -142 ml (95%CI -189; -96) and for FVC: -176 ml (95%CI -236; -117).
Conclusion In our study both non-cardioselective and cardioselective β-blockers had a 
clinically relevant effect on both FEV1 and FVC. In contrast to cardioselective β-blockers, 
use of non-cardioselective β-blockers was associated with a significantly lower FEV1/
FVC.
β-blockers and 
pulmonary function
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InTrODuCTIOn
Several highly prevalent cardiovascular diseases, including hypertension, ischemic 
heart disease, heart failure and arrhythmia, are important indications for β-blockers. 
Major adverse effects due to blockade of the β-adrenergic system are fatigue, decreased 
peripheral circulation and increased airway resistance. β-blockers have been used with 
caution in patients with obstructive lung diseases such as asthma or chronic obstruc-
tive pulmonary disease (COPD), due to the potentially increased airway reactivity and 
subsequent risk of bronchial obstruction in asthmatics 1. β-adrenoreceptor blockade, 
especially β2-blockade, can provoke bronchospasm in patients with airway hyperreac-
tivity.
These possible adverse effects of β-blockers may complicate treatment of patients 
with concomitant COPD and cardiovascular disease (CVD), since both conditions often 
coexist 2-6. Both diseases share common risk factors such as smoking and ageing. More-
over, both CVD (in case of heart failure) and COPD may elicit similar symptoms such as 
dyspnea, cough and wheezing, which can make it difficult to distinguish between both 
diseases. In the TORCH-study, 30% of mortality in patients with COPD was due to CVD 7. 
The World Health Organisation estimated that CVD and COPD will be amongst the top 
four causes of death in 2030 8. This underlines that adequate treatment of both diseases 
is highly relevant for reducing mortality and morbidity in the general population.
β1-selective (cardioselective) β-blockers are supposed to have a more beneficial profile 
than non-cardioselective β-blockers and can be safely prescribed to patients with both 
CVD and COPD or asthma 9-11. A systematic review of 22 randomized trials to evaluate 
the effects of cardioselective β-blockers showed no significant change in respiratory 
symptoms or spirometry parameters of interest in participants with obstructive syn-
dromes. The Forced Expiratory Volume in 1 second (FEV1) did not change significantly 
nor did the response in FEV1 to β2-agonist treatment 
9. Another meta-analysis analyzed 
19 randomized trials on single dose administration of cardioselective β-blockers and 
10 studies on continuous treatment 10. In this meta-analysis the authors concluded that 
the first dose of a cardioselective β-blocker produces a small decrease in FEV1 that is not 
associated with adverse respiratory effects compared to placebo 10. Sirak et al. stated 
that cardioselective β-blockers are routinely preferred to non-cardioselective β-blockers 
in treatment of congestive heart failure and can be safely prescribed 12. Recently, a large 
observational study suggested that β-blockers are well tolerated in patients with COPD 
and may reduce mortality 11.
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It is common knowledge that randomized clinical trials predominantly include highly 
selected, relatively young and healthy patients and that those results cannot always 
be generalized to clinical care in real life circumstances. Therefore, the objective of our 
study was to assess the effects of non-cardioselective and cardioselective β-blockers on 
pulmonary function in the general population.
maTErIaLs anD mEThODs
setting
This study was performed in the Rotterdam Study, a prospective population-based 
cohort study which started in 1990 in Ommoord, a suburb of Rotterdam. The Medical 
Ethics Committee of the Erasmus Medical Centre, Rotterdam, The Netherlands, approved 
the study. At baseline, all participants were visited for a standardized questionnaire, and 
were subsequently examined at the research centre. The first cohort (RS I) consists of 
7,983 participants, aged 55 years and over. Since the start of the initial cohort, two sub-
sequent cohorts have been defined in the same area. The second cohort (RS II) started in 
2000 and included 3,011 participants aged 55 years and over. The third cohort (RS III) was 
enrolled in 2006 and included 3,932 participants aged 45 years and over. As of 2009 the 
total of the combined cohorts encompasses 14,926 subjects aged 45 years or over. The 
main focus of the Rotterdam Study is on studying common diseases in the elderly. Every 
3-5 years the participants undergo a round of interviews and physical examinations, of 
which pulmonary function tests are routinely performed during every study round as of 
2002. To continuously monitor the cohort for major diseases and mortality, the database 
is linked to the electronic records of the general practitioner and the municipality. All 
prescriptions dispensed to the participants are periodically collected by linking to the 
seven pharmacies covering the Ommoord region. Main objectives and methods of the 
Rotterdam Study have been described elsewhere 13,14.
study population
The study population consisted of all participants of the Rotterdam Study with a pul-
monary function test during the fourth study round. These tests were analysed by two 
research physicians, and validated by a specialist in pulmonary medicine. During the 
validation process the quality control was performed by two researchers, of whom at 
least one was a physician. Normal spirometry, airflow obstruction and spirometry sug-
gestive of restrictive syndromes were classified.
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Exposure
To assess exposure to β-blockers, for participants with a pulmonary function test, pre-
scription data was collected from the pharmacies. We collected prescription data on 
cardioselective and non-cardioselective β-blockers using the Anatomical Therapeutic 
Chemical (ATC) classification system 15 for C07AB (cardioselective β-blockers) and C07AA 
(non-cardioselective β-blockers). For every participant, the prescription period was 
calculated and if the date of the pulmonary function test fell within the prescription 
period of a β-blocker, the study participant was classified as exposed.
Outcome
Spirometry was performed by trained paramedical personnel using a SpiroPro® portable 
spirometer (Erich Jaeger, Hoechberg, Germany), according to American Thoracic Society 
(ATS)/European Respiratory Society (ERS) guidelines 16. FEV1, FVC and FEV1/FVC-ratio 
were measured. Spirometry procedures that yielded results that did not meet ATS/ERS 
criteria for acceptability and reproducibility were classified as not interpretable 17. For 
practical reasons, reversibility testing could not be carried out. Participants were asked 
to refrain from using any prescribed pulmonary medication before the center visit.
Covariables
Information on several potential confounders or effect modifiers such as age, sex, 
height, weight and body mass index (BMI) was gathered at the study round in which the 
pulmonary function test was performed. We collected data on medication prescribed for 
obstructive pulmonary diseases such as asthma and COPD. For our analyses, we included 
inhaled short-acting β-adrenoreceptor-agonists (SABAs), long-acting β-adrenoreceptor-
agonists (LABAs), anticholinergic agents, inhaled glucocorticosteroids and combinations 
of the above mentioned substances. Furthermore, we collected information on use of 
oral glucocorticosteroids, xanthine derivatives and leukotriene-receptor antagonists.
Data on smoking was collected from the questionnaires and classified subjects were 
classified as current, former or never smokers. As a quantitative measure of tobacco 
exposure, we used the number of pack-years, with one pack-year defined as smoking 20 
cigarettes per day for 1 year. We assessed COPD using spirometry and classified according 
to the GOLD criteria 18,19. Heart failure at baseline in the Rotterdam Study was assessed 
using a validated score based on the definition of heart failure of the European Society 
of Cardiology 20. As described previously, cases of incident heart failure were obtained 
by continuously monitoring participants of the Rotterdam Study during follow-up 21. 
For these analyses, we assessed if participants were cases at the time of the pulmonary 
function test and considered cases defined before the test as prevalent heart failure 
patients. Using echocardiography, fractional shortening and E/A-ratio were calculated 
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as measures of systolic and diastolic cardiac function, respectively 22. Echocardiography 
was done on the same day as the spirometry. The methods for echocardiography in the 
Rotterdam Study have been described elsewhere 22. Systolic and diastolic blood pres-
sures were measured twice from the right upper arm with a random-zero sphygmoma-
nometer with the patient in a sitting position. The mean of the two readings was used to 
determine blood pressure levels.
Data analysis
Differences in baseline characteristics between cardioselective and non-cardioselective 
β-blocker users, and non-users were tested using a χ2-test for dichotomous variables and 
a t-test for continuous variables. The effect of cardioselective and non-cardioselective 
β-blockers on pulmonary function measures was evaluated using linear regression 
analyses for FEV1 and for FVC, selecting covariables by assessing whether there was a 
higher than 10% change in point estimate. Furthermore, we tested for possible interac-
tion by using multiplicative interaction terms. We adjusted for sex, age, height, systolic 
blood pressure, smoking status, pack-years, heart failure, obstructive and restrictive syn-
dromes and concomitant respiratory medication, with pulmonary function in non-users 
of β-blockers as a reference group. To avoid potential confounding by indication, we 
also performed analyses excluding patients with COPD and heart failure. We preferred 
this over adjustment because the occurrence of these conditions was considered as a 
contra-indication for β-blockers during a substantial number of years within the study 
period.
In 784 participants, consecutive measurements were available, with a mean follow-
up of 6.1 years (±0.5) between consecutive center visits. In this subanalysis, exposure 
categories were classified as “never exposed” (no use of β-blockers at the first as well 
as the second measurement), “starters” (no use of β-blockers at the first measurement 
but use at the second measurement), “continuous users” (use of β-blockers at the first as 
well as the second measurement), and “discontinued use” (use of β-blockers at the first 
measurement but no use at the second measurement).
All analyses above were repeated for non-cardioselective β-blockers. All statistical 
analyses were performed with SPSS PASW software (IBM Corporation, Armonk, New 
York, USA). P-values <0.05 were considered statistically significant. All graphs were made 
using R 2.9.1. 23
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rEsuLTs
Of the total of 14,926 subjects from the Rotterdam Study cohorts, a total of 6,489 pulmo-
nary function tests were performed; 4,324 spirometry tests were of sufficient quality to 
be validated as interpretable and could be used for our analyses.
subject characteristics
The population consisted of 1,880 men (43.5%) and 2,444 women (56.5%) (Table 1). The 
mean age at lung function examination was 66 years (range 46-97 years). In our cohort 
651 persons were exposed to cardioselective β-blockers at the time of the pulmonary 
function test. The mean FEV1 in the cohort was 3.23 l (±0.9 l) for men and 2.34 l (±0.6 l) 
for women. The mean FVC was 4.27 l (±1.03 l) for men and 3.03 l (±0.74 l) for women. 
We defined airflow limitation according to the GOLD definition (FEV1/FVC ratio < 0.70). 
In our sample there were 308 subjects with COPD GOLD stage I (7.1%), 330 with COPD 
GOLD stage II (7.6%) and 63 with COPD GOLD stage III (1.5%). There were no subjects 
with COPD GOLD Stage IV.
Furthermore, we identified 301 participants (7.1%) with lung function results suggestive 
of a restrictive syndrome. Of the participants with pulmonary function tests we had full 
data, including smoking history, in 4,033 subjects. These were included in our analyses. 
Missingness of data was independent of β-blocker-use and multiple imputations fol-
lowed by combined analyses did not change effect estimates.
Cardioselective β-blockers
Exposure to cardioselective β-blockers was significantly associated with a lower FEV1 
in our population of -118 ml (95% CI -157; -78 ml). To investigate the effect of cardi-
oselective β-blockers on FVC we tested similar models. Current use of cardioselective 
β-blockers was significantly associated with a lower FVC with a decrease of -167 ml 
(95% C.I. -222; -111 ml) (table 2). Testing for interaction between sex, age or COPD 
and ß-blocker exposure was non-significant but with suspected pulmonary restrictive 
disease interaction seemed to be present. When we subsequently analyzed the dataset 
stratified, the significant effect on FEV1 only persisted in the non-diseased group and 
was stronger (-145, 95% C.I. -188; -103)
To assess the effect in subjects without known heart failure and an obstructive or a 
restrictive syndrome, we separately analysed participants without these diseases. As 
asthma or COPD patients might be prone to a prescription of cardioselective β-blockers 
because of the possible adverse effects of non-cardioselective β-blockers, we also 
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excluded participants with a prescription for inhalation medication and/or oral gluco-
corticosteroids.
Table 1. Baseline characteristics of the study population.
Total unexposed β1-
selective
non-
selective
sex N (%) Male (%) 1880 (43.5%) 1533 (42.8%) 303 
(46.5%)
44 (50%)
Female (%) 2444 (56.5%) 2052 (57.2%) 348 
(53.5%)
44 (50%)
age Years (SD) 65.9 (9.5) 65.2 (9.5) 68.9 (9.0) 71.8 (9.3)*
height cm (SD) 168.9 (9.3) 169.0 (9.3) 168.1 (9.2)* 169.5 (8.7)
smoking status*† N (%) Never 1418 (32.8%) 1208 (32.9%) 210 
(32.2%)
22 (25%)
Past 2074 (48.0%) 1734 (47.2%) 340 
(52.2%)*
50 (56.8%)
Current 828 (19.1%) 727 (19.8%) 101 
(15.5%)*
16 (18.2%)
Pack years py (SD) 15.5 (21.1) 14.9 (20.8) 18.5 (22.7)* 16.3 (19.1)
Prevalent heart Failure 
N (%)
140 (3.2%) 93 (2.5%) 47 (7.3%)* 7 (8%)*
blood Pressure mmHg (SD) Systolic 142 (21) 141 (21) 150 (22)* 143 (20)
Diastolic 81 (11) 81 (11) 82 (12) 78 (11)*
bmI kg/m2 (SD) 27.6 (4.3) 27.3 (4.2) 29.0 (4.4)* 28.0 (3.6)
hx myocardial infarction 
(%)
223 (5.2) 111 (2.6) 100 (15.4)* 12 (13.6%)*
Echocardiography¶ Fractional 
Shortening % (SD)
39.7 (6.7) 40.2 (6.3) 38.0 (7.8)* 35.0 (7.7)*
E/A-Ratio 1.0 (0.3) 1.0 (0.3) 1.0 (0.3) 0.9 (0.3)
Total colesterol mmol/l 
(SD)
5.6 (1.0) 5.6 (1.0) 5.2 (1.0)* 5.3 (1.1)*
hDL cholesterol mmol/l 
(SD)
1.4 (0.4) 1.5 (0.4) 1.3 (0.3)* 1.3 (0.3)*
Obstructive Pulmonary 
Disease
GOLD Classification, N (%)
No obstruction‡ 3623 (83.8%) 3025(84.4%) 530 
(81.5%)
68 (77.3%)
I 308 (7.1%) 261 (7.3%) 41 (6.3%) 6 (6.8%)
II 330 (7.6%) 248 (6.9%) 69 (10.6%)* 13 (14.8%)*
III 63 (1.5%) 51 (1.4%) 11 (1.7%) 1 (1.1%)
BMI: Body Mass Index, E/A-ratio: ratio of early and late ventricular filling velocity, Hx: History, N: number 
of participants, SD: Standard Deviation * P-value < 0.05 for difference, exposed vs. unexposed † Smoking 
status missing: n=4 ‡ Spirometry suggestive for a restrictive syndrome: unexposed n=215, exposed to β1-
selective n=72, exposed to non-selective n=14 ¶ Available in a random subset: n= 3629
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In this sample (n = 3,157), the associations of cardioselective β-blockers exposure and a 
lower FEV1 and FVC are comparable to the complete sample. Exposure to cardioselective 
β-blockers was associated with a lower FEV1 of -142 ml (95% C.I. -189; -96 ml) and a 
change of FVC of -176 ml (95% C.I. -236; -117 ml). To minimize the effect of misclas-
sification of heart failure, we performed a sensitivity analysis in which we also adjusted 
for echocardiography, which was available in a random subset of 3,629 participants. 
Fractional shortening and E/A-ratio were used as measures of systolic and diastolic 
function, respectively. Of these measures only fractional shortening was of influence in 
our models. The effect estimate of cardioselective β-blockers changed less than 5% and 
remained significant in this analysis.
non-cardioselective β-blockers
In our cohort, exposure to non-cardioselective β-blockers was low; only 88 participants 
(2.2%) of our cohort of 4,033 participants had a prescription for non-cardioselective 
β-blockers. The majority of these users (75%) had a prescription for Sotalol. Exposure of 
non-cardioselective β-blockers was also associated with lower FEV1 and FVC (table 2). 
Table 2. Effect estimates
Pulmonary function test Effect, crude 95%CI Effect, 
adjusted‡
95%CI P-value, 
adjusted
FEV1
 Non use Reference Reference
 Non-cardioselective* -503 ml -685; -321 -198 ml -301; -96 <0.001
 Cardioselective† -307 ml -378; -236 -118 ml -157; -78 <0.001
FVC
 Non use Reference Reference
 Non-cardioselective -524 ml -752; -296 -223 ml§ -367; -79 0.001
 Cardioselective -379 ml -468; -290 -167 ml -222; -111 <0.001
FEV1/FVC
 Non use Reference Reference
 Non-cardioselective -3.52 % -5.37; -1.66 -1.38%¶ -2.74; -0.13 0.048
 Cardioselective -0.63 % -1.36; 1.01 0.12 % -0.41; 0.65 0.654
* No. exposed non-cardioselective= 88, N unexposed = 3585 † No. exposed cardioselective= 651, N 
unexposed = 3585 ‡ Adjusted for: sex, age, height, pack-years, smoking status, inhalation medication, oral 
glucocorticosteroids, heart failure, obstructive or restrictive syndromes and systolic blood pressure and 
cohort.
§ As above plus BMI. ¶ Adjusted for: age, height, BMI, pack-years, smoking status, obstructive or restrictive 
lung diseases and inhalation medication and cohort.
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The effect of non-cardioselective β-blockers was -198 ml (95% C.I. -301; -96 ml) on FEV1 
and -223 ml (95% C.I. -367; -79 ml) on FVC. We also analysed the effect in the subset of 
participants without obstructive and restrictive syndromes, heart failure and inhalation 
medication. For FEV1 the effect was -219 ml (95% C.I. -343; -94 ml) and for FVC the effect 
was -179 ml (95% C.I. -339; -19 ml).
FEV1/FVC
No significant association was shown on the FEV1/FVC-ratio in participants exposed to 
cardioselective β-blockers compared to unexposed participants, namely an effect of 
0.12% (95% C.I. -0.41; 0.65). In the adjusted analysis, a significantly lower ratio of FEV1 
over FVC of -1.38 % (95% C.I. -2.74; -0.13 %) was seen in participants exposed to non-
cardioselective β-blockers compared to unexposed subjects (figure 3). Compared to 
users of cardioselective β-blockers, the adjusted effect was -1.28 % (-2.49; -0.76).
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Figure 1. Effect of β-blocker exposure on mean FEV1 in milliliters
Exposure is divided in three classes; No use, current use of cardioselective β-blockers and current use of 
non-cardioselective β-blockers. The whiskers represent the 95 % C.I.
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Figure 2. Effect of β-blocker exposure on mean FVC in milliliters.
Exposure is divided in three classes; No use, current use of cardioselective β-blockers and current use of 
non-cardioselective β-blockers. The whiskers represent the 95 % C.I.
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Figure 3. Effect of β-blocker exposure on mean FEV1/FVC in percent.
Exposure is divided in three classes; No use, current use of cardioselective β-blockers and current use of 
non-cardioselective β-blockers. The whiskers represent the 95 % C.I.
172 Chapter 4.1
Longitudinal effects
For 1 cohort (RS-I), consecutive spirometry measurements were available in 784 par-
ticipants (table 3). Participants starting cardioselective β-blockers showed a significantly 
stronger percentual decrease in FVC than never users of β-blockers, i.e. respectively 
13.8% versus 9.6% (figure 3).
For FEV1 a similar effect was seen with a decrease of 13.5% for starters of β-blockers 
versus 9.4% for never users. When prescriptions ended between the measurements, 
participants who had been using cardioselective β-blockers showed less of a decrease in 
both FEV1 and FVC compared to starters (figures 4 and 5). Linear regression with adjust-
ment for age, sex, follow-up time, current smoking and pack years, showed a statistically 
significant stronger percentual decrease for both FEV1 and FVC compared to never users 
(figure 6).
Table 3. Baseline characteristics of the subgroup with two spirometry tests.
Characteristics
Total unexposed β1-selective
number of participants 784 648 136
sex N (%) Male (%) 337 (43.0%) 278 (43.0 %) 59 (43.4 %)
Female (%) 447 (57.0 %) 370 (57.0 %) 77 (56.6 %)
age baseline Years (SD) 72.3 72.3 (4.5) 72.7 (4.1)
height cm (SD) 167.6 (9.0) 167.7 (8.9) 166.9 (9.4)
smoking status*† N (%) Never 259 (33.0 %) 209 (32.3 %) 50 (36.8 %)
Past 453 (57.8%) 376 (58.0 %) 77 (56.6 %)
Current 72 (9.2%) 63 (9.7 %) 9 (6.6 %)
Pack years py (SD) 15.5 (21.1) 15.6 (21.5) 14.8 (18.6)
Prevalent heart Failure N (%) 23 (2.9%) 15 (2.3 %) 8 (5.9%)
blood Pressure mmHg (SD) Systolic 149 (20) 148 (20) 156 (20)
Diastolic 80 (10) 80 (10) 81 (10)
bmI kg/m2 (SD) 27.3 (3.9) 27 (3.8) 28.6 (3.8)
hx myocardial infarction (%) 52 (6.6 %) 33 (5.1 %) 19 (14.0 %)
Chronic Obstructive Pulmonary Disease
GOLD Classification, N (%)
No obstruction‡ 579 (73.9 %) 483 (74.5 %) 96 (70.6%)
I 65 (8.3 %) 54 (8.3 %) 11 (8.1 %)
II 89 (11.4 %) 70 (10.8 %) 19 (14.0 %)
III 8 (1.0 %) 8 (1.2 %) 0
Follow-up Time Years (SD) 6.6 (0.4)
BMI: Body Mass Index, Hx: History, N: number of participants, SD: Standard Deviation
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Figure 4. Longitudinal effects of cardioselective β-blocker use on FEV1 in percentages.
Divided in four exposure categories; “never exposed”, “starters”, “continuous users”, and “discontinued use”. 
The whiskers represent the 95% CI




0
5
10
15
20
25
Longitudinal Effects on FVC
Exposure
D
ec
re
as
e 
of
 F
VC
 in
 %
Never Exposed Starters Continuous Users Stoppers
n=563 n=85 n=88 n=48
*
*
* p < 0.05
Figure 5. Longitudinal effects of cardioselective β-blocker use on FVC in percentages.
Divided in four exposure categories; “never exposed”, “starters”, “continuous users”, and “discontinued use”. 
The whiskers represent the 95% CI
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DIsCussIOn
In this population-based study, exposure to cardioselective β-blockers was associated 
with a lower FEV1 of -118 ml, and FVC of -167 ml, respectively. For non-cardioselective 
β-blockers we found an association with a marginally lower FEV1/FVC of -1.38% (-2.74;-
0.13), a measure to assess airflow obstruction. For cardioselective β-blockers, although 
the sample was much larger, no such association was found. When we compared the 
effect on FEV1/FVC within users of non-cardioselective β-blockers versus cardioselec-
tive β-blockers, the association remained significant. Longitudinal effects of exposure 
showed a stronger decrease of FVC over time in participants starting on β-blockers 
Figure 6. Longitudinal effects compared to stoppers
These figures represent the decrease or increase in FEV1 and FVC for separate types of β-blockers users 
compared to never users over the consecutive time points. The linear relation is corrected for age, sex, 
follow-up time, current smoking and pack-years. 
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versus never users. For FEV1 a similar pattern was seen. When prescriptions ended 
between the two measurements, the decrease in FEV1 and FVC was less in quitters 
than in never users, however this was not significant. Although our results suggest 
negative effects of cardioselective β-blockers on pulmonary function which can be 
defined as a clinically important difference 24,25, several studies suggest beneficial ef-
fects on mortality in patients with concomitant CVD and COPD. Therefore, negative 
effects on pulmonary function may very well be outweighed by the positive effects of 
cardioselective β-blockers on CVD with respect to morbidity and mortality. Apparently, 
also cardioselective β-blockers are not completely free of pulmonary effects. Impor-
tantly, non-cardioselective β-blockers seem to have greater association with an airflow 
obstruction than cardioselective β-blockers. Only non-cardioselective β-blockers had a 
significant association with a reduced FEV1/FVC compared to non-exposed participants 
and compared to users of cardioselective β-blockers.
To our knowledge, this is the first population-based cohort study solely investigating 
the effects of β-blockers on pulmonary function. To deal with potential confounding by 
indication, we separately analysed the participants with heart failure and/or obstructive 
pulmonary disease. The results in this subset were consistent with the results in the 
complete set, suggesting that underlying obstructive pulmonary disease did not influ-
ence the magnitude of the effects. To minimize the possible misclassification of heart 
failure, we did a sensitivity analysis in which we adjusted for cardiac function, defined 
by fractional shortening and E/A-ratio. These measures hardly influenced the effect 
estimate. The decreased spirometry measures can possibly be explained by increased 
airway resistance as has been stated in the past 1. Another possible reason could be 
that some participants with a prescription for β-blockers might have already developed 
heart failure, which was still unknown at the time of pulmonary function test. But as 
participants in The Rotterdam Study were also screened for heart failure this seems less 
likely 13,14.
Our findings suggest that also cardioselective β-blockers have an adverse effect on 
pulmonary function in the general elderly population, although this is less pronounced 
than in non-cardioselective β-blockers and there is no effect on airflow obstruction. 
One, somewhat similar, study by Schnabel showed a trend for a lower FEV1 in people 
taking β-blockers and a significantly reduced FVC, but since the study focussed on other 
objectives, the association was not extensively investigated 26. Our study confirms this 
association with FVC and shows an association with FEV1.
Previous studies did not show a significant effect on FEV1 or respiratory symptoms in 
meta-analyses of randomized clinical trials 9,10. However, these meta-analyses included 
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primarily small randomized placebo controlled studies. In these studies, 80% of the 
participants were male and COPD severity was mild to moderate and according to the 
authors this could be a limitation of the study 9. In a crossover trial, Jabbour et al. showed 
a difference in FEV1 between patients with cardioselective and non-cardioselective 
β-blockers for chronic heart failure (CHF) with COPD. The authors reported a 150 ml 
lower FEV1 in patients with CHF and COPD receiving non-cardioselective β-blocker than 
in patients receiving cardioselective β-blockers. No such difference could be detected 
for FVC 27. This study in 51 males showed differences between patients receiving either of 
the β-blockers, but did not compare pulmonary function to non-users. Another study by 
Çamsari et al in 50 patients showed that metoprolol did not change pulmonary function 
according to symptoms, clinical findings and FEV1 changes 
28.Other studies focussed on 
morbidity and mortality in patients with CVD and COPD. Rutten et al. performed a large 
observational study using general practitioners records. The authors assessed all-cause 
mortality and exacerbations of COPD in the complete sample and in subsets. Rutten et 
al. showed a possible beneficial effect on survival and a reduced risk on COPD exacerba-
tion in patients taking cardioselective β-blockers 11. Misclassification of patients could 
be an issue, according to the authors, and patients could have had concealed cardiac 
disease instead of COPD, which would show a positive effect of β-blockers on survival 
2,11. On the other hand, since heart failure and COPD exacerbations were suggested to be 
closely linked with regard to mortality 29,30, treating patients with a multidrug regimen 
might provide disease-specific benefits and reduce mortality 31.
Chen et al. found that β-blocker use after an acute myocardial infarction, in patients 
with COPD without β-agonist, use significantly reduced one year mortality. The authors 
suggest that these patients may have a mild form of COPD and that the benefits of 
β-blocker therapy outweigh the risk of bronchospasm 32.
In a recent paper by Short 33, the investigators defined a cohort of COPD patients and 
compared mortality across different treatment regimens for COPD and CVD. The inves-
tigators found a 22% overall reduction of all-cause mortality for patients with COPD if 
the treatment regimen included β-blockers. Spirometry measurements were available in 
a subset of patients. The authors found no deleterious effect of β-blockers on FEV1 and 
FVC. This observational study, like any observational study, is at risk for confounding by 
indication and post hoc treatment changes by physicians can influence the results 34. 
Furthermore, the analysis of a subset with spirometry tests could be influenced by some 
form of selection bias in a retrospective database study.
The strengths of our study are the prospective, population-based cohort design and the 
large number of study subjects with pulmonary function tests. The population-based 
character and high participation rate makes selection bias less likely. Due to the prospec-
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tive nature of the data collection, also information bias is unlikely and information about 
several covariables was collected. Another strong point is that we in the Rotterdam 
study we have both prescription and interview data to check adherence to therapy. An 
earlier analysis in the Rotterdam Study showed that there was a very high concordance 
between pharmacy dispensing data of β-blockers, and actual use during interview 35.
Although longitudinal data shows interesting patterns, numbers of repeated measure-
ments were limited. Due to the observational character of our data, residual confound-
ing cannot be ruled out completely. We adjusted for confounding by (contra-) indication 
by excluding participants with COPD, and as a proxy for asthma, we excluded patients 
with prescriptions for inhalation medication to study the effects in patients without 
obstructive pulmonary disease. Since spirometry was introduced in 2002, some form of 
survival bias could have occurred, but our expectation is that this would not explain the 
fact that we observed a difference between users and non-users of β-blockers. Lastly 
we could not include disease-specific mortality data into these analyses to see if this 
reduction in FEV1 and FVC was associated with a higher mortality rate.
In conclusion, in this population-based study, we demonstrated that not only non-cardi-
oselective, but also cardioselective β-blockers had a clinically significant effect on both 
FEV1 and FVC in some patients. Unlike cardioselective β-blockers, non-cardioselective 
β-blockers were, beside FEV1 and FVC, significantly associated with a marginally de-
creased FEV1/FVC.
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absTraCT
background Studies suggest that statins decrease mortality in COPD patients but it is 
unknown which patients might benefit most.
Objectives We investigated whether statins were associated with reduced mortality 
in COPD patients and whether effects differed according to baseline high-sensitivity 
C-reactive protein (hsCRP) concentration, a marker of systemic inflammation.
methods This nested case-control study was part of the Rotterdam Study, a prospec-
tive population-based cohort study among 7983 subjects ≥ 55 years. Using automated 
pharmacy records, we evaluated statin use of 363 cases (COPD patients who died during 
follow-up of 17 years) with 2345 age and sex matched controls (COPD patients who 
survived the follow-up period of the index case).
results Compared to never use, long-term statin use (> 2 years) was associated with a 
39% decreased risk of death in COPD patients. Stratified according to the level of sys-
temic inflammation, long-term statin use was associated with a 78% reduced mortality 
if hsCRP level > 3 mg/L, versus a non-significant 21% reduced mortality if hsCRP level ≤ 
3 mg/L.
Conclusions Statin use is associated with a beneficial effect on all-cause mortality in 
COPD, depending on the baseline level of systemic inflammation.
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InTrODuCTIOn
Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause 
of morbidity and mortality worldwide. In industrialized countries about 400,000 COPD 
deaths occur each year and the mortality is expected to increase further.1 The disease 
is characterized locally by a chronic inflammation of small airways and destruction of 
alveoli and systemically, in a subset of COPD patients, by increased markers of inflam-
mation, including high-sensitivity C-reactive protein (hsCRP) and interleukin 6 (IL6) 2-4. 
The subset of COPD patients with persistent systemic inflammation has recently been 
shown to be associated with poor clinical outcomes despite similar lung impairment.5 
The chronic low-grade inflammation might be the key link to the occurrence of various 
comorbidities in COPD including cardiovascular diseases and lung cancer. Moreover, 
these comorbidities are the main causes of death in mild to moderate COPD; therefore, 
with the increased recognition of the prognostic role of comorbidities in COPD, all-cause 
mortality has become one of the major endpoints in the evaluation of novel therapies6.
Recent observational studies suggest that statins (3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase inhibitors) may reduce morbidity and mortality in COPD 
patients7-9. Statins are a class of drugs mainly used to treat hypercholesterolemia and 
to prevent cardiovascular events. Statins reduce cholesterol synthesis by inhibition of 
HMG-CoA reductase in the liver and increase low density lipoprotein-cholesterol uptake 
from the circulation. In addition to their lipid-lowering effect, statins also possess pleio-
tropic anti-inflammatory and immunomodulating properties, and are able to reduce 
levels of inflammatory markers such as CRP 10. CRP is a validated biomarker of systemic 
inflammation in COPD and increased CRP levels in patients with COPD are associated 
with increased mortality 11,12. Lee et al. recently showed in a randomized controlled trial 
with COPD patients, that pravastatin treatment significantly decreased CRP and IL6 lev-
els compared to placebo and that the improvement of exercise tolerance was greater in 
those with a greater decrease of hsCRP levels and higher baseline CRP levels 13. However, 
to our knowledge, studies exploring whether the beneficial effect of statins on all-cause 
mortality in COPD is greater in those with increased systemic inflammation, have not yet 
been published.
Therefore, the objective was to investigate whether statins have a beneficial effect on 
mortality in COPD patients with increased baseline hsCRP-levels in the Rotterdam Study, 
a large prospective population-based cohort study with long-term follow-up.
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mEThODs
study population and design
We performed a nested case-control analysis in all COPD cases within the Rotterdam 
Study, a population-based cohort study aimed at assessing the occurrence of and risk 
factors for chronic diseases in the elderly 14. The Rotterdam study cohort includes 7983 
participants aged ≥ 55 years, living in Ommoord, a well-defined suburb of Rotterdam, 
the Netherlands. Almost all participants (99.8%) are of Caucasian descent. Baseline data 
were collected from 1989 until 1993 and each participant visits the research centre every 
2 to 3 years. In addition, participants are continuously monitored for the onset of major 
events which occur during follow-up through automated linkage with files from general 
practitioners. Nearly all participants (99.7%) are registered at one or more of seven au-
tomated pharmacies serving the Ommoord area. From these pharmacies, records of all 
filled prescriptions were available as of January 1st, 1991. The medical ethics committee 
of the Erasmus Medical Centre, Rotterdam, and the review board of The Netherlands 
Ministry of Health, Welfare and Sports, approved the study. Participants gave written 
informed consent.
Definition of cases and controls
Cases and controls were nested in all participants of the source population of whom 
hsCRP was measured at baseline and of whom COPD was diagnosed by an obstructive 
spirometry (proportion of the forced vital capacity exhaled in the first second (FEV1/
FVC) < 0.7) during the research centre or pulmonologist visits or by a general practitio-
ner. Physician diagnosed asthma patients were excluded. The incident COPD date was 
defined as the date of COPD diagnosis in the medical records, or the date of a first COPD 
medication prescription or the date of obstructive lung function examination, whichever 
came first. To ensure at least three months medication history for every subject, partici-
pants of whom study follow-up started before April 1st, 1991 were excluded. Cases were 
COPD subjects who died between April 1st, 1991 and January 1st, 2008. The mortality 
date was taken as the index date. Controls were COPD subjects matched on sex and age 
(+/- 1 year) who were still alive on the same day of follow-up as their matched case. The 
duration of COPD was determined as the time between the incident COPD date and the 
index date.
statin exposure
Complete information on all filled prescriptions on a day-to-day basis was obtained in 
automated format from the pharmacies. Subjects were classified as statin users if they 
had received at least one prescription for statins between start and index date. The dura-
tion of a prescription was calculated as the total number of delivered units divided by 
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the prescribed daily number of units. The studied statins were simvastatin, pravastatin, 
fluvastatin, atorvastatin, cerivastatin and rosuvastatin. All drugs under study are only 
available on prescription in the Netherlands.
all-cause mortality & primary cause of death
Information on vital status of the Rotterdam Study participants was obtained from 
general practitioners and from municipal records. Mortality follow-up started at base-
line and was complete until January 1st, 2008. Causes of death during follow-up in the 
Rotterdam Study were coded according to the International Classification Of Diseases 
(ICD)-10 15. The following categories were applied for description in the text: cardiac 
mortality (ICD-10: I21-I73, R96), pulmonary mortality (ICD-10: J15-J44), death from bron-
chial carcinoma (ICD-10: C34), death from other malignancies (ICD-10: C15-C96 except 
C34) and other causes of death (ICD-10: all other used codes).
Covariables
The nested case-control approach makes it possible to account for age and gender by 
matching and to adjust for other drug use at the index date. Therefore, we adjusted 
mortality risk estimates for use of cardiovascular drugs (antihypertensives, diuretics, 
β-blockers, calcium channel blockers and ATC C02, C03, C07, C08 & C09 respectively), 
antidiabetics (ATC A10) and corticosteroids for systemic use (ATC H02) on the index 
date. Furthermore, the duration of COPD at index date and the following covariables 
at baseline were considered as potential confounders: pack-years of cigarette smoking, 
total serum cholesterol, hsCRP, systolic blood pressure, body-mass index (BMI), diabetes 
mellitus and cardiovascular covariables (myocardial infarction, coronary artery bypass 
graft, percutaneous transluminal coronary angioplasty, atrial fibrillation and heart 
failure); and their assessment has been described previously 2,3. One prerequisite to be 
a confounder is that the variable is associated with the exposure, here statin use. There-
fore, the relationship between the potential confounder and statin use (yes/no) was 
evaluated for categorical variables with a Chi Square test and for continuous variables 
with a Mann-Whitney U test.
statistical analysis
Crude and adjusted odds ratios for mortality were estimated using conditional logistic 
regression. All models were adjusted for covariates that were significantly related to 
the exposure and changed the point estimate by more than 10%. Statin drug use was 
categorized as no use (0 days), short-term (1-30 days), mid-term (31 days-2 year) and 
long-term use (≥ 2 year). Because every participant should have the opportunity to be 
a long-term user, COPD subjects with an incident date from January 1st, 2006 onwards, 
were excluded from analyses. Never use of statins was the reference category in all 
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analyses. To gain power in the subdivided cause-specific mortality analyses, the groups 
mid-term and long-term use were combined. hsCRP serum levels were categorized as 
high versus average and low, based on the American Heart Association classification 16. 
Total serum cholesterol levels were categorized as high versus borderline and desirable, 
based on the Adults Treatment Panel III classification 17. All statistical analyses were per-
formed using SPSS version 18 (SPSS Inc, Chicago, IL). P values below the conventional 
level of significance (p < 0.05) were considered as statistically significant.
rEsuLTs
baseline characteristics of the study population
Within the source population of 7983 subjects, hsCRP was successfully measured in 
6658 participants at baseline. (Figure 1) Of these, 758 COPD patients were identified 
with a study start date after April 1st, 1991 to ensure at least three months of medication 
history. The vast majority (82.5%) of COPD patients was confirmed by an obstructive spi-
rometry. Seventy-one patients with an incident COPD date after January 1st, 2006 were 
excluded from analyses because at least two years of follow-up between incident COPD 
and death were required to study the association of long-term statin use on mortality. 
During the potential follow-up of 17 years (1991-2008), 363 COPD patients deceased 
and were determined as cases. For each case, an average of six age- and sex-matched 
7983 participants
6658 participants with hsCRP measurement at baseline
758 COPD patients with study start date ≥ 1-4-1991
Exclusion of 71 patients 
with incident COPD date  
≥ 1-1-2006
363 Cases = COPD patients 
who died during follow-up
2345 age & sex matched 
controls = COPD patients 
who survived the follow-
up period of the index 
case
Figure 1. Study flowchart. 
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controls with COPD who survived the follow-up period of their matched case, were se-
lected for a total of 2345 controls. Because non-deceased participants with COPD could 
serve as a control in several case-control sets, the total number of controls is larger than 
the total number of incident cases of COPD. Table 1 shows the baseline characteristics 
Table 1. Baseline characteristics
Cases Controls
number of participants 363 2345
age at index date (years) 81 (75-85) 78 (74-81)
male 249 (69%) 1722 (73%)
Smoking behaviour
never smoker 39 (11%) 252 (11%)
Current smoker 145 (40%) 820 (35%)
Former smoker 164 (45%) 1170 (50%)
missing 15 (4%) 103 (4%)
median pack-years
30 (14-50) 28 (13-47)
body mass index (kg/m²) 25 (23-28) 26 (24-28)
Diabetes 43 (12%) 161 (7%)
systolic blood pressure (mmhg) 139 (123-155) 137 (124-152)
Cardiovascular covariables§ 163 (45%) 724(31%)
hsCrP (mg/L) 2.1 (1.1-4.0) 2.7 (1.3-4.8)
hsCrP categoriesa ≤ 3 mg/L
>3 mg/L
202 (56%)
161 (44%)
1524 (65%)
821 (35%)
Total serum cholesterol (mmol/l) 6.4 (5.6-7.2) 6.4 (5.7-7.3)
Total cholesterol 
categoriesb 
< 240 mg/dL
≥ 240 mg/dL
166 (46%)
197 (54%)
1055 (45%)
1290 (55%)
Drug use at index date
antidiabetics
Cardiovascular drugsb
Oral corticosteroids
41 (11%)
209 (58%)
138 (38%)
194 (8%)
1249 (53%)
303 (13%)
Duration of statin use
none
1-30 days
31 days-2 years
> 2 years
299 (82%)
5 (1%)
18 (5%)
41 (11%)
1856 (79%)
22 (1%)
197 (8%)
270 (12%)
Duration of COPD at index date (years) 7 (3-11) 5 (2-8)
Categorical variables are expressed as count (percentage). Values of continuous variables are expressed 
as median (25-75 percentiles). Cases: COPD patients who deceased during follow-up; controls: COPD 
patients who survived the follow-up period of the index case. §Cardiovascular covariables included 
myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, 
atrial fibrillation and heart failure. a hsCRP categories based on the American Heart Association 16, total 
cholesterol categories based on the Adults Treatment Panel III classification 17. b; Cardiovascular drugs 
include antihypertensives, diuretics, β-blockers and calcium channel blockers.
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of cases and controls. Cases were more frequently current smokers and had a higher 
prevalence of cardiovascular disease at baseline in comparison to the controls. Although 
age- and sex-matched, cases seem older and less often males as a consequence of the 
fact that there were more controls for males and lower age-categories.
mortality in COPD patients
The cumulative survival of COPD patients (n=758) was worse in those with a baseline 
hsCRP of more than 3 mg/L than in those with an hsCRP of 3 mg/L or less (Figure 2; 
log-rank: p < 0.0001). In contrary, COPD patients with a total cholesterol of 240 mg/
dL or more had a better survival than those with less than 240 mg/dL at baseline (data 
not shown; log-rank: p = 0.008). The most frequent causes of death in COPD patients 
are listed in Table 2. Most cases died due to cardiovascular causes (38.3%), followed 
by pulmonary complications of COPD (COPD exacerbations, emphysema or pneumo-
nia;19.6%) and bronchial carcinoma (10.5%).
statin use and the risk of mortality in COPD
Table 3 shows the association between statin use and the risk of all-cause mortality in 
COPD in a first model which is already adjusted for age and sex by matching and in a 
second model adjusted for all confounders related to the exposure which changed the 
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Figure 2: Kaplan-Meier survival curve of COPD patients (n=758) according to the hsCRP level (at baseline).
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point estimate by more than 10%. Baseline hsCRP-level was ruled out as confounder be-
cause it was not associated with statin prescriptions (nor as categorical variable neither 
continuously); however, hsCRP was evaluated as a potential effect modifier. Compared 
to never use, long-term statin use (> 2 years) was associated with a 39% decreased risk 
Table 2. Causes of death in the COPD study population
n % of Total
Pulmonary 71 19.6
COPD 59 16.3
  Pneumonia 12 3.3
Cardiovascular 139 38.3
 Mainly Heart failure 31 8.5
  Stroke 30 8.3
  Sudden (cardiac) death 30 8.3
  Cardiac arrest 18 5.0
  Acute myocardial infarction 12 3.3
  Chronic ischaemic heart disease 6 1.7
Cancer 88 24.2
 Mainly Malignant neoplasm of bronchus and lung 38 10.5
  Malignant neoplasm of colon 8 2.2
  Malignant neoplasm of pancreas 6 1.7
  Malignant neoplasm of prostate 6 1.7
Other 65 17.9
 Mainly Other ill-defined and unspecified causes of mortality 19 5.2
  Dementia 8 2.2
  Fracture of femur 7 1.9
Total: 363
Table 3. Association between statin use and the risk of (all-cause) death in COPD
Crude modela adjusted modelb
OR
95% CI
p-value OR
95%CI
p-valueLower Upper Lower Upper
No statin use Reference Reference
1 - 30 days 1.34 0.49 3.67 0.572 1.61 0.48 5.48 0.443
31 days - 2 years 0.68 0.40 1.16 0.156 0.64 0.35 1.15 0.136
> 2 years 0.82 0.55 1.22 0.331 0.61 0.38 0.99 0.045
aCrude model: adjusted for age and sex by matching
bAdjusted model: adjusted for age and sex by matching; adjusted in the analyses for the use of 
cardiovascular drugs, antidiabetics, oral corticosteroids and duration of COPD at index date, and pack-
years of cigarette smoking, total serum cholesterol, body-mass index and cardiovascular covariables at 
baseline
Abbreviations : CI, confidence interval; OR, Odds ratio
190 Chapter 4.2
of (all-cause) death in COPD patients (95%CI, 0.38-0.99) independent of age, sex, other 
drug use, duration of COPD, pack-years, total serum cholesterol, BMI and cardiovascular 
covariables.
Regarding cause-specific mortality in COPD, statin use (>30 days) compared to never use 
was associated with a significant 64% decrease in risk of pulmonary mortality (95%CI, 
0.13-0.97). (Table 4) In the adjusted model, there was a trend of decrease in risk of pul-
monary and cardiovascular mortality. Statin use did not affect cancer mortality in both, 
crude and adjusted analyses.
statin use and the risk of (all-cause) death in COPD according to the level of 
systemic inflammation
When stratified according to the level of systemic inflammation, long-term statin use 
was associated with a 78% reduced risk of death in COPD patients with a hsCRP level > 3 
mg/L (95% CI, 0.06-0.74), versus a non-significant 21% reduced risk of death in COPD pa-
tients with a hsCRP level ≤ 3 mg/L (95% CI, 0.41-1.55). (Table 5) When we excluded COPD 
patients exclusively diagnosed by GP, the point estimator did not change substantially 
(OR 0.49 in the crude model and OR 0.31 in the adjusted model, investigating the effect 
of long-term statin use compared to no use in COPD subjects with hsCRP > 3mg/L). A 
sensitivity analysis restricting the subjects to smoking COPD patients with a hsCRP level 
> 3 mg/L, confirmed that long-term statin use compared to no use was associated with a 
85% reduced risk of death (95% CI, 0.04-0.61, adjusted model). In Table 6, analyses were 
stratified according to the total serum cholesterol level at baseline. The reduced risk of 
Table 4. Association between statin use and the risk of cause-specific mortality in COPD
Pulmonary mortality
Crude modela adjusted modelb
OR
95% CI
p-value OR
95% CI
p-valueLower Upper Lower Upper
No statin use Reference Reference
>30 days of statin 0.36 0.13 0.97 0.044 0.37 0.13 1.08 0.068
Cardiovascular mortality
No statin use Reference Reference
>30 days of statin 0.87 0.54 1.41 0.579 0.58 0.33 1.01 0.053
Cancer mortality
No statin use Reference Reference
>30 days of statin 0.89 0.49 1.61 0.700 0.92 0.48 1.75 0.790
aCrude model: adjusted for age and sex by matching
bAdjusted model: adjusted for age and sex by matching; adjusted in the analyses for the use of 
cardiovascular drugs at index date, and total serum cholesterol and cardiovascular covariables at baseline
Abbreviations : CI, confidence interval; OR, Odds ratio
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death in COPD patients by long-term statin use was significant in both categories (<240 
mg/dl and ≥ 240 mg/dl).
Table 5. Association between statin use and the risk of death in COPD, stratified according to the serum 
level of hsCRP (at baseline)
Crude modela adjusted modelb
 
OR
95% CI
p-value OR
95% CI
p-valueLower Upper Lower Upper
hsCRP
≤ 3 mg/L
No statin use Reference Reference
1 - 30 days 0.66 0.14 3.16 0.606 0.77 0.14 4.09 0.756
31 days - 2 years 0.70 0.35 1.43 0.335 0.60 0.27 1.34 0.212
> 2 years 0.87 0.51 1.50 0.620 0.79 0.41 1.55 0.496
hsCRP
> 3 mg/L
No statin use Reference Reference
1 - 30 days 1.83 0.29 11.49 0.520 NA
31 days - 2 years 0.77 0.30 1.96 0.584 0.95 0.33 2.73 0.917
> 2 years 0.44 0.20 0.97 0.042 0.22 0.06 0.74 0.015
aCrude model: adjusted for age and sex by matching
bAdjusted model: adjusted for age and sex by matching; adjusted by model for the use of cardiovascular 
drugs, antidiabetics, oral corticosteroids and duration of COPD at index date, and pack-years of cigarette 
smoking, total serum cholesterol, body-mass index and cardiovascular covariables at baseline.
Abbreviations : hsCRP, high-sensitivity CRP; CI, confidence interval; OR, Odds ratio; NA, Not applicable (due 
to low numbers)
Table 6. Association between statin use and the risk of death in COPD, stratified according to the total 
serum cholesterol level (at baseline)
Crude modela adjusted modelb
 
OR
95% CI p-
value OR
95% CI p-
valueLower Upper Lower Upper
Total 
cholesterol
< 240 mg/dL
No statin use Reference Reference
1 - 30 days 1.99 0.36 10.85 0.428 5.68 0.38 84.61 0.208
31 days - 2 years 0.32 0.07 1.40 0.130 0.17 0.02 1.42 0.102
> 2 years 0.41 0.13 1.30 0.129 0.16 0.03 0.91 0.039
Total 
cholesterol ≥ 
240 mg/dL
No statin use Reference Reference
1 - 30 days 1.24 0.22 7.01 0.806 1.22 0.07 21.19 0.891
31 days - 2 years 0.69 0.37 1.32 0.266 0.65 0.32 1.33 0.238
> 2 years 0.79 0.47 1.31 0.355 0.50 0.26 0.95 0.034
aCrude model: adjusted for age and sex by matching
bAdjusted model: adjusted for age and sex by matching; adjusted by model for the use of cardiovascular 
drugs, antidiabetics oral corticosteroids and duration of COPD at index date, and pack-years of cigarette 
smoking, body-mass index and cardiovascular covariables at baseline.
Abbreviations : CI, confidence interval; OR, Odds ratio
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DIsCussIOn
This is the first prospective study in a general population showing that the beneficial 
effect of long-term statin use on the risk of mortality in COPD patients is modified by 
the baseline level of systemic inflammation. The results suggest that the subset of COPD 
patients characterized by increased markers of systemic inflammation might benefit 
most from long-term statin therapy. One in three COPD patients in our study died from 
cardiovascular causes - figures which have also been described by other authors 6,18. 
Although the protective effect of statins in COPD patients could represent solely an 
indirect effect on the cardiovascular comorbidities associated with COPD, our results 
also suggest an effect on respiratory mortality by statin use compared to never use.
Increasing insights into the pleiotropic effects of statins unravel several possible mecha-
nisms for the beneficial effects seen in COPD patients. Beyond their known ability to 
inhibit endogenous cholesterol synthesis, statins exert immunomodulating effects in 
both systemic and pulmonary cytokine driven inflammation by inhibiting guanosine 
triphosphatase proteins 19. Statins down regulate the expression of adhesion mol-
ecules involved in the recruitment of inflammatory cells, and of chemokines which are 
increased in COPD, such as CCL2 and CXCL8 20. Furthermore, simvastatin reduces the 
expression of matrix metalloproteinases (MMPs) involved in COPD matrix remodelling, 
such as MMP2, MMP9 and MMP12 21,22. In support of a direct effect of statins in COPD, 
Lee et al. demonstrated in a rat model of smoking-induced emphysema that simvastatin 
ameliorated the structural and functional derangements of the lungs partly by sup-
pressing inflammation and matrix MMP9 induction 23. Statins may even reduce oxidative 
stress, related to their ability to scavenge oxygen derived free radicals 24.
The 39% reduced risk of death in COPD patients by using (long-term) statin therapy is 
consistent with findings of previous (retrospective) observational studies 8,9. Similar to 
the retrospective study of Frost et al., we found a protective effect of statin use on the 
risk of pulmonary mortality in COPD 25. Furthermore, our results showed that having 
an hsCRP baseline level of more than 3 mg/L was associated with increased mortality 
and therefore we expected, if statins were effective, that the pre-specified subset of 
COPD patients with high hsCRP levels would benefit most of treatment. Surprisingly 
but consistent with other prospective population-based studies in the elderly, we found 
that COPD patients with a total cholesterol of 240 mg/dL or more had a better survival 
26,27. Selective survival or changes in the arterial wall by aging might yield individuals re-
sistant to the effects of high cholesterol concentrations in the blood or high cholesterol 
levels might be associated with less frailty.
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Importantly, we demonstrate a significant interaction between statin use and the degree 
of systemic inflammation because the protective effect of statins was only significant in 
COPD patients with the highest hsCRP serum level. There was no significant effect in 
COPD patients with a low-to-moderate degree of systemic inflammation, which cannot 
be explained due to lack of power as numbers were even higher in this stratum. The 
same phenomenon has also been reported in cardiovascular studies and one RCT in 
COPD patients. Kinjo et al. described a decreased hazard by statin therapy for 1-year 
mortality in patients with a CRP level above 2.9 mg/L who had an acute myocardial 
infarction 28. In addition, the JUPITER trial of apparently healthy persons without hyper-
lipidemia but with elevated hsCRP levels, demonstrated that rosuvastatin significantly 
reduced the incidence of all-cause mortality and was associated with a 60% decreased 
risk for cardiovascular endpoints 29. However, a recent RCT in persons at high risk of 
vascular events, could not confirm that these vascular benefits of statin therapy were 
affected by the baseline CRP concentration 22. The RCT in COPD patients by Lee et al. 
demonstrated that the improvement in exercise time by statin treatment is modified by 
plasma hsCRP-levels 13. Because both the inflammation and therapeutic interventions in 
COPD have been studied merely in (ex)smoking subjects, we furthermore restricted the 
analyses to smoking COPD patients, which confirmed the beneficial effects of long-term 
statin use in the subgroup with greater inflammation.
Because of its observational character, a possible limitation of our study is that treat-
ment with statins was not randomly assigned. Our results could therefore be flawed 
by confounding by indication. However, because statins are selectively prescribed in 
subjects who have substantial comorbidities such as diabetes mellitus and cardiovas-
cular disease, this kind of confounding would only underestimate the protective effect 
of statins on the risk of death. Consequently, this would mean that the true protective 
effect is even stronger than we measured. Secondly, we cannot exclude a healthy user 
bias if statins are prescribed more readily in health-conscious, medical-attention-seeking 
patients or in those patients who are expected to live long enough to benefit from statin 
treatment. Importantly, however, this would not explain effect modification by baseline 
hsCRP as this measurement was not used for usual patient care. Finally, of a minority of 
COPD patients diagnosed by GP (17,5%), we do not have the certainty that diagnosis 
was confirmed by an obstructive spirometry. However, exclusion of this subgroup did 
not change the point estimator substantially.
The strengths of this study are the high quality information available about exposures 
prior to outcome with a prospective data collection, the general population based set-
ting, the large number of subjects that participated in the Rotterdam Study and the long 
duration of follow-up. The high response rate and virtually complete follow-up for every 
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participant makes information and selection bias for these data unlikely. An important 
advantage is the availability of continuous pharmacy dispensing data with complete 
pharmacy records of all filled prescriptions on practically all members of the cohort, 
providing very specific and detailed information on drug use and thus minimizing 
the risk of exposure misclassification. Furthermore, the nested case-control approach 
made it possible to account for other drug use at index date, a major confounder in the 
association between statins and mortality. It is important that these results should be 
further investigated in randomized controlled trials before recommending widespread 
statin use in COPD patients. According to Clinicaltrials.gov, several randomized clinical 
trials are ongoing.
In conclusion, statin use is associated with a decreased risk of all-cause mortality in 
patients with COPD, depending on the degree of systemic inflammation. These results 
suggest that in an older population of COPD patients, CRP levels might guide the clini-
cian better than total cholesterol levels in his decision to start lipid lowering therapy. 
This study may provide a rationale for undertaking more definitive randomized clinical 
trials to confirm the impact of statin use on the outcome of COPD and to elucidate the 
mechanisms by which they may work.
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InTrODuCTIOn
“Chronic Obstructive Pulmonary Disease (COPD), a common preventable and treatable 
disease, is characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and the lung 
to noxious particles or gases. Exacerbations and co-morbidities contribute to the overall 
severity in individual patients.” 1
This is the definition as stated by the Global initiative for Chronic Obstructive Lung 
Disease (GOLD). The incidence of COPD is increasing and the disease is estimated to be 
the third leading cause of death worldwide2. Although inhalation of noxious particles 
and gases is the main cause of COPD, there seems to be a discrepancy between the 
number of smokers and the occurrence of COPD. Common and rare genetic factors 
may explain part of the susceptibility to the damage inflicted by these particles and 
gases. Furthermore, genetics may account for impaired lung growth during fetal de-
velopment, childhood and adolescence, resulting in a maximum lung capacity which is 
already reduced compared to the population average3. During the course of adult life, 
lung function diminishes which can result in disability, oxygen dependency or death 
4. COPD is a very heterogeneous disease, but one of the cornerstones of diagnosis of 
COPD remains spirometry, a highly reproducible and fairly easy to implement assess-
ment of lung volumes and function. Due to the heterogeneity of the etiology of COPD 
and the assumption that complex diseases consist of a compound of quantitative traits 
5, spirometry measurements have been proven to be valuable to investigate common 
genetic polymorphisms 6-8 and to identify genes like Human Hedgehog Interacting 
Protein (HHIP) which seem to have a strong relationship to COPD 9.
The main objectives of this thesis were to investigate the association between spirom-
etry and COPD in the general population. This includes, but is not limited to, genetic 
components of and genetic susceptibility to COPD. This discussion places the results of 
our research in perspective, elaborates on general methodological considerations and 
provides some future perspectives of genetics and pharmacogenetics with respect to 
obstructive lung diseases.
maIn FInDInGs
spirometry in an aging population
Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC) and the ratio 
of FEV1 over FVC (FEV1/FVC) are the most commonly used measures of pulmonary func-
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tion and essential in the diagnosis of COPD, assessing disease severity, and monitoring 
treatment responses 1,10,11. Pulmonary function also predicts mortality in the general 
population even among people who have never smoked, who have only modestly re-
duced pulmonary function, and who have no respiratory symptoms 12. The peak level 
of pulmonary function is attained in early adulthood and declines subsequently over 
time3,4. Many of the currently used reference values were calculated several decades 
ago and did not include elderly participants due to the lack of data in large groups of 
elderly 13-17. Being above or below the cut-off for the FEV1/FVC, in diagnosis of COPD, is 
one of the most important diagnostically used evaluations. The most frequently used 
cut-off is the fixed ratio of 70% 1. One important drawback of using reference values, 
which have been evaluated only in younger people, is that healthy elderly, who have a 
normal lung function for their age but have a FEV1/FVC below 70%, will be incorrectly 
considered to have an airflow limitation. This will lead to an overestimation of COPD in 
the healthy elderly. One of the possible consequences could be unnecessary treatment 
with (inhalation) medication15.
In chapter 2.1 the objective was to investigate the spirometry measures from a large 
group of healthy elderly from the Rotterdam Study. For the selection of the study 
population of healthy elderly, we excluded current and ex-smokers and participants 
with symptoms of respiratory diseases, participants taking pulmonary (inhalation) 
medication and β-blockers. The exclusion of β-blockers was considered necessary as we 
showed an association between β-blockers use and spirometry (see chapter 4.1). We 
decided to select such a strict subset in order to remove any participants who might 
suffer from (previously) undiagnosed COPD and were not comparable to the entire 
population. Although this decreased the size of the study group, we were still able to 
investigate the pulmonary function tests in 1,125 people of whom more than 25 % 
was aged 72 years and over. The spirometric measures from these people were used 
to calculate reference equations using quantile-regression. Interestingly, although we 
allowed for several mathematical transformations of the outcome and predictors, FEV1 
and FVC followed a linear decrease in the elderly, whereas in children and adolescents 
the trajectory is all but linear. The ratio of FEV1/FVC decreased in females more rapidly 
between 50 and 70 years of age after which it seems to decrease at a slower rate. The 
majority of female participants had an age between 61 and 77, so perhaps the estimates 
for the younger age categories are not as precise as we had aimed for. Compared to two 
of the most commonly used references 15,18, we showed a narrow range for prediction 
of pulmonary function across several different ages and mean heights. Furthermore, 
after evaluating prediction formulas, we concluded that healthy elderly can have lower 
spirometry values (FEV1, FVC and FEV1/FVC) without classifying them as diseased.
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These data hopefully shed some extra light on the issue of inadequate reference values 
in the elderly and may contribute to the evidence that the fixed ratio, as it is still pro-
posed by GOLD 1, could use more flexibility. Our study has of course some limitations, of 
which sample size is one. Although we have a relatively large study compared to other 
single study analyses, specific studies or large scale collaborations aimed to analyze lung 
function in healthy elderly, and especially in people over 80 years old, are still necessary. 
Another limitation of calculating reference values in relatively small age strata, is that 
they cannot be collided with reference values from adjacent age categories, introducing 
uncertainty about the equations at the ends of the stratum.
During the same period as our study, a large effort has been made to calculate the refer-
ence values for people aged 8 – 95 years19, and while this study was much larger than 
our study, the number of subjects in the people aged over 80 years decreased drastically 
compared to all other categories. We were also not able to investigate pulmonary func-
tion in people from other than European descent. Quanjer and colleagues did analyze 
the results from subjects from other than European descent, but there are almost no 
data in the age categories over 80 years old in people from Asian or African descent. 
These are some major issues which need to be addressed in future research especially 
since spirometry is not only useful in assessing pulmonary disease, but can play a role in 
the prediction of mortality, even in absence of respiratory disease 20-25.
Because spirometry is also closely related to cardiac function, we evaluated the correla-
tion between the association between echocardiographic measures and pulmonary 
function in the general population (chapter 2.2). Although the presence of elevated 
pulmonary arterial systolic pressure (PASP) in patients with a lung disease is a well-
known occurrence, the relation between pulmonary ventilatory function and PASP 
is less well investigated. Furthermore, data on both pulmonary arterial pressure and 
spirometry measurements, from the general population are scarce. We found indeed 
strong evidence for an association between PASP and spirometry, but the effect sizes 
were limited. Therefore, it remains to be seen if this is merely normal physiological varia-
tion or if this can further elucidate the etiology of secondary pulmonary hypertension 
or be of use in developing treatment of pulmonary hypertension. This highlights the 
fact that lung function extends its effects to more organs than only the lungs and that 
more research is needed to grasp the clinical implications and diagnostic opportunities 
of these associations.
Genome-wide association studies of spirometry
After the initial genome-wide association studies (GWAs) which have been performed 
in single study analyses, consortia of several population-based cohorts were formed to 
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increase sample size and thereby power to detect small effects in the common variants. 
The first GWAs in 2.5 million common variants across the genome was done in 2009 6 and 
showed evidence for the association between Human Hedgehog Interacting Protein 
(HHIP) and airflow obstruction as defined by a combination of a decreased FEV 1/FVC 
and FEV1. After this initial GWAs, a working group was founded within the Cohorts for 
Heart and Aging Research in Genomic Epidemiology consortium or CHARGE. This con-
sortium is founded by the five following population-based cohort studies: Age, Gene/
Environment, Susceptibility—Reykjavik (AGES), Atherosclerosis Risk in Communities 
Study (ARIC), Cardiovascular Health Study (CHS), Framingham Heart Study (FHS), and 
Rotterdam Study (RS). The large scale meta-analysis in 20,890 individuals resulted in the 
association of seven previously unidentified loci for FEV1 and FEV1/FVC and the confir-
mation of HHIP as gene associated with lung function 8. Parallel to these analyses, the 
Europe based consortium SpiroMeta carried out a similar analysis in 20,288 individuals, 
resulting in the identification of five new loci. The results from these analyses have been 
cross-checked in both cohorts. The identified loci together only explained a small pro-
portion of the heritability, leading to the hypothesis that many more common variants 
remained undetected. After these separate analyses, the consortia decided to combine 
the samples in order to be able to meta-analyze all cohorts and thereby increase power.
This collaboration included a combined sample size of meta-analysis and follow-up of 
94,612 subjects and has been very productive in identifying new loci. The results from 
this collaboration can be found in chapter 3.1. We brought the total number of identified 
variants associated with FEV1 and/or FEV 1/FVC up to 26. Table 1 below provides a brief 
overview of the loci for spirometry, discovered by the most recent GWAs. In general, 
GWAs in spirometry seem to identify loci which influence lung development, e.g. HHIP, 
PTCH1, and RARB which are involved in branching morphogenesis of the airway during 
embryological development 26-28. Other interesting genes that were discovered in these 
analyses were MMP-15 and ADAM19 which are involved in airway remodeling and repair, 
and therefore could probably be associated with respiratory diseases. Genes from the 
same family of proteases, either matrix metalloproteases (MMPs) or disintegrins and 
metalloproteases (ADAMs), were associated with asthma and lung function; e.g. MMP-12 
and ADAM33 29-31.
As shown in the table, the first GWAs in spirometry did not include Forced Vital Capacity 
(FVC). Therefore, we proposed and performed an analysis plan to focus on the genetic 
determinants of FVC. The description of this effort can be found in chapter 3.2. FVC is an 
approximation of total lung capacity and can be measured by spirometry by assessing a 
person’s maximal in- and expiration. A reduced ratio of FEV1 to FVC (FEV1/FVC) indicates 
airflow obstruction when FEV1 is reduced disproportionately relative to FVC. In contrast, 
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a decreased FVC in combination with an elevated FEV1/FVC, suggests a restrictive ven-
tilatory defect. In clinical practice, FVC is often used as a surrogate measure of disease 
progression in patients with established restrictive lung disorders, such as idiopathic 
pulmonary fibrosis32,33. Reduced FVC is a strong predictor of mortality in the general 
population, independently of the forced expiratory volume in 1 second (FEV1) and stan-
dard risk factors such as age and cigarette smoking22-25,34. In conjunction with FEV1, FVC 
is used to diagnose various respiratory diseases. Comparable to the previous CHARGE-
SpiroMeta collaborations, we meta-analyzed data from 26 cohorts in a first stage, after 
which we followed up the sentinel SNPs showing most evidence (n = 7) for association 
with FVC in 7 independent cohorts encompassing a total sample size of n = 77,093. 
Lastly we tested expression in lung tissue, expression quantitative trait locus-analysis in 
whole blood and replicated the top genetic associations in African-American subjects.
In the last 4 years, genome-wide research has taken major leaps forward in identifying 
genetic variations. Altogether, however, these loci explain only 1.5% for FEV1, approxi-
mately 1% for FVC and 3.2% for FEV1/FVC. When putative undiscovered variants with a 
similar distribution are taken into account, the proportion variance explained may reach 
3.4% for FEV1 and 7.5% for FEV1/FVC
35,36. This technique36 to include currently undiscov-
ered loci into account assumes a heritability of lung function of 40% 37,38. The proportion 
variance explained is low but comparable to other quantitative traits 36,39. However, this 
is a major drawback of the results from many GWAs. The great power available to detect 
associations often leaves many questions regarding the true causal relationship and 
determinants of heritability unanswered. On the other hand, although these loci may 
Table 1. Genes implicated to be associated with spirometry
                Trait
article
FEV1 FVC FEV1/FVC Proportion 
variance 
explained (%)
Wilk e.a. HHIP n.a.
hancock e.a. 20108 INTS12-GSTCD-NPNT HHIP, GPR126, 
ADAM19, AGER-PPT2, 
FAM13A, PTCH1, PID1, 
HTR4
FEV1: 0.07-0.14%
FEV1/FVC: 0.09 %
repapi e.a. 2010 7 GSTCD, TNS1, HTR4 AGER, THSD4
soler artigas e.a. 
201135
(chapter 3.1)
MECOM, ZKSCAN3/
ZNF323, CDC123, 
c10orf11, CCDC38
MFAP2, TGFB2, HDAC4, 
RARB, SPATA9, NCR3, 
ARMC2, CDC123, LRP1, 
MMP15, CFDP1, KCNE2
FEV1: 1.5%, FEV1/
FVC: 3.2%
Loth e.a.
(chapter 3.2)
6 newly identified 
loci, currently 
unpublished
FVC: 1%
FEV1 = Forced Expiratory Volume in 1 second, FVC = Forced Vital Capacity.
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not exert massive effects, the identification contributes to the understanding of the 
pathogenesis of lung diseases and lung development. The transcripts of genes usually 
do not act on a single target, but are part of bigger pathway networks. Associating loci 
to spirometry can help disentangling these networks and identifying pathways. Eventu-
ally, this can help in the development of new therapeutic agents.
To evaluate somewhat more complex associations between genetics and spirometry, 
we followed two approaches. In chapter 3.3, we explored the association between 
smoking and genetic variants, a so called gene-by-environment interaction (G x E). Since 
smoking is one of the strongest risk factors for pulmonary diseases, this is usually taken 
into account as a co-variable in the regression models. However, some patients seem to 
be more susceptible to nicotine dependency and the harmful effects of smoking than 
others40,41, implying interaction between genetic variants and the environment. Despite 
the direct exposure to cigarette smoke, interaction between smoke exposure and cer-
tain genetic traits on spirometry values had previously only been investigated through 
candidate gene analyses but without consistent results. In order to fully investigate the 
(multiplicative) interaction between smoking and genes on spirometry, we investigated 
FEV1 and FEV1/FVC and the relation of smoking status. Secondly, we investigated the 
dose response by analyzing the interaction of genes with pack-years smoked (pack-year 
= packs smoked per day × years as a smoker) over time and spirometry measures. This 
collaboration included spirometry from 50,047 subjects and we investigated the interac-
tion using a meta-analysis of SNPmain and SNPinteractioneffects (‘two degrees of freedom’ test 
of the null hypothesis βSNP = 0 and βINT = 0) 
42. This method has been compared to regular 
G x E analysis and main effect analyses and had a greater power to detect effects than 
the two methods separately 43. We showed associations for FEV1 & FEV1/FVC by ever-
smoking (DNER, HLA-DQB1/HLA-DQB2) and for FEV1/FVC by pack-year (KCNJ2/SOX9). 
The Major Histocompatibility Complex, where HLA-DQB1and HLA-DQB2 are localized, 
is a highly polymorphic area with complex linkage disequilibrium, making it currently 
too difficult to further investigate the associated genes and their modes of action. For 
DNER (associated with FEV1/FVC ) and KJNC2/SOX9 (associated with FEV1) expression 
was detected in lung tissue. The DNER protein product is a ligand of the Notch signaling 
pathway which is a critical controller of cellular differentiation in multiple organs includ-
ing the lung 44,45. This region is enriched for long-range regulatory elements for SOX9, 
although the possibility of this region containing KCNJ2 regulatory elements cannot be 
discounted 46. KCNJ2 is a member of the inwardly-rectifying potassium channel family, 
which regulates membrane potential and cell excitability and is expressed in many 
tissues including myocardium, neurons, and vasculature. This potassium channel also 
affects human bronchial smooth muscle tone and may play a role in airflow limitation 
47. SOX9 is a transcription factor that is essential for cartilage formation, SOX9−/− and 
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SOX9+/− mice have multiple skeletal anomalies and severe tracheal cartilage malforma-
tions and die prematurely from respiratory insufficiency 48,49. Although we were looking 
for interaction effects, the p-values for interaction were not significant, implying that 
the loci are associated with SNP main-effects. One main problem with G x E-interaction 
analysis is sample size;most studies (including ours) are grossly underpowered to detect 
multiplicative interaction50. With the approach we used, the model is fully saturated for 
smoking as a covariable, thereby improving power to detect SNPmain effects. However, 
power to detect true and straightforward interaction effects was still insufficient. Ap-
parently, interaction GWAs cannot fully replace the need for additional candidate gene 
studies.
A second interaction analysis that we carried out was the interaction between genetics 
and time-varying lung function (chapter 3.4). The curve of FEV1 over time, first shown 
by Fletcher and Peto4, shows a decrease of lung function over the years. However, this 
graph is a representation of the mean decrease over time of the population and does 
not account for the individual decrease of pulmonary function over time. While the 
decrease is dramatically accelerated by smoking, it is hypothesized that also genetics 
play an important role 51,52. Family- and twin studies of the longitudinal change in lung 
function report heritability estimates between 10 and 39%53,54. Within the CHARGE and 
SpiroMeta consortia 14 cohorts with at least two spirometry measurements carried out 
a linear mixed effects GWA-analysis. Of these 14 cohorts, 5 cohorts had more than two 
measurements over the course of time. A separate analysis was carried out, in order 
to achieve greater precision of estimating the trajectory. The results of this study were 
looked up in a population based cohort (AGES-Reykjavik) and a COPD cohort (Lung 
Health Study). In the total consortium, across approximately 27,000 persons with at least 
2 spirometry assessments, this only yielded suggestive evidence for a single genetic as-
sociation. The subset analyses across 5 cohorts with at least 3 measurements yielded 
one genome wide hit. Since these types of analyses are extremely time-consuming it is 
vital to identify the technical difficulties associated with these analyses. Beside lack of 
power, which is usually a problem in GWAs, heterogeneity across cohorts might cause 
the absence of strong signals. An important observation in the current study is the 
phenotypic variation among the cohort studies in the meta-analyses, in aspects such as 
baseline age and cigarette smoking, and in factors that are of special importance to this 
longitudinal meta-analysis, such as the number of FEV1 measurements per participant 
and follow-up duration, and changes in the lung function apparatus over time within 
individual cohorts. Phenotypic heterogeneity represents a general challenge in genetic 
epidemiology, particularly in the investigation of longitudinal phenotypes.
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While we have explained the importance of quantitative phenotypes above, eventually 
we would like to identify causes for pulmonary diseases and to be able to predict COPD. 
In the final chapter (chapter 3.5) of the genetic analyses, we describe our approach 
to COPD as a disease state rather than the independent quantitative traits underly-
ing the diagnosis. According to the previous and very widely used GOLD guidelines, 
COPD is diagnosed by spirometry (FEV1/FVC < 70%). The staging is according to the 
predicted percentage which a person can exhale in the first second (FEV1 percent 
predicted). As we addressed in chapter 2.1, these fixed cut-offs may not be applicable 
to elderly participants. In our analysis we assessed COPD according to the prediction 
equations proposed by Hankinson 15. With a case-control analysis across 3,368 affected 
and 29,507 unaffected participants from fifteen population based cohort studies one 
region was associated with airflow obstruction which included CHRNA5/CHRNA3 which 
encodes for nicotinic acetylcholine receptor subunit alpha-3 and 5. These genes have 
been previously associated with both COPD 55 and nicotine dependency 41,54, but the 
close correlation between smoking and COPD makes it difficult to disentangle any 
causal relation. In our cross-sectional analysis, we show evidence for an independent 
association betweenCHRNA5/CHRNA3 and COPD. Results from gene expression studies 
demonstrated that both CHRNA5 and CHRNA3 were expressed in whole lung, airway 
smooth muscle, and bronchial epithelial cells 56. The correlation between associated 
SNP genotypes and CHRNA5 expression levels in the lung and sputum, combined with 
our finding of increased risk of airflow obstruction in never smokers suggests that the 
variants in this region may be associated with a risk of airflow obstruction that is not 
simply mediated by an influence on nicotine dependency. Supporting a direct influence 
of variants in this region on lung phenotypes, a CHRNA3/5 variant was recently found to 
be associated with bronchial hyperresponsiveness in children not exposed to cigarette 
smoke 57. On the other hand, colleagues have analyzed the direct link with CHRNA3/5 
and lung function decline and found no evidence for an independent effect but through 
smoking habits 58. Nevertheless this is a very interesting region which, through smoking 
habits or directly, influences lung function and the risk to develop COPD. It would be 
very interesting to further investigate this region.
spirometry, COPD and therapeutic agents
In the fourth part of this thesis, we explored the association between spirometry or COPD, 
and two drug groups which are commonly used in people with pulmonary diseases.
In chapter 4.1, we demonstrated an association between β-blockers and spirometry. 
In this population-based study, exposure to cardioselective β-blockers was associated 
with a lower FEV1 of -118 ml, and FVC of -167 ml, respectively. For non-cardioselective 
β-blockers we found an association with a marginally lower FEV1/FVC of -1.38%, a mea-
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sure to assess airflow obstruction. For cardioselective β-blockers, although the sample 
was much larger, no such association was found. The difference of effects (adjusted for 
several co-variables) between cardioselective and non-cardioselective β-blockers and 
the lack of a strong association with FEV1/FVC implies that the non-cardiac effects are 
in fact limited, but not completely absent. Our objective was to investigate whether 
this association was modified by common variants in the ADRB2-gene, encoding for the 
Beta-2-adrenergic receptor which is the target of cardioselective β-blockers, to identify 
markers for a higher susceptibility to this unwanted effect. Unfortunately, our dataset 
was not powerful enough to detect such effect or there was no effect modification 
between the genetic variants.
While we show a deleterious effect on pulmonary function, there is ample evidence 
that β-blockers are beneficial in the treatment of cardiovascular disease (CVD) in COPD 
patients. Since heart failure and COPD exacerbations are associated with an increased 
risk of mortality 59,60, treating patients with a multidrug regimen might provide disease-
specific benefits and reduce mortality 61. Our findings are probably outweighed by the 
beneficial effects of the treatment on CVD but might have clinical consequences in 
those with end-stage COPD.
Lastly, we investigated another very frequently used class of prescription drug in CVD, 
i.e. statins and their effect on survival in patients with COPD. The airflow obstruction 
is most notable in COPD patients, but there is evidence that COPD is also a systemic 
inflammatory disease and that statins might decrease the risk of mortality in patients 
with COPD. In addition to their lipid-lowering effect, statins also possess pleiotropic 
anti-inflammatory and immunomodulating properties, and are able to reduce levels of 
inflammatory markers such as CRP 62. This is the first prospective study in a general popu-
lation showing that the beneficial effect of long-term statin use on the risk of mortality 
in COPD patients is modified by the baseline level of systemic inflammation. Although 
the protective effect of statins in COPD patients might represent solely an indirect effect 
on the cardiovascular co-morbidities associated with COPD, our results also suggest a 
favorable effect on respiratory mortality by statin use compared to never use. One in 
three COPD patients in our study died from cardiovascular causes – figures which have 
also been described by other authors 61,63.
We describe both positive and negative effects from treatments mainly used in CVD with 
respect to the lungs. This further emphasizes the close correlation between the heart 
and lungs. While one drug class (β-blockers) may have apparent negative effects on spi-
rometry, in COPD patients it is still beneficial. Although statins have not been marketed 
for the indication COPD or advertised as being beneficial to COPD patients, our results 
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show effects on mortality independent of cardiovascular mortality. That means that we 
might in the future prescribe statins to COPD patients irrespective of their cardiovascular 
risk profile or cholesterol levels. However, before we reach that conclusion, large scale 
placebo controlled trials would be needed, with the specific purpose of evaluating the 
inflammatory risk profile, to further clarify the effects of statins in COPD.
mEThODOLOGICaL COnsIDEraTIOns
Per chapter, most relevant methodological issues have been addressed in the discus-
sions. In these paragraphs we will further highlight some general methods and problems 
we encountered.
study design and setting.
All studies in this thesis were embedded in the Rotterdam Studies I, II & III. The Rot-
terdam Study is a prospective population-based cohort study which started in 1990 in 
Ommoord, a suburb of Rotterdam. The objectives and design of the Rotterdam Study 
have been described earlier 62,64. In brief, at baseline, all participants were visited for a 
standardized questionnaire, and were subsequently examined at the research centre. 
The first cohort (RS-I) consists of 7,983 participants, aged 55 years and over. Since the 
start of the initial cohort, two subsequent cohorts have been defined in the same area. 
The second cohort (RS-II) started in 2000 and included 3,011 participants aged 55 years 
and over. The third cohort (RS-III) was enrolled in 2006 and included 3,932 participants 
aged 45 years and over.
Every 3-5 years, participants undergo a round of interviews and physical examinations, 
of which pulmonary function tests were routinely performed during every study round 
as of 2002. To continuously monitor the cohort for major diseases and mortality, the da-
tabase is linked to the electronic records of the general practitioner and the municipal-
ity. All prescriptions dispensed to the participants are periodically collected by linking to 
the seven pharmacies covering the Ommoord region.
Spirometry was performed by trained paramedical personnel using a SpiroPro®portable 
spirometer (Erich Jaeger, Hoechberg, Germany) and as of 2009 with the CareFusion Mas-
terScreen TM PFT, according to American Thoracic Society (ATS)/European Respiratory 
Society (ERS) guidelines 10. FEV1, FVC and FEV1/FVC-ratio were measured. Spirometry 
procedures that yielded results that did not meet ATS/ERS criteria for acceptability and 
reproducibility were classified as ‘not interpretable’65.
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During the investigations at the research center, all measurements are limited to strict 
timeslots in order to keep the process efficient and make it possible for the elderly to 
within without demanding too much effort. This time restriction does, in some cases, 
prohibits us from repeating the spirometry test until sufficient quality tests are obtained. 
Most of the times we can acquire up to 5 tests. The failure rate, being less that 10%, is 
very low. Participants were asked to refrain from smoking and/or using any prescribed 
pulmonary medication before the center visit. For practical reasons, reversibility testing 
could not be carried out which might be considered as a methodological limitation. 
Although asthma prevalence figures in the elderly are not very well investigated, esti-
mates of asthma occurrence range from 4 to 8 % 63,66. In order to be able to take asthma 
into account in our analyses, asthma cases were ascertained by 1) Doctor’s diagnosis 
of Asthma and 2) no conflicting respiratory diagnosis. Additionally, prescriptions for 
respiratory medicines were used for case finding.
The great advantages of the Rotterdam Study, as our study base, are the prospectively 
(unbiased) data collection, long-term follow-up and detailed information on a large 
variety of phenotypes. This allows for association testing with a relatively low chance of 
confounding by indication or protopathic bias in an observational study. Furthermore, 
we were able to adjust for many co-morbidities and co-variables. The follow-up allows 
for survival analyses like in chapter 4.2.
Genome-wide association studies
In the third part of this thesis, we showed several straightforward cross-sectional GWAs 
and two interaction analyses. The quantitative cross-sectional analyses proved to be 
most successful in identifying associations, a success mainly due to their large sample 
sizes. The drawback of these consortia is that they consist of many cohorts, increasing 
the heterogeneity across the studied phenotypes and genotypes. Hereby, we will only 
be able to identify very consistent effects of SNPs in all cohorts. Due to geographical 
differences between cohorts, there might be specific variants which we were not able 
to detect. Thereby, we may have missed large parts of unidentified genetic variants 
with tiny effects. The clinical relevance of these undiscovered loci may be limited but 
the evidence provides pieces of the puzzle, a puzzle of which we do not know size and 
character yet.
Gene–environment interactions have been proposed to hold a key to a proportion of 
unexplained heritability. The sample sizes needed for such studies are a major hurdle, 
illustrated by our G x E analysis in chapter 3.3. The most direct interaction expected 
to be demonstrable in pulmonary medicine would be the one of smoking by genetic 
susceptibility. However, even with a very powerful statistical technique we were not able 
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to identify clear-cut interaction effects. This poses a problem when studying gene-drug 
interactions in which we would like to identify patients who have a good response as 
well as those who are more susceptible to the harmful effects of medication. Since we 
were not able to identify an interaction by one of the strongest and most widely used 
exposures (smoking), it is a great challenge to identify gene-drug interactions. This is 
partially due to power issues, but also the difference in exposure windows create extra 
complexity. For smoking, the effects occur after chronic exposure for years, in drug-gene 
interaction one would expect acute effects within the exposure window. Finally, most of 
the genes are part of complex biological networks which attributes to Gene-Gene and 
Gene-Gene-Environment interactions. Although very interesting, these are currently dif-
ficult to analyze because of a lack of sufficient sample size and computational resources.
FuTurE DIrECTIOns
To identify more of the genetic heritability and pharmacogenetic effects, new tools are 
needed.
Beside the new arrays such as the exome chip, we are standing at the brink of extensive 
sequencing of DNA in the individuals of the Rotterdam Study and similar population-
based cohort studies. The analyses to be performed will most likely focus firstly on the 
fine mapping of GWA results and identification of rare variants with small or moderate 
effects. Besides that, we should widen our scope and look into the candidate gene ap-
proach for testing hypotheses on gene-environment (drugs) interactions. By sequencing 
and analyzing the exomes, the functional parts of the genes, we may increase power to 
detect interactions with prescribed medication or assess why some patients experience 
more adverse effects than others. Further down the pathway, more research is needed 
with respect to the modification proteins, coded by the genes, undergo (proteomics) 
and the metabolites of the cellular processes (metabolomics). These might provide 
more insight into interindividual variation.
COnCLuDInG rEmarK
The identification of genetic determinants underlying the heritability of spirometry is far 
from complete. However, it has been more powerful than the genetic case-control analy-
ses of COPD. The discoveries in this thesis do provide information on the pathogenesis 
of chronic obstructive pulmonary diseases. New approaches may be more successful in 
identifying gene-drug interactions than the current tools we have and pave the path 
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to personalized medicine in respiratory diseases. In the meantime, we should not over-
look candidate gene analyses and given part IV, non-genetic pharmacoepidemiology 
remains an important tool.
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summary
Spirometry is a standardized and reliable measure to assess pulmonary ventilatory 
function and evaluate lung volume. Spirometry is mainly used to diagnose obstructive 
respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), 
and to assess treatment response. COPD is a common respiratory disease which is pri-
marily caused by inhalation of noxious particles and gases from e.g. cigarette smoke, air 
pollution or indoor fossil fuel combustion. COPD is characterized by a not fully reversible 
airflow limitation in combination with several symptoms, such as chronic cough with or 
without excess sputum production. The disease is usually progressive. In addition to the 
severity of airflow limitation, the number of co-morbid conditions, and the frequency 
and severity of exacerbations determine the overall survival in COPD patients. While 
cigarette exposure is the strongest risk factor for COPD, susceptibility seems heritable 
and some genetic determinants are known to contribute to the development of COPD. 
A homozygous mutation in SERPINA1 leading to Alfa-1 Antitrypsin-deficiency is one of 
the most well-known genetic determinants for emphysema. Affected smokers develop 
COPD much earlier in life, before 40 years of age, than affected non-smokers and unaf-
fected smokers. Other genetic determinants such as hedgehog interacting protein 
(HHIP) and Transforming Growth Factor Beta-1 (TGFB1) have been associated with COPD, 
but cannot fully explain the heritability.
The main objectives of this thesis were, 1) to explore the epidemiology of (ab)normal 
spirometric measurements in elderly, 2) to identify genetic determinants for lung func-
tion, smoking susceptibility, lung function decline and COPD, 3) to assess the effects 
of drugs on lung function or disease progression and to elucidate the genetic- and 
environmental modifiers of drug response. Four of the studies in this thesis were con-
ducted within the Rotterdam Study, a large population-based cohort study. In five of the 
studies, the Rotterdam Study collaborated with up to 33 similar ohorts from Europe, the 
United States and Australia.
In Part II, two epidemiological topics regarding spirometry were studied. In chapter 2.1 
we calculated reference values for three spirometry measures; Forced Expiratory Volume 
in 1 second (FEV1), Forced Vital Capacity (FVC) and the ratio of FEV1 over FVC. These find-
ings showed that healthy elderly may have a physiologically decreased lung function, 
even if they do not suffer from obstructive lung disease. Possible misclassification of 
COPD in the elderly may overestimate the incidence and prevalence of COPD in popula-
tion-based studies. In chapter 2.2 we studied the relationship between pulmonary and 
cardiovascular function, showing evidence for a strong correlation between spirometric 
measurements and pulmonary artery systolic pressure. We described a physiological 
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relationship which need to be further explored to identify if, and if so, which clinical 
implications this may have.
In Part III we described the results of three “standard” genome-wide association analyses 
across two large consortia (CHARGE and SpiroMeta) for: 1) FEV1 and FEV1/FVC, 2) FVC 
and 3) COPD. Furthermore, we showed the results from a gene-environment interaction 
of cigarette smoke exposure on FEV1 and FEV1/FVC. Lastly in this series, we evaluated 
the interaction between genes and time on FEV1. For FEV1 and FEV1/FVC, we undertook 
a large scale meta-analysis with several look-up strategies in order to identify new loci 
associated with both traits (chapter 3.1). We were able to identify 16 new loci for FEV1 
and FEV1/FVC bringing the total amount of loci known for these traits up to 26. The loci 
implicated in pulmonary function may lead to a better understanding of the embryo-
logic development of the lungs, their damage repair system and related immunological 
processes. In chapter 3.2, we identified nine loci associated with FVC and although FVC 
and FEV1 are highly correlated, we identified loci to be independently associated with 
FVC. Furthermore, we confirmed two loci to be associated with both FEV1 and FVC.
Chapters 3.3 and 3.4, report on two interaction analyses. In chapter 3.3, we explored the 
interaction between genetics and the environment. One of the most direct exposures 
influencing lung function is (cigarette) smoking. As mentioned previously, susceptibil-
ity to the damaging effects differs. We undertook analyses with smoking status (ever/
never) and cumulative exposure described in pack years. Remarkably, our statistical 
approach proved to be more powerful to identify SNP effects than effects of interaction 
with smoking. Two reasons may underlie this observation. Firstly, the models are fully 
saturated for the exposure, thereby reducing confounding to a minimum. Secondly, 
for pure interaction effects, we were probably underpowered although the sample size 
exceeded 50,000 participants. For interaction with time (chapter 3.4), we were able to 
find suggestive evidence for loci associated with an accelerated lung function decline. 
However, we were not able to replicate our findings in a separate independent cohort. 
Possible heterogeneity across cohorts (e.g. in participants, lung function apparatus and 
timing/interval between lung function measurements) and power issues were probably 
limiting factors in these analyses.
Lastly, we identified a potential independent effect of the nicotinic acetylcholine recep-
tors (CHRNA3/5) on the risk of airflow obstruction. These results were independent of 
smoking and can be found in chapter 3.5.
In part IV we assessed the effects of pharmacological treatment for cardiovascular 
diseases on pulmonary function and COPD. Use of β-blockers was associated with 
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a lower FEV1 and FVC (chapter 4.1). This effect was stronger in non-cardioselective 
β-blockers than in selective β-blockers, which is consistent with the different receptors 
these classes target and the less harmful risk profile selective β-blockers tend to have. 
Althoughβ-blockers may decrease pulmonary function, recent studies have shown that 
β-blockers are beneficial in patients with COPD and cardiovascular disease, mainly due 
to a reduction of the high cardiovascular mortality in COPD patients. Lastly, we showed 
that statins reduce mortality in COPD patients. This reduction in all-cause mortality is 
modified by the baseline level systemic inflammation, as evidenced by serum levels of 
high-sensitivity C-reactive protein and may be due to anti-inflammatory and immuno-
modulatory properties of this drug class.
Part V gives a general interpretation of our results, places the findings into perspective 
and highlights some of the methodological issues regarding our studies. The successes 
of the genome-wide association studies, but also the limitation in sample size are high-
lighted. Furthermore, some general considerations and future perspectives are given to 
further explore (pharmaco)genetic susceptibility to diseases and treatment.
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samEnVaTTInG
Spirometrie is een gestandaardiseerde en betrouwbare methode om de functie van 
de longen te meten en het volume van de longen te schatten. Spirometrie wordt met 
name gebruikt voor de diagnose van obstructieve longziekten zoals astma en chronic 
obstructive pulmonary disease (COPD) en het evalueren van de therapie effecten. COPD 
is een veel voorkomende longziekte, welke met name wordt veroorzaakt door de inha-
latie van schadelijke deeltjes en gassen in bijvoorbeeld sigarettenrook, luchtvervuiling 
of het binnenshuis verbranden van fossiele brandstoffen. COPD wordt gekarakteriseerd 
door een niet volledig omkeerbare luchtwegobstructie in combinatie met verscheidene 
symptomen zoals chronische hoest en overmatige slijmproductie. De ziekte is meestal 
progressief. Naast de ernst van de luchtwegobstructie, wordt de mortaliteit beïnvloed 
door het aantal comorbiditeiten en de frequentie en ernst van de COPD exacerbaties. 
Hoewel sigarettenrook de sterkste risicofactor voor COPD is, lijkt er tevens een erfelijke 
component te bestaan en van sommige genetische determinanten is bekend dat ze 
het risico op het ontwikkelen van COPD verhogen. Een homozygote mutatie in het 
SERPINA1 gen, resulterend in een Alfa-1 Antitrypsine-deficiëntie is 1 van de reeds lang 
bekende genetische determinanten voor het ontwikkelen van emfyseem. Rokers die 
aangedaan zijn door deze mutatie ontwikkelen COPD veel vroeger, vaak reeds voor het 
40ste levensjaar, dan niet-rokers met deze mutatie of rokers zonder de mutatie. Andere 
genetische determinanten, zoals Hedgehog Interacting Protein (HHIP) en Transforming 
Growth Factor Beta-1 (TGFB1) zijn geassocieerd met COPD, maar kunnen de erfelijkheid 
niet volledig voorspellen.
De doelstellingen van dit proefschrift waren, 1) het bestuderen van de epidemiologie 
van normale en afwijkende metingen bij spirometrie in ouderen, 2) het identificeren 
van genetische determinanten voor longfunctie, gevoeligheid voor roken, longfunctie-
vermindering en COPD, 3) het analyseren van effecten van geneesmiddelen op de long-
functie of het ziekteverloop en het identificeren van genetische en omgevingsfactoren 
die de mogelijke geneesmiddeleneffecten beïnvloeden. Vier van de onderzoeken in dit 
proefschrift zijn uitgevoerd binnen de Rotterdam Studie, een grote cohort studie in de 
algemene populatie. In vijf onderzoeken zijn we de samenwerking aangegaan met 33 
vergelijkbare studies uit Europa, de Verenigde Staten en Australië.
In Deel II hebben we twee epidemiologische onderwerpen bestudeerd. In hoofdstuk 
2.1 hebben we referentiewaarden berekend voor drie spirometriematen: Forced Expi-
ratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC) en de ratio van deze twee 
maten (FEV1/FVC). Deze bevindingen tonen aan dat gezonde ouderen een fysiologisch 
verminderde longfunctie kunnen hebben ondanks het feit dat ze niet lijden aan een ob-
structieve longziekte. Mogelijk worden hierdoor de prevalentie en incidentie van COPD 
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in studies bij ouderen overschat. In hoofdstuk 2.2 onderzochten we de relatie tussen 
spirometrie en de cardiale functie. We tonen een sterke correlatie aan tussen maten van 
longfunctie en de druk in de pulmonaalarterie. We beschrijven een fysiologische relatie, 
maar verder onderzoek zal moeten uitwijzen wat de klinische consequenties van deze 
relatie zullen zijn.
In Deel III, beschrijven we drie associatie studies over het gehele genoom in twee grote 
consortia (CHARGE en SpiroMeta) voor: FEV1, FEV1/FVC, 2) FVC en 3) COPD. Verder laten 
we resultaten zien van een gen-omgeving interactiestudie tussen blootstelling aan 
sigarettenrook en FEV1 en FEV1/FVC. Tenslotte hebben we interactie tussen genen en tijd 
geëvalueerd ten aanzien van het verloop in longfunctie over de jaren. Voor FEV1 en FEV1/
FVC hebben we een grote meta-analyse verricht en verschillende strategieën gebruikt 
om nieuwe genetische varianten te voor deze spirometriematen te identificeren en te 
bevestigen (hoofdstuk 3.1). We hebben met dit onderzoek 16 varianten kunnen identifi-
ceren voor FEV1 en FEV1/FVC, waarmee we het totaal aantal bekende genetische loci naar 
een totaal van 26 hebben gebracht. De loci die geassocieerd zijn met longfunctie leiden 
mogelijk tot een beter begrip over de longontwikkeling gedurende de embryonale fase, 
de herstelmechanismen van de long en de immunologische processen. In hoofstuk 3.2, 
identificeerden we negen loci, die geassocieerd zijn met FVC. Hoewel FVC en FEV1 zeer 
gecorreleerd zijn, waren we in staat om loci te identificeren die onafhankelijk met FVC 
geassocieerd zijn. Tevens hebben we opnieuw twee loci aangetoond die we eerder met 
FEV1 en FVC geassocieerd hadden.
Hoofdstukken 3.3 en 3.4, beschrijven 2 interactie analyses. In hoofdstuk 3.3, hebben 
we de interactie onderzocht tussen genen en omgevingsfactoren. Een van de meest 
directe en sterke factoren, die de longfunctie beïnvloed, is sigarettenrook. Zoals eerder 
genoemd, is de gevoeligheid voor de schadelijke effecten verschillend per persoon. We 
hebben analyses uitgevoerd met rookstatus (‘ooit’/’nooit’) en met de totale cumula-
tieve blootstelling, uitgedrukt in zogeheten ‘pak-jaren’. Opmerkelijk genoeg, bleek onze 
statistische benadering gevoeliger voor het ontdekken van effecten van genetische 
varianten dan voor het ontdekken van interactieeffecten. Twee mogelijke redenen kun-
nen hieraan ten grondslag liggen. Ten eerste, waren de statistische modellen volledig 
verzadigd met correctiefactoren voor roken, teneinde de verstorende factoren van 
roken tot een minimum te beperken. Ten tweede, om pure interactie effecten te iden-
tificeren, hadden we een té kleine onderzoekspopulatie ondanks het feit dat het aantal 
onderzochte deelnemers groter was dan 50.000. Voor interactie met tijd (hoofdstuk 3.4), 
waren we in staat om ondersteunend bewijs te leveren voor loci die geassocieerd zijn 
met een versnelde achteruitgang van de longfunctie. Helaas waren we echter niet in 
staat om deze bevindingen in een onafhankelijke populatie te bevestigen. Mogelijke 
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heterogeniteit tussen de cohorten (bijvoorbeeld in deelnemers, longfunctiemetingen 
en tijd/interval tussen de longfunctiemetingen) en te weinig statistische ‘power’ waren 
mogelijk beperkende factoren.
Voorts vonden we aanwijzingen voor een mogelijk onafhankelijk effect op obstructieve 
uitademing geassocieerd met de genen die coderen voor nicotine acetylcholine recep-
toren (CHRNA3/5). Deze resultaten waren onafhankelijk van roken en staan beschreven 
in hoofdstuk 3.5.
In deel IV hebben we de effecten van farmacotherapie voor cardiovasculaire aandoenin-
gen op longfunctie en COPD onderzocht. Het gebruik van β-blokkers was geassocieerd 
met een lagere FEV1 en FVC (hoofdstuk 4.1). Dit effect was sterker in gebruikers van niet-
cardioselectieve β-blokkers dan in gebruikers van selectieve β-blokkers, hetgeen con-
sistent is met het verschil in farmacologische aangrijpingspunten van deze twee klassen 
en het gunstiger risicoprofiel dat selectieve β-blokkers hebben. Hoewel β-blokkers de 
longfunctie lijkten te verminderen, hebben recente onderzoeken aangetoond dat ze wel 
degelijk van therapeutische betekenis zijn bij patiënten met COPD en cardiovasculaire 
ziekten, dankzij verlaging van de cardiovasculaire mortaliteit.
Tenslotte hebben we laten zien dat statines de sterfte bij patiënten met COPD verlagen 
(hoofdstuk 4.2). Deze reductie in totale mortaliteit (alle sterfteoorzaken) lijkt te worden 
beïnvloed door de aanwezigheid van systemische inflammatie, aangetoond door 
verhoogde bloedwaarden van high-sensitivity C-reactive protein. Dit is mogelijk het 
gevolg van de anti-inflammatoire en immuunmodulerende eigenschappen van deze 
geneesmiddelenklasse.
Deel V geeft een algemene interpretatie van de resultaten, plaatst de bevindingen 
in perspectief en licht enige methodologische problemen toe van onze studies. De 
successen van de analyses over het gehele genoom, maar ook de beperkingen in de 
grootte van de studiepopulatie worden hierbij besproken. Vervolgens geven we enige 
algemene overwegingen en bespreken mogelijkheden voor toekomstig onderzoek 
met betrekking tot de genetische risicofactoren voor het ontstaan van COPD en voor 
de behandeling bij ouderen van deze toenemend frequente aandoening met ernstige 
consequenties.
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